US20180030095A1 - Silstatin compounds - Google Patents
Silstatin compounds Download PDFInfo
- Publication number
- US20180030095A1 US20180030095A1 US15/550,727 US201615550727A US2018030095A1 US 20180030095 A1 US20180030095 A1 US 20180030095A1 US 201615550727 A US201615550727 A US 201615550727A US 2018030095 A1 US2018030095 A1 US 2018030095A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- compound
- protecting group
- linking unit
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 305
- 238000000034 method Methods 0.000 claims abstract description 111
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 31
- 125000006239 protecting group Chemical group 0.000 claims description 297
- 125000000217 alkyl group Chemical group 0.000 claims description 207
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 159
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 103
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 99
- 239000004473 Threonine Substances 0.000 claims description 97
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 97
- 206010028980 Neoplasm Diseases 0.000 claims description 77
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 73
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 73
- 239000004474 valine Substances 0.000 claims description 73
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 72
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 72
- 210000004027 cell Anatomy 0.000 claims description 58
- 201000011510 cancer Diseases 0.000 claims description 55
- 150000003839 salts Chemical class 0.000 claims description 47
- 150000001413 amino acids Chemical class 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 37
- 210000004881 tumor cell Anatomy 0.000 claims description 25
- 230000001580 bacterial effect Effects 0.000 claims description 22
- 230000002401 inhibitory effect Effects 0.000 claims description 20
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- 208000035143 Bacterial infection Diseases 0.000 claims description 17
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 17
- 206010017533 Fungal infection Diseases 0.000 claims description 16
- 208000031888 Mycoses Diseases 0.000 claims description 16
- 230000012010 growth Effects 0.000 claims description 16
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 230000005764 inhibitory process Effects 0.000 claims description 11
- 230000035755 proliferation Effects 0.000 claims description 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 230000004614 tumor growth Effects 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 230000001472 cytotoxic effect Effects 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 230000002538 fungal effect Effects 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 239000006143 cell culture medium Substances 0.000 claims description 4
- 230000002147 killing effect Effects 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 167
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 156
- 125000000753 cycloalkyl group Chemical group 0.000 description 154
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 107
- 238000003776 cleavage reaction Methods 0.000 description 98
- 230000007017 scission Effects 0.000 description 98
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 90
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 85
- DJZAVKNBQZFEAL-QMMMGPOBSA-N (2s)-2-amino-3-(2-aminophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1N DJZAVKNBQZFEAL-QMMMGPOBSA-N 0.000 description 47
- DDLYNVBJVVOUGB-QMMMGPOBSA-N (2s)-2-amino-3-(3-aminophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(N)=C1 DDLYNVBJVVOUGB-QMMMGPOBSA-N 0.000 description 47
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 47
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 46
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 42
- 238000005160 1H NMR spectroscopy Methods 0.000 description 42
- 238000004809 thin layer chromatography Methods 0.000 description 40
- 235000002639 sodium chloride Nutrition 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 239000007787 solid Substances 0.000 description 36
- 238000004440 column chromatography Methods 0.000 description 33
- -1 p-aminobenzyloxycarbonyl Chemical group 0.000 description 29
- 238000000926 separation method Methods 0.000 description 29
- 239000000203 mixture Substances 0.000 description 28
- 239000011734 sodium Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 24
- 229960002173 citrulline Drugs 0.000 description 24
- 239000002253 acid Substances 0.000 description 21
- 238000000746 purification Methods 0.000 description 21
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 108010002156 Depsipeptides Proteins 0.000 description 20
- 108090000371 Esterases Proteins 0.000 description 20
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 20
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 20
- 108091005804 Peptidases Proteins 0.000 description 20
- 102000035195 Peptidases Human genes 0.000 description 20
- 229930182480 glucuronide Natural products 0.000 description 20
- 150000008134 glucuronides Chemical class 0.000 description 20
- 150000007857 hydrazones Chemical class 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 235000019833 protease Nutrition 0.000 description 20
- 239000000651 prodrug Substances 0.000 description 18
- 229940002612 prodrug Drugs 0.000 description 18
- 238000010504 bond cleavage reaction Methods 0.000 description 17
- 125000006850 spacer group Chemical group 0.000 description 17
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 16
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 150000003588 threonines Chemical group 0.000 description 16
- 150000003668 tyrosines Chemical group 0.000 description 16
- 125000005842 heteroatom Chemical group 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 239000002246 antineoplastic agent Substances 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 12
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 229940127089 cytotoxic agent Drugs 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 125000001072 heteroaryl group Chemical group 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 10
- 241000193998 Streptococcus pneumoniae Species 0.000 description 9
- 0 [1*]C1OC(=O)C([11*])N(C)C(=O)C([10*])OC(=O)C([9*])N(C)C(=O)C([8*])OC(=O)C([7*])N(C)C(=O)C([6*])OC(=O)C([5*])N(C)C(=O)C([4*])OC(=C)CN(C)C(=O)C([3*])OC(=O)C([2*])N(C)C1=O Chemical compound [1*]C1OC(=O)C([11*])N(C)C(=O)C([10*])OC(=O)C([9*])N(C)C(=O)C([8*])OC(=O)C([7*])N(C)C(=O)C([6*])OC(=O)C([5*])N(C)C(=O)C([4*])OC(=C)CN(C)C(=O)C([3*])OC(=O)C([2*])N(C)C1=O 0.000 description 9
- 230000010261 cell growth Effects 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 9
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 9
- SWZCTMTWRHEBIN-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(O)C=C1 SWZCTMTWRHEBIN-QFIPXVFZSA-N 0.000 description 8
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 7
- 241000233866 Fungi Species 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000000611 antibody drug conjugate Substances 0.000 description 6
- 229940049595 antibody-drug conjugate Drugs 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 210000002307 prostate Anatomy 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 241000193996 Streptococcus pyogenes Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- JWWAHGUHYLWQCQ-UHFFFAOYSA-N cereulide Chemical compound CC(C)CC1OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C)NC(=O)C(CC(C)C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C)NC(=O)C(CC(C)C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C)NC1=O JWWAHGUHYLWQCQ-UHFFFAOYSA-N 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 4
- 229940097042 glucuronate Drugs 0.000 description 4
- 230000009036 growth inhibition Effects 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 3
- LVRFTAZAXQPQHI-RXMQYKEDSA-N (R)-2-hydroxy-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](O)C(O)=O LVRFTAZAXQPQHI-RXMQYKEDSA-N 0.000 description 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 3
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 3
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- BDMNNPMNWDQQQN-MRPMUTLKSA-N CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)CCC1=O Chemical compound CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)CCC1=O BDMNNPMNWDQQQN-MRPMUTLKSA-N 0.000 description 3
- OBYVGQWTWDVQAJ-LTDHTIOHSA-N CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC(=O)CNC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC1=O Chemical compound CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC(=O)CNC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC1=O OBYVGQWTWDVQAJ-LTDHTIOHSA-N 0.000 description 3
- GFFSWEVTLNJFDZ-QSZOLWPLSA-N CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)CCC1=O Chemical compound CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)CCC1=O GFFSWEVTLNJFDZ-QSZOLWPLSA-N 0.000 description 3
- CFXGEPINDOWFCJ-SPMKXNKFSA-N CC(C)[C@@H]1CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC(=O)CNC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC(=O)[C@@H](CC2CCCCC2)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC1=O Chemical compound CC(C)[C@@H]1CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC(=O)CNC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC(=O)[C@@H](CC2CCCCC2)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC1=O CFXGEPINDOWFCJ-SPMKXNKFSA-N 0.000 description 3
- KNCISKQZCMDZIU-HFMBJNOISA-N CC(C)[C@@H]1CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)CCC(=O)[C@@H](CC2CCCCC2)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC1=O Chemical compound CC(C)[C@@H]1CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)CCC(=O)[C@@H](CC2CCCCC2)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC1=O KNCISKQZCMDZIU-HFMBJNOISA-N 0.000 description 3
- 102100025221 CD70 antigen Human genes 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000010956 Glypican Human genes 0.000 description 3
- 108050001154 Glypican Proteins 0.000 description 3
- 108050007237 Glypican-3 Proteins 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 3
- 108010067973 Valinomycin Proteins 0.000 description 3
- APSACYJSUSNJJO-MPJDBJFZSA-N [Si](C)(C)(C(C)(C)C)OCC1=CC(=C(C=C1)[C@]1(O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H](O1)C(=O)OC)[N+](=O)[O-] Chemical compound [Si](C)(C)(C(C)(C)C)OCC1=CC(=C(C=C1)[C@]1(O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H](O1)C(=O)OC)[N+](=O)[O-] APSACYJSUSNJJO-MPJDBJFZSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- FCFNRCROJUBPLU-UHFFFAOYSA-N compound M126 Natural products CC(C)C1NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC1=O FCFNRCROJUBPLU-UHFFFAOYSA-N 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 239000003966 growth inhibitor Substances 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- KSNQMHVBCOBSQE-KVIJGQROSA-N methyl (2s,3s,4s,5r,6r)-3,4,5-triacetyloxy-6-(4-formyl-2-nitrophenyl)-6-hydroxyoxane-2-carboxylate Chemical compound CC(=O)O[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](C(=O)OC)O[C@]1(O)C1=CC=C(C=O)C=C1[N+]([O-])=O KSNQMHVBCOBSQE-KVIJGQROSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FCFNRCROJUBPLU-DNDCDFAISA-N valinomycin Chemical compound CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O FCFNRCROJUBPLU-DNDCDFAISA-N 0.000 description 3
- WMHUKKRNWMPXKB-MRVPVSSYSA-N (2r)-3-cyclohexyl-2-hydroxypropanoic acid Chemical compound OC(=O)[C@H](O)CC1CCCCC1 WMHUKKRNWMPXKB-MRVPVSSYSA-N 0.000 description 2
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 2
- NWXOLMBBOHPPQK-ACQPPXRZSA-N (3r,6r,9s,12s,15r,18r,21s,24s,27r,30r,33s,36s)-6,18,30-tris[(2s)-butan-2-yl]-12,24,36-trimethyl-3,9,15,21,27,33-hexa(propan-2-yl)-1,7,13,19,25,31-hexaoxa-4,10,16,22,28,34-hexazacyclohexatriacontane-2,5,8,11,14,17,20,23,26,29,32,35-dodecone Chemical compound CC[C@H](C)[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H]([C@@H](C)CC)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H]([C@@H](C)CC)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC1=O NWXOLMBBOHPPQK-ACQPPXRZSA-N 0.000 description 2
- KVJGVUIUGIEWCD-RPUMXUQMSA-N (3r,6r,9s,12s,15r,18r,21s,24s,27r,30r,33s,36s)-6,18-bis[(2s)-butan-2-yl]-12,24,36-trimethyl-30-(2-methylpropyl)-3,9,15,21,27,33-hexa(propan-2-yl)-1,7,13,19,25,31-hexaoxa-4,10,16,22,28,34-hexazacyclohexatriacontane-2,5,8,11,14,17,20,23,26,29,32,35-dodecone Chemical compound CC[C@H](C)[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H]([C@@H](C)CC)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC1=O KVJGVUIUGIEWCD-RPUMXUQMSA-N 0.000 description 2
- BSSNZUFKXJJCBG-UPHRSURJSA-N (z)-but-2-enediamide Chemical group NC(=O)\C=C/C(N)=O BSSNZUFKXJJCBG-UPHRSURJSA-N 0.000 description 2
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 2
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 2
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 2
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 2
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 2
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-aminoisobutyric acid Chemical compound NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 2
- FBSFUMQJHSPHMC-NBFZJHMMSA-N CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)CNC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC1=O Chemical compound CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)CNC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC1=O FBSFUMQJHSPHMC-NBFZJHMMSA-N 0.000 description 2
- VWNGHTYNZGRLGF-UFEUIPRPSA-N CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC(=O)[C@H]([C@@H](C)OC(=O)CCCN(C)C(=O)OCC2=CC=C(O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)C([N+](=O)[O-])=C2)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC1=O Chemical compound CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC(=O)[C@H]([C@@H](C)OC(=O)CCCN(C)C(=O)OCC2=CC=C(O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)C([N+](=O)[O-])=C2)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC1=O VWNGHTYNZGRLGF-UFEUIPRPSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 201000007336 Cryptococcosis Diseases 0.000 description 2
- 241000221204 Cryptococcus neoformans Species 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N DL-isoserine Natural products NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 108010088261 bacillistatin 1 Proteins 0.000 description 2
- NWXOLMBBOHPPQK-UHFFFAOYSA-N bacillistatin 1 Natural products CCC(C)C1OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)CC)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)CC)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC1=O NWXOLMBBOHPPQK-UHFFFAOYSA-N 0.000 description 2
- 108010088253 bacillistatin 2 Proteins 0.000 description 2
- KVJGVUIUGIEWCD-UHFFFAOYSA-N bacillistatin 2 Natural products CCC(C)C1OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(CC(C)C)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)CC)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC1=O KVJGVUIUGIEWCD-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000002815 broth microdilution Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 201000007455 central nervous system cancer Diseases 0.000 description 2
- 108010061320 cereulide Proteins 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 238000010829 isocratic elution Methods 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- BSPMWFRGZQDRIU-UHFFFAOYSA-N (2-amino-1h-imidazol-5-yl)methanol Chemical class NC1=NC(CO)=CN1 BSPMWFRGZQDRIU-UHFFFAOYSA-N 0.000 description 1
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DATPFTPVGIHCCM-BYPYZUCNSA-N (2s)-2-(ethylamino)propanoic acid Chemical compound CCN[C@@H](C)C(O)=O DATPFTPVGIHCCM-BYPYZUCNSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- HBJGLYBWNNQMOW-LURJTMIESA-N (2s)-2-azaniumyl-2-methylpentanoate Chemical compound CCC[C@](C)(N)C(O)=O HBJGLYBWNNQMOW-LURJTMIESA-N 0.000 description 1
- CECJQMSUPRBHAX-OFKSJOQMSA-N (2s,3s,4s,5r,6r)-3,4,5-triacetyloxy-6-bromo-6-hydroxyoxane-2-carboxylic acid Chemical compound CC(=O)O[C@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@](O)(Br)O[C@@H]1C(O)=O CECJQMSUPRBHAX-OFKSJOQMSA-N 0.000 description 1
- APOKYMYZOKIMLM-LUMVZWMBSA-N (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-[4-[[(2s,3s,4s,6r)-3-hydroxy-2-methyl-6-[[(1s,3s)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1h-tetracen-1-yl]oxy]oxan-4-yl]carbamoyloxymethyl]-2-nitrophenoxy]oxane-2-carboxylic acid Chemical compound N([C@H]1C[C@@H](O[C@@H](C)[C@H]1O)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C(=O)OCC(C=C1[N+]([O-])=O)=CC=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O APOKYMYZOKIMLM-LUMVZWMBSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- OWQPOVKKUWUEKE-UHFFFAOYSA-N 1,2,3-benzotriazine Chemical compound N1=NN=CC2=CC=CC=C21 OWQPOVKKUWUEKE-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- SZCBDIVMCGFVPW-UHFFFAOYSA-N 1-[4-(aminomethyl)-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OC)=C1 SZCBDIVMCGFVPW-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006019 1-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006021 1-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000006018 1-methyl-ethenyl group Chemical group 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- UFCRQKWENZPCAD-UHFFFAOYSA-N 2-(2-aminophenyl)propanamide Chemical class NC(=O)C(C)C1=CC=CC=C1N UFCRQKWENZPCAD-UHFFFAOYSA-N 0.000 description 1
- QEVGZEDELICMKH-UHFFFAOYSA-L 2-(carboxylatomethoxy)acetate Chemical compound [O-]C(=O)COCC([O-])=O QEVGZEDELICMKH-UHFFFAOYSA-L 0.000 description 1
- HEPOIJKOXBKKNJ-UHFFFAOYSA-N 2-(propan-2-ylazaniumyl)acetate Chemical compound CC(C)NCC(O)=O HEPOIJKOXBKKNJ-UHFFFAOYSA-N 0.000 description 1
- BHUGZIJOVAVBOQ-UHFFFAOYSA-N 2-(propylazaniumyl)acetate Chemical compound CCCNCC(O)=O BHUGZIJOVAVBOQ-UHFFFAOYSA-N 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
- RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 1
- QXPXILGITKUCLM-UHFFFAOYSA-N 2-benzylidenepropane-1,3-diol Chemical compound OCC(CO)=CC1=CC=CC=C1 QXPXILGITKUCLM-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006049 2-methyl-2-pentenyl group Chemical group 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- YZPJYHCJKCSXBS-UHFFFAOYSA-N 3-(ethylamino)propanoic acid Chemical compound CCNCCC(O)=O YZPJYHCJKCSXBS-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-aminobutanoic acid Chemical compound CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000006046 3-methyl-1-pentenyl group Chemical group 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- AOKCDAVWJLOAHG-UHFFFAOYSA-N 4-(methylamino)butyric acid Chemical compound C[NH2+]CCCC([O-])=O AOKCDAVWJLOAHG-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
- WCVPFJVXEXJFLB-UHFFFAOYSA-N 4-aminobutanamide Chemical class NCCCC(N)=O WCVPFJVXEXJFLB-UHFFFAOYSA-N 0.000 description 1
- IVUOMFWNDGNLBJ-UHFFFAOYSA-N 4-azaniumyl-2-hydroxybutanoate Chemical compound NCCC(O)C(O)=O IVUOMFWNDGNLBJ-UHFFFAOYSA-N 0.000 description 1
- YTHJCZRFJGXPTL-UHFFFAOYSA-N 4-hydroxy-3-nitrobenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1[N+]([O-])=O YTHJCZRFJGXPTL-UHFFFAOYSA-N 0.000 description 1
- 125000006047 4-methyl-1-pentenyl group Chemical group 0.000 description 1
- 125000006051 4-methyl-2-pentenyl group Chemical group 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- MRUWJENAYHTDQG-UHFFFAOYSA-N 4H-pyran Chemical compound C1C=COC=C1 MRUWJENAYHTDQG-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- ALHWZNSKKPMQOS-LXXGYWCPSA-N C.C=CCOC(=O)O[C@H]1[C@H](C)[C@@H](C(=O)OCC=C)O[C@@H](OC2=CC=C(CO)C=C2[N+](=O)[O-])[C@@H]1OC(=O)OCC=C.C=CCOC(=O)O[C@H]1[C@H](C)[C@@H](C(=O)OCC=C)O[C@@H](OC2=CC=C(CO[Si](C)(C)C(C)(C)C)C=C2[N+](=O)[O-])[C@@H]1OC(=O)OCC=C.C=CCOC(=O)[C@H]1O[C@@H](OC2=CC=C(CO[Si](C)(C)C(C)(C)C)C=C2[N+](=O)[O-])[C@H](O)[C@@H](O)[C@@H]1O.CC(C)(C)[Si](C)(C)Cl.COC(=O)[C@H]1O[C@@H](OC2=CC=C(C=O)C=C2[N+](=O)[O-])[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1C.COC(=O)[C@H]1O[C@@H](OC2=CC=C(CO)C=C2[N+](=O)[O-])[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1C.COC(=O)[C@H]1O[C@@H](OC2=CC=C(CO[Si](C)(C)C(C)(C)C)C=C2[N+](=O)[O-])[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1C.COC(=O)[C@H]1O[C@H](Br)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1C.O=CC1=CC([N+](=O)[O-])=C(O)C=C1.O=[Ag][Ag] Chemical compound C.C=CCOC(=O)O[C@H]1[C@H](C)[C@@H](C(=O)OCC=C)O[C@@H](OC2=CC=C(CO)C=C2[N+](=O)[O-])[C@@H]1OC(=O)OCC=C.C=CCOC(=O)O[C@H]1[C@H](C)[C@@H](C(=O)OCC=C)O[C@@H](OC2=CC=C(CO[Si](C)(C)C(C)(C)C)C=C2[N+](=O)[O-])[C@@H]1OC(=O)OCC=C.C=CCOC(=O)[C@H]1O[C@@H](OC2=CC=C(CO[Si](C)(C)C(C)(C)C)C=C2[N+](=O)[O-])[C@H](O)[C@@H](O)[C@@H]1O.CC(C)(C)[Si](C)(C)Cl.COC(=O)[C@H]1O[C@@H](OC2=CC=C(C=O)C=C2[N+](=O)[O-])[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1C.COC(=O)[C@H]1O[C@@H](OC2=CC=C(CO)C=C2[N+](=O)[O-])[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1C.COC(=O)[C@H]1O[C@@H](OC2=CC=C(CO[Si](C)(C)C(C)(C)C)C=C2[N+](=O)[O-])[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1C.COC(=O)[C@H]1O[C@H](Br)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1C.O=CC1=CC([N+](=O)[O-])=C(O)C=C1.O=[Ag][Ag] ALHWZNSKKPMQOS-LXXGYWCPSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- JDGLJKOSZVNKDN-JDVHKJFESA-N C=CCOC(=O)O[C@@H]1[C@@H](C(=O)OCC=C)O[C@@H](OC2=CC=C(COC(=O)N(C)CCCC(=O)O[C@H](C)[C@@H]3NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC4CCCCC4)OC3=O)C=C2[N+](=O)[O-])[C@H](C)[C@H]1OC(=O)OCC=C.C=CCOC(=O)O[C@H]1[C@H](C)[C@@H](C(=O)OCC=C)O[C@@H](OC2=CC=C(COC(=O)N(C)CCCC(=O)O)C=C2[N+](=O)[O-])[C@@H]1OC(=O)OCC=C.C=CCOC(=O)O[C@H]1[C@H](C)[C@@H](C(=O)OCC=C)O[C@@H](OC2=CC=C(COC(=O)OC3=CC=C([N+](=O)[O-])C=C3)C=C2[N+](=O)[O-])[C@@H]1OC(=O)OCC=C.CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC(=O)[C@H]([C@@H](C)OC(=O)CCCN(C)C(=O)OCC2=CC=C(O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)C([N+](=O)[O-])=C2)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC1=O Chemical compound C=CCOC(=O)O[C@@H]1[C@@H](C(=O)OCC=C)O[C@@H](OC2=CC=C(COC(=O)N(C)CCCC(=O)O[C@H](C)[C@@H]3NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC4CCCCC4)OC3=O)C=C2[N+](=O)[O-])[C@H](C)[C@H]1OC(=O)OCC=C.C=CCOC(=O)O[C@H]1[C@H](C)[C@@H](C(=O)OCC=C)O[C@@H](OC2=CC=C(COC(=O)N(C)CCCC(=O)O)C=C2[N+](=O)[O-])[C@@H]1OC(=O)OCC=C.C=CCOC(=O)O[C@H]1[C@H](C)[C@@H](C(=O)OCC=C)O[C@@H](OC2=CC=C(COC(=O)OC3=CC=C([N+](=O)[O-])C=C3)C=C2[N+](=O)[O-])[C@@H]1OC(=O)OCC=C.CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC(=O)[C@H]([C@@H](C)OC(=O)CCCN(C)C(=O)OCC2=CC=C(O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)C([N+](=O)[O-])=C2)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC1=O JDGLJKOSZVNKDN-JDVHKJFESA-N 0.000 description 1
- SQCGLJSXIPHNDK-VVHYTBNCSA-N CC(C)C[C@H](C(N[C@H](C(C)C)C(O[C@@H](C)C(N[C@@H](C(C)C)C(O[C@H](CC(C)C)C(N[C@H](C(C)C)C(O[C@@H](C)C(N[C@@H]([C@@H](C)OC(CCCN(C)C(OCc(cc1)cc([N+]([O-])=O)c1O[C@@H]([C@@H]([C@H]([C@@H]1O)O)O)O[C@@H]1C(O)=O)=O)=O)C(O[C@H](CC1CCCCC1)C(N[C@H](C(C)C)C(O[C@@H](C)C(N[C@H]1C(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)OC1=O Chemical compound CC(C)C[C@H](C(N[C@H](C(C)C)C(O[C@@H](C)C(N[C@@H](C(C)C)C(O[C@H](CC(C)C)C(N[C@H](C(C)C)C(O[C@@H](C)C(N[C@@H]([C@@H](C)OC(CCCN(C)C(OCc(cc1)cc([N+]([O-])=O)c1O[C@@H]([C@@H]([C@H]([C@@H]1O)O)O)O[C@@H]1C(O)=O)=O)=O)C(O[C@H](CC1CCCCC1)C(N[C@H](C(C)C)C(O[C@@H](C)C(N[C@H]1C(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)OC1=O SQCGLJSXIPHNDK-VVHYTBNCSA-N 0.000 description 1
- FHSDPTYOVWLZME-VNLLZONVSA-N CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC(=O)[C@H]([C@@H](C)OC(=O)CCCN(C)C(=O)OCC2=CC=C(O[C@@H]3C[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)C([N+](=O)[O-])=C2)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC1=O Chemical compound CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC(=O)[C@H]([C@@H](C)OC(=O)CCCN(C)C(=O)OCC2=CC=C(O[C@@H]3C[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)C([N+](=O)[O-])=C2)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC1=O FHSDPTYOVWLZME-VNLLZONVSA-N 0.000 description 1
- IPFDCDWGRQPWFN-WXPAKUCESA-N CC.CC.CC.CC.CC(=O)OC(C)(C)C.CC(C)C[C@@H](O)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C.CC(C)[C@@H](NC(=O)OC(C)(C)C)C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1.CO.CO[C@H](CC(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)O)C(C)C.CO[C@H](CC(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C.C[C@H](O)C(=O)OCC1=CC=CC=C1 Chemical compound CC.CC.CC.CC.CC(=O)OC(C)(C)C.CC(C)C[C@@H](O)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C.CC(C)[C@@H](NC(=O)OC(C)(C)C)C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1.CO.CO[C@H](CC(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)O)C(C)C.CO[C@H](CC(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C.C[C@H](O)C(=O)OCC1=CC=CC=C1 IPFDCDWGRQPWFN-WXPAKUCESA-N 0.000 description 1
- LMXUHYJFLSYFJL-WSAGPESFSA-N CC.CC.CC.CC.CC(C)C[C@@H](OC(=O)[C@@H](NC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)N[C@H](C(=O)O[C@H](CC(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C)C(C)C)C(C)C.CC(C)C[C@@H](OC(=O)[C@@H](NC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C.CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)CNC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC1=O.CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)CNC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC1=O.CO[C@H](CC(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)N[C@H](C(=O)O[C@H](CC(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)N[C@H](C(=O)O[C@H](CC(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C Chemical compound CC.CC.CC.CC.CC(C)C[C@@H](OC(=O)[C@@H](NC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)N[C@H](C(=O)O[C@H](CC(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C)C(C)C)C(C)C.CC(C)C[C@@H](OC(=O)[C@@H](NC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C.CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)CNC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC1=O.CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)CNC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC1=O.CO[C@H](CC(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)N[C@H](C(=O)O[C@H](CC(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)N[C@H](C(=O)O[C@H](CC(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C LMXUHYJFLSYFJL-WSAGPESFSA-N 0.000 description 1
- KTFIFVUZWMDIEE-OWIXYQASSA-N CC.CC.CC.CC.CC(C)C[C@@H](OC(=O)[C@@H](NC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)N[C@H](C(=O)O[C@H](CC(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C)C(C)C)C(C)C.CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)CNC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC1=O.CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)CNC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC1=O.CO[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)N[C@H](C(=O)O[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)N[C@H](C(=O)O[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C Chemical compound CC.CC.CC.CC.CC(C)C[C@@H](OC(=O)[C@@H](NC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)N[C@H](C(=O)O[C@H](CC(C)C)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C)C(C)C)C(C)C.CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)CNC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC1=O.CC(C)C[C@H]1OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)[C@H](C(C)C)CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)OC(=O)CNC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC1=O.CO[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)N[C@H](C(=O)O[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)N[C@H](C(=O)O[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C KTFIFVUZWMDIEE-OWIXYQASSA-N 0.000 description 1
- JNOSNWHWGGUKSY-RZFDAINGSA-N CC.CC.CC.CC.CC(C)[C@@H](NC(=O)OC(C)(C)C)C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1.CC(C)[C@@H](NC[C@H](O)CC1CCCCC1)C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1.CO.CO[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)O)C(C)C.CO[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C Chemical compound CC.CC.CC.CC.CC(C)[C@@H](NC(=O)OC(C)(C)C)C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1.CC(C)[C@@H](NC[C@H](O)CC1CCCCC1)C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1.CO.CO[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)O)C(C)C.CO[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C JNOSNWHWGGUKSY-RZFDAINGSA-N 0.000 description 1
- VNZQHVCZGLEETO-UQFJRDINSA-N CC.CC.CC.CC.CC(C)[C@@H]1CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC(=O)CNC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC(=O)[C@@H](CC2CCCCC2)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC1=O.CC(C)[C@@H]1CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC(=O)CNC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC(=O)[C@@H](CC2CCCCC2)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC1=O.CC(C)[C@H](NC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)O[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)N[C@H](C(=O)O[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C)C(C)C)C(C)C.CC(C)[C@H](NC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)O[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C.CO[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)N[C@H](C(=O)O[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)N[C@H](C(=O)O[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C Chemical compound CC.CC.CC.CC.CC(C)[C@@H]1CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC(=O)CNC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC(=O)[C@@H](CC2CCCCC2)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC1=O.CC(C)[C@@H]1CC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC(=O)CNC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)CC(=O)[C@@H](CC2CCCCC2)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC2CCCCC2)OC1=O.CC(C)[C@H](NC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)O[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)N[C@H](C(=O)O[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C)C(C)C)C(C)C.CC(C)[C@H](NC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)O[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C.CO[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)N[C@H](C(=O)O[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)N[C@H](C(=O)O[C@H](CC1CCCCC1)C(=O)N[C@@H](C(=O)O[C@@H](C)C(=O)OCC1=CC=CC=C1)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C VNZQHVCZGLEETO-UQFJRDINSA-N 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical compound NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- JMQMNWIBUCGUDO-UHFFFAOYSA-N L-Djenkolic acid Natural products OC(=O)C(N)CSCSCC(N)C(O)=O JMQMNWIBUCGUDO-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- JMQMNWIBUCGUDO-WHFBIAKZSA-N L-djenkolic acid Chemical compound OC(=O)[C@@H](N)CSCSC[C@H](N)C(O)=O JMQMNWIBUCGUDO-WHFBIAKZSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- DWPCPZJAHOETAG-IMJSIDKUSA-N L-lanthionine Chemical compound OC(=O)[C@@H](N)CSC[C@H](N)C(O)=O DWPCPZJAHOETAG-IMJSIDKUSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 1
- 108010065338 N-ethylglycine Proteins 0.000 description 1
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 1
- VDIPNVCWMXZNFY-UHFFFAOYSA-N N-methyl-beta-alanine Chemical compound CNCCC(O)=O VDIPNVCWMXZNFY-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241001291918 Solibacillus silvestris Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000037831 acute erythroleukemic leukemia Diseases 0.000 description 1
- 208000037832 acute lymphoblastic B-cell leukemia Diseases 0.000 description 1
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 description 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000012871 anti-fungal composition Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 238000002827 antifungal susceptibility testing Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- ZYTLPUIDJRKAAM-QMMMGPOBSA-N benzyl (2s)-2-hydroxypropanoate Chemical compound C[C@H](O)C(=O)OCC1=CC=CC=C1 ZYTLPUIDJRKAAM-QMMMGPOBSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- GICLSALZHXCILJ-UHFFFAOYSA-N ctk5a5089 Chemical group NCC(O)=O.NCC(O)=O GICLSALZHXCILJ-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- GCHPUFAZSONQIV-UHFFFAOYSA-N isovaline Chemical compound CCC(C)(N)C(O)=O GCHPUFAZSONQIV-UHFFFAOYSA-N 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- HHRZAEJMHSGZNP-UHFFFAOYSA-N mebanazine Chemical compound NNC(C)C1=CC=CC=C1 HHRZAEJMHSGZNP-UHFFFAOYSA-N 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 1
- DWPCPZJAHOETAG-UHFFFAOYSA-N meso-lanthionine Natural products OC(=O)C(N)CSCC(N)C(O)=O DWPCPZJAHOETAG-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000003308 potassium ionophore Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- CAEWJEXPFKNBQL-UHFFFAOYSA-N prop-2-enyl carbonochloridate Chemical compound ClC(=O)OCC=C CAEWJEXPFKNBQL-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000108 silver(I,III) oxide Inorganic materials 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 231100000338 sulforhodamine B assay Toxicity 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- Pettit et al. reported the isolation and structures of two very potent cancer cell growth inhibitors, cyclodepsipeptides designated bacillistatins 1 and 2 1.2 from Bacillus silvestris carried by a South Pacific (Chile) crab. Subsequently, Pettit et al. completed the total synthesis of bacillistatin 2. 2 Meanwhile, the promise of marine derived microorganisms as productive sources of new anticancer and antiproliferative drugs continues to expand.
- Recent examples includes discoveries of marine microorganisms containing small molecule cancer cell growth inhibitors, 3a-h antibiotics from bacteria, 4a-f antibiotics from fungi, 5a-f various inhibitors from cyanobacteria 6a-c and the increasing potential of deep-sea microorganisms.
- 7a-d Structurally, the bacillistatins are similar to valinomycin, a well-known antibiotic and cytotoxic cyclodepsipeptide that acts as a carrier-type potassium ionophore ( FIG. 1 ).
- Another cyclic depsipeptide that resembles the structures of valinomycin and bacillistatins is cereulide, a toxin isolated in 1995 from Bacillus cereus. 8
- the cancer cell growth inhibition values for these molecules are in the order of 10 ⁇ 4 -10 ⁇ 5 ⁇ g/mL which makes them good candidates as therapeutic agents for cancer treatment and specially when linked to monoclonal antibodies. That is a powerful technique to reduce side effects and increase selectivity as well as other targeting systems that allow the release of the drug, from a non-toxic precursor (prodrug), in the solid tumors microenvironment or inside the cancer cells.
- One of the major obstacles for this approach with the bacillistatins is the lack of easily derivatizable groups (e.g. —NH 2 , —SH, —OH, —COOH, etc) necessary for conjugation of these K + ionophores.
- the present disclosure relates to Silstatin compounds, pharmaceutical compositions comprising such compounds, kits, and methods for using such compounds or pharmaceutical compositions.
- the compounds of the present disclosure contain an easily derivatizable group for conjugation to monoclonal antibodies.
- the compounds have, or are believed to have, suitable cancer cell growth inhibition values and antibacterial activities.
- the present disclosure provides a compound of formula (I):
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are independently selected from —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl and —(C 2 -C 6 )alkynyl,
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are independently selected from —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl and —(C 2 -C 6 )alkynyl,
- FIG. 1 shows the structures of valinomycin, cereulide, bacillistatin 1 and bacillistatin 2.
- the invention includes the following:
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are independently selected from —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl and —(C 2 -C 6 )alkynyl,
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are independently selected from —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl and —(C 2 -C 6 )alkynyl,
- A is a Stretcher Unit
- a is or 1
- each —W— is independently an Amino Acid Unit
- w is an integer ranging from 0 to 12
- Y is a Spacer Unit
- y 0, 1 or 2.
- aa 1 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit.
- A is a Stretcher Unit
- a is 0 or 1
- each —W— is independently an Amino Acid Unit
- w is an integer ranging from 0 to 12
- Y is a Spacer Unit
- y 0, 1 or 2.
- aa 1 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit.
- A is a Stretcher Unit
- a is 0 or 1
- each —W— is independently an Amino Acid Unit
- w is an integer ranging from 0 to 12
- Y is a Spacer Unit
- y 0, 1 or 2.
- aa 1 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit.
- A is a Stretcher Unit
- a is 0 or 1
- each —W— is independently an Amino Acid Unit
- w is an integer ranging from 0 to 12
- Y is a Spacer Unit
- y 0, 1 or 2.
- aa 2 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit.
- A is a Stretcher Unit
- a is 0 or 1
- each —W— is independently an Amino Acid Unit
- w is an integer ranging from 0 to 12
- Y is a Spacer Unit
- y 0, 1 or 2.
- aa 2 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit.
- A is a Stretcher Unit
- a is 0 or 1
- each —W— is independently an Amino Acid Unit
- w is an integer ranging from 0 to 12
- Y is a Spacer Unit
- y 0, 1 or 2.
- aa 2 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit.
- A is a Stretcher Unit
- a is 0 or 1
- each —W— is independently an Amino Acid Unit
- w is an integer ranging from 0 to 12
- Y is a Spacer Unit
- y 0, 1 or 2.
- phrases “pharmaceutically acceptable salt,” as used herein, refers to pharmaceutically acceptable organic or inorganic salts of a compound of the disclosure.
- Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., 1,1′-methylene-bis-(2-hydroxy-3
- pharmaceutically acceptable carrier refers to a diluent, adjuvant or excipient, with which a compound of the disclosure may be administered.
- Pharmaceutically acceptable carriers include any and all solvents, diluents, or other liquid vehicles, dispersions or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
- Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof.
- any conventional carrier medium is incompatible with the compounds of the disclosure such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this disclosure.
- Examples of pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients
- the term “therapeutically effective amount” refers to an amount of a compound of the disclosure effective to treat a disease or disorder in a patient.
- the therapeutically effective amount of the compound may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer.
- the compound may inhibit the growth of and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic.
- efficacy can, for example, be measured by assessing the time to disease progression (TTP) and/or determining the response rate (RR).
- TTP time to disease progression
- RR response rate
- the therapeutically effect amount of the compound may reduce or inhibit the growth of bacteria or fungus.
- beneficial or desired results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, remission (whether partial or total), whether detectable or undetectable and prevention of relapse.
- Treatment can also include prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already having the condition or disorder as well as those prone to have the condition or disorder.
- treating includes any or all of inhibiting growth of tumor cells, cancer cells, or of a tumor; inhibiting replication of tumor cells or cancer cells, lessening of overall tumor burden or decreasing the number of cancerous cells, and ameliorating one or more symptoms associated with the disease.
- treating includes inhibiting the growth of bacteria or fungus, preventing the growth of bacteria or fungus and ameliorating one or more symptoms associated with the infection.
- patient includes, but is not limited to, a human, rat, mouse, guinea pig, monkey, pig, goat, cow, horse, dog, cat, bird and fowl. In some embodiments, the patient is a human.
- cancer and “cancerous” refer to or describe the physiological condition or disorder in mammals that is typically characterized by unregulated cell growth.
- a “tumor” comprises one or more cancerous cells.
- Exemplary cancers include, but not limited to, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer, ovarian cancer, prostate cancer, esophogeal cancer, stomach cancer, oral cancer, nasal cancer, throat cancer, central nervous system cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma,
- cytotoxic activity refers to a cell-killing, a cytostatic or an anti-proliferative effect of a compound of the disclosure. Methods for measuring cytotoxic activity are well-known in the art. Cytotoxic activity may be expressed as the IC 50 value, which is the concentration (molar or mass) per unit volume at which half the cells survive.
- (C 1 -C 6 )alkyl refers to saturated linear and branched hydrocarbon structures having 1, 2, 3, 4, 5, or 6 carbon atoms.
- alkyl residue having a specific number of carbons when named, all geometric isomers having that number of carbons are intended to be encompassed; thus, for example, “propyl” includes n-propyl and iso-propyl and “butyl” includes n-butyl, sec-butyl, iso-butyl and tert-butyl.
- Examples of (C 1 -C 6 )alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, tert-butyl, n-pentyl, n-hexyl, and the like.
- (C 1 -C 4 )alkyl refers to saturated linear and branched hydrocarbon structures having 1, 2, 3 or 4 carbon atoms.
- alkyl residue having a specific number of carbons When an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed; thus, for example, “propyl” includes n-propyl and iso-propyl and “butyl” includes n-butyl, sec-butyl, iso-butyl and tert-butyl.
- Examples of (C 1 -C 4 )alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, tert-butyl and the like.
- (C 1 -C 3 )alkyl refers to saturated linear and branched hydrocarbon structures having 1, 2 or 3 carbon atoms. When an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed; thus, for example, “propyl” includes n-propyl and iso-propyl. Examples of (C 1 -C 3 )alkyl groups include methyl, ethyl, n-propyl and iso-propyl.
- (C 2 -C 6 )alkenyl refers to a straight-chain or branched unsaturated hydrocarbon radical having 2, 3, 4, 5 or 6 carbon atoms and a double bond in any position, e.g., ethenyl, 1 propenyl, 2 propenyl (allyl), 1-butenyl, 2-butenyl, 3-butenyl, 1-methylethenyl, 1-methyl-1 propenyl, 2 methyl-2-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 2-methyl-2-pentenyl, 4-methyl-2-pentenyl, 4-methyl-1-pentenyl, 3-methyl-1-pentenyl, and the like.
- (C 2 -C 6 )alkynyl refers to a straight chain or branched hydrocarbon having 2, 3, 4, 5 or 6 carbon atoms and including at least one carbon-carbon triple bond.
- Examples of (C 2 -C 6 )alkynyls include ethynyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-methyl-2-pentynyl and the like.
- (C 6 -C 14 )aryl refers to a monovalent aromatic hydrocarbon group which may be monocyclic, bicyclic or tricyclic, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3, 4, 5, 6 or 7 ring members.
- Examples of (C 6 -C 14 )aryl groups include without limitation phenyl, naphthyl, indanyl, indenyl, tetralinyl, anthryl and phenanthryl.
- (5- or 6-membered)heteroaryl refers to a monocyclic aromatic heterocycle ring of 5 or 6 members, i.e., a monocyclic aromatic ring comprising at least one ring heteroatom, e.g., 1, 2, 3, or 4 ring heteroatoms, each independently selected from nitrogen, oxygen, and sulfur.
- a (5- or 6-membered)heteroaryl group can be attached to the parent structure through a carbon or heteroatom.
- Examples of (5- or 6-membered)heteroaryls include pyridyl, pyrrolyl, pyrazolyl, furyl, imidazolyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, 1,2,3 oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5 oxadiazolyl, 1,2,3-triazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidyl, pyrazinyl, 1,2,3 thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,5 triazinyl, and thiophenyl.
- (5-membered)heteroaryl refers to a monocyclic aromatic heterocycle ring of 5 members, i.e., a monocyclic aromatic ring comprising at least one ring heteroatom, e.g., 1, 2, 3, or 4 ring heteroatoms, each independently selected from nitrogen, oxygen, and sulfur.
- a (5-membered)heteroaryl group can be attached to the parent structure through a carbon or heteroatom.
- Examples of (5-membered)heteroaryls include pyrrolyl, pyrazolyl, furyl, imidazolyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, 1,2,3 oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5 oxadiazolyl, 1,2,3-triazolyl, pyrazolyl, isothiazolyl, 1,2,3 thiadiazolyl, 1,3,4-thiadiazolyl and 1,2,5-thiadiazolyl.
- (6-membered)heteroaryl refers to a monocyclic aromatic heterocycle ring of 6 members, i.e., a monocyclic aromatic ring comprising at least one ring heteroatom, e.g., 1, 2, 3, or 4 ring heteroatoms, each independently selected from nitrogen, oxygen, and sulfur.
- a (6-membered)heteroaryl group can be attached to the parent structure through a carbon or heteroatom.
- (6-membered)heteroaryls include pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, 1,3,5 triazinyl, and thiophenyl.
- 9- or 10-membered bicyclic heteroaryl refers to a bicyclic aromatic heterocycle ring of 9 or 10 members, i.e., a bicyclic aromatic ring comprising at least one ring heteroatom, e.g., 1, 2, 3, or 4 ring heteroatoms, each independently selected from nitrogen, oxygen, and sulfur.
- a (9- or 10-membered)heteroaryl group can be attached to the parent structure through a carbon or heteroatom.
- (9- or 10-membered)heteroaryl examples include benzofuran, benzothiophene, benzoxazole, benzothiazzole, indole, indazole, benzotriazole, benzoimidazole, quinolone, cinnoline, benzotriazine, quinazoline, quinoxaline and the like.
- (C 3 -C 7 )cycloalkyl refers to a saturated cyclic hydrocarbon containing 3, 4, 5, 6 or 7 ring carbon atoms.
- Examples of (C 3 -C 7 )cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
- (5- or 6-membered)heterocyclyl refers to a 5- or 6-membered, saturated or partially unsaturated, monocyclic-heterocycle containing 1, 2, or 3 ring heteroatoms, each independently selected from nitrogen, oxygen, and sulfur, wherein said nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
- Examples of “(5- or 6-membered)heterocyclyl groups include pyrrolidinyl, piperidinyl, piperazinyl, tetrahydro-oxazinyl, tetrahydrofuran, thiolane, dithiolane, pyrroline, pyrrolidine, pyrazoline, pyrazolidine, imidazoline, imidazolidine, tetrahydrofuranone, ⁇ -butyrolactone, 2H-pyran, 4H-pyran, dioxolane, tetrahydropyran, dioxane, dihydrothiophene, piperazine, morpholine, thiomorpholine, oxazine, tetrahydro-oxazinyl, and the like.
- (C 6 )heterocycloalkyl refers to a 6-membered, saturated or partially unsaturated, bridged, mono- or bicyclic-heterocycle containing 1, 2, or 3 ring heteroatoms each independently selected from nitrogen, oxygen, and sulfur, wherein said nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
- a heterocycloalkyl group can be attached to the parent structure through a carbon or heteroatom.
- Examples of (C6)heterocycloalkyl groups include piperidinyl, piperazinyl, tetrahydro-oxazinyl, tetrahydropyran, dioxane, morpholine, thiomorpholine, and the like.
- amino acid refers to both natural and unnatural amino acids.
- amino acids include alanine, ⁇ -alanine, N-methyl alanine, N-ethyl alanine, N-methyl- ⁇ -alanine, N-ethyl- ⁇ -alanine, arginine, asparagine, aspartic acid, cysteine, homocysteine, cystine, glutamic acid, glutamine, glycine, N-ethyl glycine, N-propyl glycine, N-isopropyl glycine, phenylalanine, 4-aminophenylalanine, 3-aminophenylalanine, 2-aminophenylalanine, histidine, isoleucine, alloisoleucine, lysine, ornithine, citrulline, leucine, norleucine, t-leucine, methionine, proline, pipecolic acid, serine, homos
- Protecting Group refers to any group that is capable of reversibly protecting another functional group from undergoing an undesired reaction. Suitable protecting groups, as well as suitable conditions for protection and deprotection are well-known in the art and are described e.g., in T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis”, Third edition, Wiley, New York 1999, and references cited therein.
- antibody as used herein includes whole antibodies, monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments that exhibit the desired biological activity.
- An antibody may be of any type or class (e.g., IgG, IgE, IgM, IgD, and IgA) or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2).
- the antibody may be derived from any suitable species.
- the antibody is of human or murine origin.
- An antibody may be, for example, human, humanized or chimeric.
- monoclonal antibodies refers to antibodies produced by a single clone of cells or cell line and comprising identical antibody molecules.
- polyclonal antibodies refers to antibodies produced by more than one type of cell or cell line and comprising different antibody molecules.
- a compound of the disclosure can contain one, two, or more asymmetric centers and thus can give rise to enantiomers, diastereomers, and other stereoisomeric forms.
- the disclosure encompasses compounds with all such possible forms, as well as their racemic and resolved forms or any mixture thereof, unless specifically otherwise indicated.
- a compound of the disclosure contains an olefinic double bond, a C ⁇ N double bond, or any other center of geometric asymmetry, it is intended to include all “geometric isomers”, e.g., both Z and E geometric isomers, unless specifically otherwise indicated.
- tautomers e.g., amine-imine, enamine-enimine, enamine-imine, urea-isourea, ketone-enol, amide-imidic acid, lactam-lactim, are intended to be encompassed by the disclosure as well unless specifically otherwise indicated.
- the present disclosure provides a compound of formula (I),
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are independently selected from —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl and —(C 2 -C 6 )alkynyl,
- the compound of formula (I) is conjugated directly or indirectly to an antibody. In one embodiment, the compound of formula (I) is conjugated directly to an antibody. In another embodiment, the compound of formula (I) is conjugated to an antibody through a Linker Unit. The compound may be conjugated to an antibody through a Linker Unit at aa 1 . The Linker Unit can operate to provide a suitable release of the compound of formula (I).
- the preparation of antibody drug conjugates is known to those of skill in the art.
- the Linker Unit may comprise a cleavable linker in one embodiment and a non-cleavable linker in another embodiment.
- the cleavable linker may be cleaved by methods known in the art.
- the cleavable linker may be cleaved by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage.
- the cleavage method is selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage.
- the cleavage method is selected from the group consisting of glycosidase-induced cleavage, peptidase-induced cleavage, and esterase-induced cleavage.
- the cleavage method is selected from glycosidase-induced cleavage or peptidase-induced cleavage.
- the cleavage method is selected from glycosidase-induced cleavage or esterase-induced cleavage. In another embodiment, the cleavage method is selected from peptidase-induced cleavage or esterase-induced cleavage.
- the cleavable linker may comprise a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond.
- the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, or an ester bond.
- the cleavable linker comprises a glycosidic bond, a hydrazone, or a cathepsin-B-cleavable peptide.
- the cleavable linker comprises a glycosidic bond, a hydrazone, or an ester bond. In one embodiment, the cleavable linker comprises a glycosidic bond, a cathepsin-B-cleavable peptide, or an ester bond. In one embodiment, the cleavable linker comprises a hydrazone, a cathepsin-B-cleavable peptide, or an ester bond.
- the cleavable linker comprises a glycosidic bond. In one embodiment, the cleavable linker comprises glucuronide.
- the compounds of formula (I) may be conjugated to any antibody, e.g., an antibody that binds to a tumor associated antigen.
- the antibody used in the antibody drug conjugate of the disclosure is a monoclonal antibody.
- the antibody used in the antibody drug conjugate of the disclosure binds at least one of CD19, CD20, CD30, CD33, CD70, BCMA, Glypican-3, Liv-1 and Lewis Y antigen.
- the Linker Unit is a bifunctional moiety that can be used to conjugate a compound of formula (I) to an antibody.
- Such bifuncitional moieties are known in the art and include, but are not limited to, alkyldiyl, an aryldiyl, a heteroaryldiyl, moieties such as: repeating units of alkyloxy (e.g., polyethylenoxy, PEG, polymethyleneoxy) and alkylamino (e.g., polyethyleneamino, JeffamineTM); and diacid ester and amides including succinate, succinamide, diglycolate, malonate, and caproamide. See, e.g., U.S. Pat. Nos. 6,214,345 and 7,745,394, the contents of both of which are incorporated by reference in their entireties.
- the Linker Unit is as described in U.S. Pat. Nos. 6,214,345 and 7,745,394 and has formula:
- A is a Stretcher Unit, a is 0 or 1, each —W— is independently an Amino Acid Unit, w is an integer ranging from 0 to 12,
- Y is a Spacer Unit
- y 0, 1 or 2.
- the Stretcher Unit (-A-), when present, is capable of linking an antibody to an Amino Acid Unit (—W—).
- the antibody has a functional group that can form a bond with a functional group of a Stretcher.
- Useful functional groups that can be present on an antibody, either naturally or via chemical manipulation include, but are not limited to, sulfhydryl, amino, hydroxyl, carboxy, the anomeric hydroxyl group of a carbohydrate, and carboxyl.
- the antibody functional groups are sulfhydryl and amino. Sulfhydryl groups can be generated by reduction of an intramolecular disulfide bond of an antibody.
- sulfhydryl groups can be generated by reaction of an amino group of a lysine moiety of an antibody using 2-iminothiolane (Traut's reagent) or another sulfhydryl generating reagent.
- W w — is a dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide, decapeptide, undecapeptide or dodecapeptide unit.
- the Amino Acid may be any amino acid.
- the Amino Acid Unit comprises natural amino acids.
- the Amino Acid Unit comprises non-natural amino acids.
- Suitable Spacer Units include, but are not limited to a glycine-glycine unit; a glycine unit; p-aminobenzyl alcohol (PAB) unit or aromatic compounds that are electronically similar to the PAB group such as 2-aminoimidazol-5-methanol derivatives (Hay et al. (1999) Bioorg. Med. Chem. Lett.
- PAB p-aminobenzyl alcohol
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 6 )alkyl. In some embodiments, at least two of R 1 , R 4 , and R 8 are (C 1 -C 6 )alkyl. In some embodiments, each of R 1 , R 4 , and R 8 is (C 1 -C 6 )alkyl. In some embodiments, at least one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl. In some embodiments, at least two of R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl. In some embodiments, at least one of R 1 , R 4 , and R 8 is (C 4 )alkyl. In some embodiments, at least two of R 1 , R 4 , and R 8 are (C 4 )alkyl. In some embodiments, each of R 1 , R 4 , and R 8 is (C 4 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 6 )alkyl substituted with (C 4 -C 7 )cycloalkyl. In some embodiments, at least two of R 1 , R 4 , and R 8 are (C 1 -C 6 )alkyl substituted with (C 4 -C 7 )cycloalkyl. In some embodiments, each of R 1 , R 4 , and R 8 is (C 1 -C 6 )alkyl substituted with (C 4 -C 7 )cycloalkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl. In some embodiments, at least two of R 1 , R 4 , and R 8 are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl. In some embodiments, each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 )alkyl substituted with (C 4 -C 7 )cycloalkyl. In some embodiments, at least two of R 1 , R 4 , and R 8 are (C 1 )alkyl substituted with (C 4 -C 7 )cycloalkyl. In some embodiments, each of R 1 , R 4 , and R 8 is (C 1 )alkyl substituted with (C 4 -C 7 )cycloalkyl. In some embodiments, at least one of R 1 , R 4 , and R 8 is (C 1 -C 6 )alkyl substituted with (C 6 )cycloalkyl.
- R 1 , R 4 , and R 8 are (C 1 -C 6 )alkyl substituted with (C 6 )cycloalkyl. In some embodiments, each of R 1 , R 4 , and R 8 is (C 1 -C 6 )alkyl substituted with (C 6 )cycloalkyl. In some embodiments, at least one of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 6 )cycloalkyl. In some embodiments, at least two of R 1 , R 4 , and R 8 are (C 1 -C 3 )alkyl substituted with (C 6 )cycloalkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 6 )cycloalkyl. In some embodiments, at least one of R 1 , R 4 , and R 8 is (C 1 )alkyl substituted with (C 6 )cycloalkyl. In some embodiments, at least two of R 1 , R 4 , and R 8 are (C 1 )alkyl substituted with (C 6 )cycloalkyl. In some embodiments, each of R 1 , R 4 , and R 8 is (C 1 )alkyl substituted with (C 6 )cycloalkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 6 )alkyl or (C 1 -C 6 )alkyl substituted with (C 4 -C 7 )cycloalkyl.
- one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and the others are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl.
- two of R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and the other is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl. In another embodiment, each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl.
- each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl. In some embodiments, each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl. In some embodiments, each of R 3 , R 6 , and R 10 is (C 1 )alkyl.
- each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl. In some embodiments, each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H. In some embodiments, at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 -C 6 )alkyl and the other are H.
- At least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 -C 3 )alkyl and the other are H. In some embodiments, at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- aa 1 is a natural amino acid. In other embodiments, aa 1 is an unnatural amino acid. In some embodiments, aa 1 comprises a functional group selected from —NH 2 , —SH, —OH or —COOH. In some embodiments, aa 1 comprises —NH 2 . In some embodiments, aa 1 comprises —SH. In some embodiments, aa 1 comprises —OH. In some embodiments, aa 1 comprises —COOH. In some embodiments, aa 1 is valine. In other embodiments, aa 1 is threonine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 1 is threonine.
- aa 1 is threonine substituted with a Protecting Group. In other embodiments, aa 1 is threonine substituted with a Linking Unit. In other embodiments, aa 1 is tyrosine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 1 is tyrosine. In other embodiments, aa 1 is tyrosine substituted with a Protecting Group. In other embodiments, aa 1 is tyrosine substituted with a Linking Unit. In some embodiments, aa 1 is 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- aa 1 is 4-aminophenylalanine. In other embodiments, aa 1 is 4-aminophenylalanine substituted with a Protecting Group. In other embodiments, aa 1 is 4-aminophenylalanine substituted with a Linking Unit. In some embodiments, aa 1 is 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 1 is 3-aminophenylalanine. In other embodiments, aa 1 is 3-aminophenylalanine substituted with a Protecting Group. In other embodiments, aa 1 is 3-aminophenylalanine substituted with a Linking Unit.
- aa 1 is 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 1 is 2-aminophenylalanine. In other embodiments, aa 1 is 2-aminophenylalanine substituted with a Protecting Group. In other embodiments, aa 1 is 2-aminophenylalanine substituted with a Linking Unit.
- the Linking Unit comprises a cleavable linker.
- the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage.
- the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond.
- the cleavable linker comprises glucuronide.
- a a is maleimidocaproyl.
- W w is Valine-Citrulline.
- Y y is p-aminobenzyloxycarbonyl.
- a a is maleimidocaproyl
- W w is Valine-Citrulline
- Y y is p-aminobenzyloxycarbonyl.
- the Linking Unit comprises a monoclonal antibody.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl. In one embodiment, at least two of R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- at least one of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- R 1 , R 4 , and R 8 are (C 4 )alkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl. In another embodiment, at least two of R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl. In another embodiment, each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl. In another embodiment, at least two of R 1 , R 4 , and R 8 are (C 4 )alkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl. In another embodiment, each of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of R 3 , R 6 , and R 10 is (C 1 )alkyl. In another embodiment, at least two of R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and each of R 3 , R 6 , and R 10 is (C 1 )alkyl. In another embodiment, each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of R 3 , R 6 , and R 10 is (C 1 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of R 3 , R 6 , and R 10 is (C 1 )alkyl. In another embodiment, at least two of R 1 , R 4 , and R 8 are (C 4 )alkyl and each of R 3 , R 6 , and R 10 is (C 1 )alkyl. In another embodiment, each of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of R 3 , R 6 , and R 10 is (C 1 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl.
- at least two of R 1 , R 4 , and R 8 are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl.
- at least two of R 1 , R 4 , and R 8 are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 3 , R 6 , and R 10 is (C 1 )alkyl.
- at least two of R 1 , R 4 , and R 8 are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 3 , R 6 , and R 10 is (C 1 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 3 , R 6 , and R 10 is (C 1 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl or (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and the other two are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 6 )alkyl.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and the other is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl or (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl.
- one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and the other two are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and the other is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl.
- R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl or (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 3 , R 6 , and R 10 is (C 1 )alkyl.
- one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and the other two are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 3 , R 6 , and R 10 is (C 1 )alkyl.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and the other is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 3 , R 6 , and R 10 is (C 1 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of R 3 , R 6 , and R 10 is (C 1 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 3 , R 6 , and R 10 is (C 1 )alkyl.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl. In another embodiment, at least two of R 1 , R 4 , and R 8 are (C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- at least one of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- R 1 , R 4 , and R 8 are (C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H. In another embodiment, each of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- At least one of R 1 , R 4 , and R 8 is (C 4 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- at least two of R 1 , R 4 , and R 8 are (C 4 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- each of R 1 , R 4 , and R 8 is (C 4 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- at least two of R 1 , R 4 , and R 8 are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- at least two of R 1 , R 4 , and R 8 are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- at least two of R 1 , R 4 , and R 8 are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C)alkyl and the other are H.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl or (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and the other two are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and the other is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl or (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl 1 and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and the other two are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and the other is (C 1 -C 6 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl or (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and the other two are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and the other is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- each of R 3 , R 6 , and R 10 is (C 1 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- each of R 3 , R 6 , and R 10 is (C 1 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- each of R 3 , R 6 , and R 10 is (C 1 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- At least one of R 1 , R 4 , and R 8 is (C 4 )alkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- R 1 , R 4 , and R 8 are (C 4 )alkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of R 1 , R 4 , and R 8 is (C 4 )alkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- R 1 , R 4 , and R 8 are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl or (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and the other two are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- two of R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and the other is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of R 3 , R 6 , and R 10 is (C 1 )alkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- At least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- the present disclosure provides a compound has formula (Ia):
- aa 1 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit.
- aa 1 is valine. In other embodiments, aa 1 is threonine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 1 is threonine. In other embodiments, aa 1 is threonine substituted with a Protecting Group. In other embodiments, aa 1 is threonine substituted with a Linking Unit. In other embodiments, aa 1 is tyrosine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 1 is tyrosine. In other embodiments, aa 1 is tyrosine substituted with a Protecting Group. In other embodiments, aa 1 is tyrosine substituted with a Linking Unit.
- the Linking Unit comprises a cleavable linker.
- the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage.
- the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond.
- the cleavable linker comprises glucuronide.
- a a is maleimidocaproyl.
- W w is Valine-Citrulline.
- Y y is p-aminobenzyloxycarbonyl.
- a a is maleimidocaproyl
- W w is Valine-Citrulline
- Y y is p-aminobenzyloxycarbonyl.
- the Linking Unit comprises a monoclonal antibody.
- the present disclosure provides a compound has formula (Ib):
- aa 1 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit.
- aa 1 is valine. In other embodiments, aa 1 is threonine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 1 is threonine. In other embodiments, aa 1 is threonine substituted with a Protecting Group. In other embodiments, aa 1 is threonine substituted with a Linking Unit. In other embodiments, aa 1 is tyrosine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 1 is tyrosine. In other embodiments, aa 1 is tyrosine substituted with a Protecting Group. In other embodiments, aa 1 is tyrosine substituted with a Linking Unit.
- the Linking Unit comprises a cleavable linker.
- the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage.
- the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond.
- the cleavable linker comprises glucuronide.
- a a is maleimidocaproyl.
- W w is Valine-Citrulline.
- Y y is p-aminobenzyloxycarbonyl.
- a a is maleimidocaproyl
- W w is Valine-Citrulline
- Y y is p-aminobenzyloxycarbonyl.
- the Linking Unit comprises a monoclonal antibody.
- the present disclosure provides a compound has formula (Ic):
- aa 1 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit.
- aa 1 is valine. In other embodiments, aa 1 is threonine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 1 is threonine. In other embodiments, aa 1 is threonine substituted with a Protecting Group. In other embodiments, aa 1 is threonine substituted with a Linking Unit. In other embodiments, aa 1 is tyrosine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 1 is tyrosine. In other embodiments, aa 1 is tyrosine substituted with a Protecting Group. In other embodiments, aa 1 is tyrosine substituted with a Linking Unit.
- the Linking Unit comprises a cleavable linker.
- the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage.
- the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond.
- the cleavable linker comprises glucuronide.
- a a is maleimidocaproyl.
- W w is Valine-Citrulline.
- Y y is p-aminobenzyloxycarbonyl.
- a a is maleimidocaproyl
- W w is Valine-Citrulline
- Y y is p-aninobenzyloxycarbonyl.
- the Linking Unit comprises a monoclonal antibody.
- the present disclosure provides a compound of formula (II),
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are independently selected from —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl and —(C 2 -C 6 )alkynyl,
- the Linker Unit is as defined for Compound of Formula (I).
- the compound of formula (II) is conjugated directly or indirectly to an antibody. In one embodiment, the compound of formula (II) is conjugated directly to an antibody. In another embodiment, the compound of formula (II) is conjugated to an antibody through a Linker Unit. The compound may be conjugated to an antibody through a Linker Unit at aa 1 . The Linker Unit can operate to provide a suitable release of the compound of formula (II).
- the preparation of antibody drug conjugates is known to those of skill in the art.
- the compounds of formula (II) may be conjugated to any antibody, e.g., an antibody that binds to a tumor associated antigen.
- the antibody used in the antibody drug conjugate of the disclosure is a monoclonal antibody.
- the antibody used in the antibody drug conjugate of the disclosure binds at least one of CD19, CD20, CD30, CD33, CD70, BCMA, Glypican-3, Liv-1 and Lewis Y antigen.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 6 )alkyl. In some embodiments, at least two of R 1 , R 4 , and R 8 are (C 1 -C 6 )alkyl. In some embodiments, each of R 1 , R 4 , and R 8 is (C 1 -C 6 )alkyl. In some embodiments, at least one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl. In some embodiments, at least two of R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl. In some embodiments, at least one of R 1 , R 4 , and R 8 is (C 4 )alkyl. In some embodiments, at least two of R 1 , R 4 , and R 8 are (C 4 )alkyl. In some embodiments, each of R 1 , R 4 , and R 8 is (C 4 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 6 )alkyl substituted with (C 4 -C 7 )cycloalkyl. In some embodiments, at least two of R 1 , R 4 , and R 8 are (C 1 -C 6 )alkyl substituted with (C 4 -C 7 )cycloalkyl. In some embodiments, each of R 1 , R 4 , and R 8 is (C 1 -C 6 )alkyl substituted with (C 4 -C 7 )cycloalkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl. In some embodiments, at least two of R 1 , R 4 , and R 8 are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl. In some embodiments, each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 )alkyl substituted with (C 4 -C 7 )cycloalkyl. In some embodiments, at least two of R 1 , R 4 , and R 8 are (C 1 )alkyl substituted with (C 4 -C 7 )cycloalkyl. In some embodiments, each of R 1 , R 4 , and R 8 is (C 1 )alkyl substituted with (C 4 -C 7 )cycloalkyl. In some embodiments, at least one of R 1 , R 4 , and R 8 is (C 1 -C 6 )alkyl substituted with (C 6 )cycloalkyl.
- R 1 , R 4 , and R 8 are (C 1 -C 6 )alkyl substituted with (C 6 )cycloalkyl. In some embodiments, each of R 1 , R 4 , and R 8 is (C 1 -C 6 )alkyl substituted with (C 6 )cycloalkyl. In some embodiments, at least one of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 6 )cycloalkyl. In some embodiments, at least two of R 1 , R 4 , and R 8 are (C 1 -C 3 )alkyl substituted with (C 6 )cycloalkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 6 )cycloalkyl. In some embodiments, at least one of R 1 , R 4 , and R 8 is (C 1 )alkyl substituted with (C 6 )cycloalkyl. In some embodiments, at least two of R 1 , R 4 , and R 8 are (C 1 )alkyl substituted with (C 6 )cycloalkyl. In some embodiments, each of R 1 , R 4 , and R 8 is (C 1 )alkyl substituted with (C 6 )cycloalkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 6 )alkyl or (C 1 -C 6 )alkyl substituted with (C 4 -C 7 )cycloalkyl.
- one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and the other two are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and the other is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl.
- each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl. In some embodiments, each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 3 )alkyl. In some embodiments, each of R 3 , R 6 , and R 10 is (C 1 )alkyl.
- each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl. In some embodiments, each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H. In some embodiments, at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 -C 6 )alkyl and the other are H.
- At least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 -C 3 )alkyl and the other are H. In some embodiments, at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- aa 2 is a natural amino acid. In other embodiments, aa 2 is an unnatural amino acid. In some embodiments, aa 2 comprises a functional group selected from —NH 2 , —SH, —OH or —COOH. In some embodiments, aa 1 comprises —NH 2 . In some embodiments, aa 1 comprises —SH. In some embodiments, aa 1 comprises —OH. In some embodiments, aa 1 comprises —COOH. In some embodiments, aa 2 is valine. In other embodiments, aa 2 is threonine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 2 is threonine.
- aa 2 is threonine substituted with a Protecting Group. In other embodiments, aa 2 is threonine substituted with a Linking Unit. In other embodiments, aa 2 is tyrosine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 2 is tyrosine. In other embodiments, aa 2 is tyrosine substituted with a Protecting Group. In other embodiments, aa 2 is tyrosine substituted with a Linking Unit. In some embodiments, aa 2 is 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- aa 2 is 4-aminophenylalanine. In other embodiments, aa 2 is 4-aminophenylalanine substituted with a Protecting Group. In other embodiments, aa 2 is 4-aminophenylalanine substituted with a Linking Unit. In some embodiments, aa 2 is 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 2 is 3-aminophenylalanine. In other embodiments, aa 2 is 3-aminophenylalanine substituted with a Protecting Group. In other embodiments, aa 2 is 3-aminophenylalanine substituted with a Linking Unit.
- aa 2 is 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 2 is 2-aminophenylalanine. In other embodiments, aa 2 is 2-aminophenylalanine substituted with a Protecting Group. In other embodiments, aa 2 is 2-aminophenylalanine substituted with a Linking Unit.
- the Linking Unit comprises a cleavable linker.
- the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage.
- the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond.
- the cleavable linker comprises glucuronide.
- a a is maleimidocaproyl.
- W w is Valine-Citrulline.
- Y y is p-aminobenzyloxycarbonyl.
- a a is maleimidocaproyl
- W w is Valine-Citrulline
- Y y is p-aminobenzyloxycarbonyl.
- the Linking Unit comprises a monoclonal antibody.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl. In one embodiment, at least two of R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- at least one of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- R 1 , R 4 , and R 8 are (C 4 )alkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl. In another embodiment, at least two of R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and each of R 2 , R 1 , R 7 , R 9 , and R 11 is (C 1 )alkyl. In another embodiment, each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl. In another embodiment, at least two of R 1 , R 4 , and R 8 are (C 4 )alkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl. In another embodiment, each of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of R 3 , R 6 , and R 10 is (C 3 )alkyl. In another embodiment, at least two of R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and each of R 3 , R 6 , and R 10 is (C 3 )alkyl. In another embodiment, each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of R 3 , R 6 , and R 10 is (C 3 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of R 3 , R 6 , and R 10 is (C 3 )alkyl. In another embodiment, at least two of R 1 , R 4 , and R 8 are (C 4 )alkyl and each of R 3 , R 6 , and R 10 is (C 3 )alkyl. In another embodiment, each of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of R 3 , R 6 , and R 10 is (C 3 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl.
- at least two of R 1 , R 4 , and R 8 are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl.
- at least two of R 1 , R 4 , and R 8 are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 3 , R 6 , and R 10 is (C 3 )alkyl.
- at least two of R 1 , R 4 , and R 8 are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 3 , R 6 , and R 10 is (C 3 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 3 , R 6 , and R 10 is (C 3 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl or (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and the other two are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and the other is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl.
- R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl or (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl.
- one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and the other two are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and the other is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl.
- R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl or (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 3 , R 6 , and R 10 is (C 3 )alkyl.
- one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and the other two are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 3 , R 6 , and R 10 is (C 3 )alkyl.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and the other is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 3 , R 6 , and R 10 is (C 3 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of R 3 , R 6 , and R 10 is (C 3 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of R 3 , R 6 , and R 10 is (C 3 )alkyl.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl. In another embodiment, at least two of R 1 , R 4 , and R 8 are (C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- at least one of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- R 1 , R 4 , and R 8 are (C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H. In another embodiment, each of R 1 , R 4 , and R 8 is (C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- At least one of R 1 , R 4 , and R 8 is (C 4 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- at least two of R 1 , R 4 , and R 8 are (C 4 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- each of R 1 , R 4 , and R 8 is (C 4 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 6 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- at least two of R 1 , R 4 , and R 8 are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- at least two of R 1 , R 4 , and R 8 are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 6 )alkyl substituted with (C 4 -C 7 )cycloalkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- at least two of R 1 , R 4 , and R 8 are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C)alkyl and the other are H.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl or (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and the other two are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and the other is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl or (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl 1 and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and the other two are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and the other is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl or (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and the other two are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and the other is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- each of R 3 , R 6 , and R 10 is (C 3 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl.
- each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- each of R 3 , R 6 , and R 10 is (C 3 )alkyl and each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H.
- each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl and at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H.
- R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- At least one of R 1 , R 4 , and R 8 is (C 4 )alkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- R 1 , R 4 , and R 8 are (C 4 )alkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of R 1 , R 4 , and R 8 is (C 4 )alkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- R 1 , R 4 , and R 8 are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of R 1 , R 4 , and R 8 is (C 1 -C 6 )alkyl substituted with (C 4 -C 7 )cycloalkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- At least one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl or (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- one of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl and the other two are (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- two of R 1 , R 4 , and R 8 are (C 1 -C 4 )alkyl and the other is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of R 1 , R 4 , and R 8 is (C 1 -C 4 )alkyl aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of R 1 , R 4 , and R 8 is (C 1 -C 3 )alkyl substituted with (C 4 -C 7 )cycloalkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of R 2 , R 3 , R 5 , R 6 , R 7 , R 9 , R 10 and R 11 is independently (C 1 -C 3 )alkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of R 2 , R 5 , R 7 , R 9 , and R 11 is (C 1 )alkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of R 3 , R 6 , and R 10 is (C 3 )alkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is independently H or (C 1 -C 6 )alkyl and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- each of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is H and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- At least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is (C 1 )alkyl and the other are H and aa 1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- the present disclosure provides a compound of formula (Ia):
- aa 2 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit.
- aa 2 is valine. In other embodiments, aa 2 is threonine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 2 is threonine. In other embodiments, aa 2 is threonine substituted with a Protecting Group. In other embodiments, aa 2 is threonine substituted with a Linking Unit. In other embodiments, aa 2 is tyrosine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 2 is tyrosine. In other embodiments, aa 2 is tyrosine substituted with a Protecting Group. In other embodiments, aa 2 is tyrosine substituted with a Linking Unit.
- the Linking Unit comprises a cleavable linker.
- the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage.
- the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond.
- the cleavable linker comprises glucuronide.
- a a is maleimidocaproyl.
- W w is Valine-Citrulline.
- Y y is p-aminobenzyloxycarbonyl.
- a a is maleimidocaproyl
- W w is Valine-Citrulline
- Y y is p-aminobenzyloxycarbonyl.
- the Linking Unit comprises a monoclonal antibody.
- the present disclosure provides a compound of formula (IIb):
- aa 2 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit.
- aa 2 is valine. In other embodiments, aa 2 is threonine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 2 is threonine. In other embodiments, aa 2 is threonine substituted with a Protecting Group. In other embodiments, aa 2 is threonine substituted with a Linking Unit. In other embodiments, aa 2 is tyrosine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 2 is tyrosine. In other embodiments, aa 2 is tyrosine substituted with a Protecting Group. In other embodiments, aa 2 is tyrosine substituted with a Linking Unit.
- the Linking Unit comprises a cleavable linker.
- the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage.
- the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond.
- the cleavable linker comprises glucuronide.
- a a is maleimidocaproyl.
- W w is Valine-Citrulline.
- Y y is p-aminobenzyloxycarbonyl.
- a a is maleimidocaproyl
- W w is Valine-Citrulline
- Y y is p-aminobenzyloxycarbonyl.
- the Linking Unit comprises a monoclonal antibody.
- the present disclosure provides a compound of formula (IIc):
- aa 2 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit.
- aa 2 is valine. In other embodiments, aa 2 is threonine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 2 is threonine. In other embodiments, aa 2 is threonine substituted with a Protecting Group. In other embodiments, aa 2 is threonine substituted with a Linking Unit. In other embodiments, aa 2 is tyrosine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa 2 is tyrosine. In other embodiments, aa 2 is tyrosine substituted with a Protecting Group. In other embodiments, aa 2 is tyrosine substituted with a Linking Unit.
- the Linking Unit comprises a cleavable linker.
- the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage.
- the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond.
- the cleavable linker comprises glucuronide.
- a a is maleimidocaproyl.
- W w is Valine-Citrulline.
- Y y is p-aminobenzyloxycarbonyl.
- a a is maleimidocaproyl
- W w is Valine-Citrulline
- Y y is p-aninobenzyloxycarbonyl.
- the Linking Unit comprises a monoclonal antibody.
- Representative compounds of formulae (I) and (II) include:
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- compositions of the disclosure may be formulated for administration in solid or liquid form, including those adapted for administration by oral, nasal, parenteral, rectal, topical, ocular, inhalation and intra-tumor administration.
- Parenteral administration includes subcutaneous injections, intravenous, intramuscular or intrasternal injection or infusion techniques.
- the compositions are administered parenterally.
- the compositions are administered intravenously.
- the pharmaceutical composition of the disclosure may be in the form of a liquid, e.g., a solution, emulsion or suspension, pellets, powders, sustained-release formulations, or any other form suitable for use.
- the pharmaceutical composition may comprise sterile diluents such as water, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono- or digylcerides, which can serve as the solvent or suspending medium, polyethylene glycols, glycerin, cyclodextrin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates, phosphates or amino acids; agents for the adjustment of tonicity such as sodium chloride or dextrose; surfactants; preservatives
- a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the type of patient (e.g., human), the activity of the specific compound employed, the composition employed, the manner of administration, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the nature and the severity of the particular disorder being treated.
- the amount of active ingredients will also depend upon the particular compound in the composition. The amount of active ingredient can be determined by standard clinical techniques. In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges.
- the compositions are formulated so that a dosage of between about 0.01 to about 20 mg/kg body weight/day of the compound of formula (I) can be administered to a patient receiving the composition.
- the dosage administered to the patient is between about 0.01 mg/kg and about 10 mg/kg of the patient's body weight.
- the dosage administered to the patient is between about 0.1 mg/kg and about 10 mg/kg of the patient's body weight.
- the dosage administered to the patient is between about 0.1 mg/kg and about 5 mg/kg of the patient's body weight.
- the dosage administered is between about 0.1 mg/kg and about 3 mg/kg of the patient's body weight.
- the dosage administered is between about 1 mg/kg and about 3 mg/kg of the patient's body weight.
- compositions comprise an effective amount of a compound described herein such that a suitable dosage will be obtained. Typically, this amount is at least about 0.01% of a compound by weight of the composition. In a preferred embodiment, pharmaceutical compositions are prepared so that a parenteral dosage unit contains from about 0.01% to about 2% by weight of the compound of the disclosure.
- the pharmaceutical composition may comprise from about 0.01 to about 100 mg of a compound described herein per kg of the patient's body weight. In one aspect, the composition may include from about 1 to about 100 mg of a compound described herein per kg of the patient's body weight. In another aspect, the amount administered will be in the range from about 0.1 to about 25 mg of a compound described herein per kg of body weight.
- compositions of the present disclosure may optionally further comprise a second therapeutic agent in a therapeutically effective amount.
- the second therapeutic agent includes those that are known and those discovered to be effective in the reatment of cancer, a bacterial infection or a fungal infection.
- the second therapeutic agent is selected from the group consisting of a tubulin-forming inhibitor, a topoisomerase inhibitor, and a DNA binder.
- the present disclosure also provides methods of using the compounds described herein or pharmaceutical compositions thereof.
- the compounds and compositions are useful for killing or inhibiting the proliferation of tumor cells or cancer cells.
- the compounds and compositions are also useful for treating cancer in a patient.
- the compounds and compositions are useful for inhibiting bacterial or fungal growth.
- the compounds and compositions are useful in treating a bacterial or fungal infection in a patient.
- the present disclosure provides methods of killing or inhibiting the proliferation of tumor cells or cancer cells.
- the method comprises contacting the tumor cells or cancer cells with a compound described herein, or a pharmaceutically acceptable salt thereof, in an amount effective to kill or inhibit the proliferation of the tumor cells or cancer cells.
- the method comprises contacting the tumor cells or cancer cells with a pharmaceutical composition comprising a compound described herein in an amount effective to kill or inhibit the proliferation of the tumor cells or cancer cells.
- the method further comprises contacting the cells with an effective amount of a second therapeutic agent or a pharmaceutical composition thereof.
- the second therapeutic agent can be selected from the group consisting of a tubulin-forming inhibitor, a topoisomerase inhibitor, and a DNA binder.
- the cells may be contacted with the compound described herein and the second therapeutic agent simultaneously in either the same or different compositions or sequentially in any order.
- the amounts of compound described herein and the second therapeutic agent and the relative timings of their contact will be selected in order to achieve the desired combined effect.
- the present disclosure provides a method of determining inhibition of cellular proliferation by a compound described herein.
- the method comprises contacting cells in a cell culture medium with the compound described herein and measuring the cytotoxic activity of the compound, whereby proliferation of the cells is inhibited.
- the method further comprises culturing the cells for a period from about 6 hours to about 5 days.
- Suitable cell lines are known to those skilled in the art and include those used for evaluating other anti-cancer drugs.
- Such cell lines include, but are not limited to, 786-O (a renal cell carcinoma); Caki-1 (a renal cell carcinoma): L428 (Hodgkin's disease); UMRC-3 (renal cell carcinoma); LP-1 (human myeloma); U251 (glioblastoma cell line); BXPC-3 (pancreas); MCF-7 (breast); SF-268 (CNS); NCI-H460 (lung); KM20L2 (colon); and DU-145 (prostate).
- the cells are obtained from a patient having a disease to be treated (e.g., cancer) or from a relevant cell line.
- the present disclosure provides a method of measuring cell viability in the presence of a compound described herein.
- the method comprises contacting cells in a cell culture medium with the compound of described herein, culturing the cells for a period from about 6 hours to about 5 days, preferably 96 hours; and measuring cell viability.
- the cells are obtained from a patient having a disease to be treated (e.g., cancer) or from a relevant cell line.
- the present disclosure provides a method for treating cancer in a patient.
- the method comprises administering to the patient a compound described herein, or a pharmaceutically acceptable salt thereof, in an amount effective to treat cancer.
- the method comprises administering to the patient a composition comprising a compound described herein in an amount effective to treat cancer.
- the patient receives an additional treatment, such as radiation therapy, surgery, chemotherapy with another chemotherapeutic agent or combinations thereof.
- an additional treatment such as radiation therapy, surgery, chemotherapy with another chemotherapeutic agent or combinations thereof.
- the compound of the disclosure is administered concurrently with the chemotherapeutic agent or with radiation therapy or with surgery.
- the chemotherapeutic agent or radiation therapy or surgery is administered or performed prior or subsequent to administration of a compound of the disclosure.
- the method for treating cancer further comprises administering to the patient an effective amount of a second therapeutic agent, e.g., a chemotherapeutic agent.
- a second therapeutic agent e.g., a chemotherapeutic agent.
- chemotherapeutic agents such as a standard of care chemotherapeutic agent(s)
- the chemotherapeutic agent may be selected from the group consisting of a tubulin-forming inhibitor, a topoisomerase inhibitor, and a DNA binder.
- the compound described herein and the chemotherapeutic agent may be administered simultaneously in either the same or different pharmaceutical composition or sequentially in any order.
- the amounts of compound described herein and the chemotherapeutic agent and the relative timings of their administration will be selected in order to achieve the desired combined effect.
- the present disclosure provides a method of inhibiting the growth of tumor cells that overexpress a tumor-associated antigen in a patient.
- the method comprises administering to the patient a compound described herein conjugated to an antibody that is specific for said tumor-associated antigen, wherein the compound described herein is administered in amount effective to inhibit growth of tumor cells in the patient.
- the method comprises administering to the patient a pharmaceutical composition comprising a compound described herein conjugated to an antibody that is specific for said tumor-associated antigen, wherein the compound described herein is administered in amount effective to inhibit growth of tumor cells in the patient.
- the method may optionally further comprises administering to the patient a chemotherapeutic agent, or a pharmaceutical composition thereof, in an amount effective to inhibit the growth of tumor cells in the patient.
- the compound sensitizes the tumor cells to the chemotherapeutic agent.
- the compound induces cell death. In other embodiments, the compound induces apoptosis.
- the tumor cells are associated with a cancer selected from the group consisting of breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon, colorectal, thyroid, pancreatic, prostate, central nervous system and bladder cancer.
- the compound described herein is conjugated to an antibody selected from the group consisting of CD19, CD20, CD30, CD33, CD70, BCMA, Glypican-3, Liv-1 and Lewis Y.
- the present disclosure provides methods of inhibiting bacterial or fungal growth in a sample.
- the method comprises contacting the sample with a compound described herein, or a pharmaceutically acceptable salt thereof, in an amount effective to inhibit growth of bacteria or fungus in the sample.
- the method comprises contacting the sample with a pharmaceutical composition comprising a compound described herein in an amount effective to inhibit the growth of bacteria or fungus in the sample.
- the present disclosure provides methods of treating a bacterial or fungal infection in a patient.
- the method comprises administering to the patient a compound described herein, or a pharmaceutically acceptable salt thereof, in an amount effective to treat the bacterial or fungal infection.
- the method comprises administering to the patient a composition comprising a compound described herein in an amount effective to the bacterial or fungal infection.
- the compounds of the present disclosure may be used in methods for inhibiting bacterial or fungal growth and in methods for treating bacterial or fungal infections.
- the compounds are used in a method for inhibiting bacterial growth in one embodiment, in a method for treating a bacterial infection in a second embodiment, in a method for inhibiting fungal growth in a third embodiment, and in a method for treating a fungal infection in a four embodiment.
- the bacteria is selected from gram-negative bacteria or gram-positive bacteria.
- the bacteria or fungi is selected from vancomycin-resistant Enterococcus faecalis, Staphylococcus aureus , methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae , multi-drug-resistant Streptococcus pneumoniae, Streptococcus pyogenes, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Cryptococcus neoformans and Candida albicans .
- the bacteria is Streptococcus pneumoniae (including a penicillin-resistant strain and a multi-drug resistant strain) or Streptococcus pyogenes.
- the method for treating a bacterial or fungal infection further comprises administering to the patient an effective amount of a second therapeutic agent.
- a second therapeutic agent such as a standard of care therapeutic agent(s) for bacterial or fungal infections, can be administered.
- the compound described herein is administered to a patient in a composition comprising a pharmaceutically acceptable carrier.
- the composition is administered intravenously.
- the compound is formulated in a unit dosage injectable form.
- the patient is a human.
- the present disclosure provides the use of a compound of described herein in the manufacture of a medicament for the treatment of any of the above mentioned conditions.
- the medicament is useful for the treatment of any of the above mentioned cancers.
- the medicament is useful for the treatment of a bacterial or fungal infection. It will be appreciated that a compound described herein and one or more second therapeutic agents may be used in the manufacture of the medicament.
- the present disclosure provides an article of manufacture comprising a compound described herein, a container, and a package insert or label indicating that the compound can be used to treat cancer characterized by the overexpression of at least one tumor-associated antigen.
- the present disclosure provides an article of manufacture comprising a compound described herein, a container, and a package insert or label indicating that the compound can be used to treat a bacterial or fungal infection.
- package insert is used to refer to instructions customarily included in commercial packages of therapeutic products that contain information about the indication(s), usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products.
- Reagents and anhydrous solvents were purchased from Sigma-Aldrich Chemical Company and Alfa-Aesar Inc, and were used as received.
- Degussa type E101 NE/W was employed for 20% palladium hydroxide on carbon. The reactions were carried out under an atmosphere of nitrogen unless specified otherwise.
- Column chromatography was conducted using silica gel (E. Merck 60 ⁇ , 230-400 mesh), applying a low-pressure stream of nitrogen.
- Analytical thin layer chromatography separations were carried out on glass plates coated with silica gel (Analtech, GHLF uniplates). The TLC chromatograms were visualized using UV (short wave) lamp irradiation or by immersing the plates in ceric ammonium molybdate (CAM) staining solution followed by heating with a heat gun.
- CAM ceric ammonium molybdate
- unit 2 (492 mg, 1.25 mmol) was coupled to Fmoc-Thr(tBu) (596 mg, 1.50 mmol) using DMAP (46 mg, 0.38 mmol) and DCC (285 mg, 1.38 mmol) in 15 mL of anhydrous DCM. After separation by column chromatography 3b was obtained as a colorless solid.
- unit 2 (492 mg, 1.25 mmol) was coupled to Fmoc-Tyr(tBu) (584 mg, 1.27 mmol) using DMAP (39 mg, 0.32 mmol) and DCC (241 mg, 1.17 mmol) in 15 mL of anhydrous DCM. After separation by column chromatography 3c was obtained as a colorless solid.
- unit 5 (345 mg, 0.31 mmol) was deprotected with 2,2′,2′′-triaminotriethylamine (467 ⁇ L, 453 mg, 3.10 mmol) in 10 mL of DCM and then coupled to unit 4a (194 mg, 0.31 mmol) using HBTU (235 mg, 0.62 mmol) and TEA (43 ⁇ L, 31 mg, 0.42 mmol) in 5 mL of anhydrous DMF. After separation by column chromatography 6a was obtained as a colorless solid.
- unit 5 (300 mg, 0.27 mmol) was deprotected with 2,2′,2′′-triaminotriethylamine (407 ⁇ L, 395 mg, 2.70 mmol) in 12 mL of DCM and then coupled to unit 4b (184 mg, 0.27 mmol) using HBTU (205 mg, 0.54 mmol) and TEA (37 ⁇ L, 27 mg, 0.27 mmol) in 5 mL of anhydrous DMF. After separation by column chromatography 6b was obtained as a colorless solid.
- unit 5 (630 mg, 0.57 mmol) was deprotected with 2,2,2′,2′′-triaminotriethylamine (850 ⁇ L, 834 mg, 5.70 mmol) in 20 mL of DCM and then coupled to unit 4c (425 mg, 0.57 mmol) using HBTU (434 mg, 1.14 mmol) and TEA (79 ⁇ L, 58 mg, 0.57 mmol) in 5 mL of anhydrous DMF. After separation by column chromatography 6c was obtained as a colorless solid.
- depsipeptide 6b (300 mg, 0.20 mmol) was deprotected using 20% palladium hydroxide-on-carbon (300 mg) in 10 mL of 4:1 ethyl acetate/methanol and then cyclized with PyBroP (373 mg, 0.80 mmol) and TEA (111 ⁇ L, 81 mg, 0.80 mmol) in 200 mL of anhydrous DCM. After separation by column chromatography 7b was obtained as a colorless solid.
- depsipeptide 6c (700 mg, 0.44 mmol) was deprotected using 20% palladium hydroxide-on-carbon (300 mg) in 10 mL of 4:1 ethyl acetate/methanol and then cyclized with PyBroP (373 mg, 0.80 mmol) and TEA (111 ⁇ L, 81 mg, 0.80 mmol) in 200 mL of anhydrous DCM. After separation by column chromatography 7c was obtained as a colorless solid.
- cyclodepsipeptide 7c (7 mg, 5.5 ⁇ mol) was deprotected with TFA (250 ⁇ L) in 1 mL of anhydrous DCM. After separation by column chromatography 8b (silstatin 3) was obtained as a colorless solid.
- unit 1 (2.52 g, 6.64 mmol) was deprotected with TFA (7.5 mL) in 30 mL of anhydrous DCM and then coupled to (2R)-2-hydroxy-3-cyclohexylpropionic acid (1.23 g, 7.14 mmol) using HOBt (1.35 g, 9.96 mmol), TEA (1.38 mL, 1.10 g, 9.96 mmol) and EDCI hydrochloride (1.91 g, 9.96 mmol) in 30 mL of anhydrous DCM. After separation by column chromatography 9 was obtained as a colorless oil (solidifies upon standing).
- unit 9 (1.80 g, 4.15 mmol) was coupled to Fmoc-Val (1.55 g, 4.57 mmol) using DCC (943 mg, 4.57 mmol) and DMAP (152 mg, 1.25 mmol) in 50 mL of anhydrous DCM. After separation by column chromatography 10a was obtained as a colorless solid.
- unit 9 (1.80 g, 4.15 mmol) was coupled to Fmoc-Thr(OtBu) (381 mg, 0.96 mmol) using DCC (198 mg, 0.96 mmol) and DMAP (32 mg, 0.26 mmol) in 10 mL of anhydrous DCM. After separation by column chromatography 10b was obtained as a colorless solid.
- unit 9 (376 mg, 0.87 mmol) was coupled to Fmoc-Tyr(OtBu) (441 mg, 0.96 mmol) using DCC (198 mg, 0.96 mmol) and DMAP (32 mg, 0.26 mmol) in 10 mL of anhydrous DCM. After separation by column chromatography 10b was obtained as a colorless solid.
- unit 10a (300 mg, 0.40 mmol) was deprotected with 2,2′,2′′-triaminotriethylamine (605 ⁇ L, 588 mg, 4.00 mmol) in 10 mL of DCM and then coupled to unit 11a (266 mg, 0.40 mmol) using HBTU (303 mg, 0.80 mmol) and TEA (55 ⁇ L, 40 mg, 0.40 mmol) in 5 mL of anhydrous DMF. After separation by column chromatography 12 was obtained as a colorless solid.
- unit 12 (320 mg, 0.27 mmol) was deprotected with 2,2′,2′′-triaminotriethylamine (281 ⁇ L, 273 mg, 2.16 mmol) in 6 mL of DCM and then coupled to unit 11a (179 mg, 0.27 mmol) using HBTU (205 mg, 0.54 mmol) and TEA (37 ⁇ L, 27 mg, 0.27 mmol) in 5 mL of anhydrous DMF. After separation by column chromatography 13a was obtained as a colorless solid.
- unit 12 500 mg, 0.42 mmol was deprotected with 2,2′,2′′-triaminotriethylamine (633 ⁇ L, 614 mg, 4.2 mmol) in 15 mL of DCM and then coupled to unit 11b (306 mg, 0.42 mmol) using HBTU (319 mg, 0.84 mmol) and TEA (58 ⁇ L, 42 mg, 0.42 mmol) in 7 mL of anhydrous DMF. After separation by column chromatography 13b was obtained as a colorless solid.
- unit 12 500 mg, 0.42 mmol was deprotected with 2,2′,2′′-triaminotriethylamine (633 ⁇ L, 614 mg, 4.2 mmol) in 15 mL of DCM and then condensed to unit 11c (329 mg, 0.42 mmol) using HBTU (319 mg, 0.84 mmol) and TEA (58 ⁇ L, 42 mg, 0.42 mmol) in 7 mL of anhydrous DMF. Following separation by column chromatography 13c was obtained as a colorless solid.
- depsipeptide 13a (193 mg, 0.12 mmol) was deprotected using 20% palladium hydroxide-on-carbon (100 mg) in 8 mL of 4:1 ethyl acetate/methanol and then cyclized with PyBroP (224 mg, 0.48 mmol) and TEA (35 ⁇ L, 24 mg, 0.24 mmol) in 120 mL of anhydrous DCM. After separation by column chromatography silstatin 4 (14a) was obtained as a colorless solid.
- depsipeptide 13b (530 mg, 0.26 mmol) was deprotected using 20% palladium hydroxide-on-carbon (200 mg) in 10 mL of 4:1 ethyl acetate/methanol and then cyclized with PyBroP (485 mg, 1.04 mmol) and TEA (144 ⁇ L, 105 mg, 1.04 mmol) in 260 mL of anhydrous DCM. After separation by column chromatography 14b was obtained as a colorless solid.
- depsipeptide 13c (502 mg, 0.29 mmol) was deprotected using 20% palladium hydroxide-on-carbon (200 mg) in 8 mL of 4:1 ethyl acetate/methanol and then cyclized with PyBroP (541 mg, 1.16 mmol) and TEA (160 ⁇ L, 118 mg, 1.17 mmol) in 290 mL of anhydrous DCM. After separation by column chromatography cyclodepsipeptide 14c was obtained as a colorless solid.
- cyclodepsipeptide 14b 80 mg, 60 ⁇ mol was deprotected with TFA (250 ⁇ L) in 2 mL of anhydrous DCM. After isolation by column chromatography yielded cyclodepsipeptide 15a (silstatin 5) as a colorless solid.
- unit 5 (264 mg, 0.24 mmol) was deprotected with 2,2′,2′′-triaminotriethylamine (362 ⁇ L, 351 mg, 2.4 mmol) in 15 mL of DCM and then coupled to unit 11b (170 mg, 0.24 mmol) using HBTU (182 mg, 0.48 mmol) and TEA (33 ⁇ L, 24 mg, 0.24 mmol) in 5 mL of anhydrous DMF. Separation by column chromatography provided 16a which was obtained as a colorless solid.
- unit (5) (221 mg, 0.20 mmol) was deprotected with 2,2′,2′′-triaminotriethylamine (302 ⁇ L, 293 mg, 2.0 mmol) in 15 mL of DCM and then coupled to unit 11c (158 mg, 0.20 mmol) using HBTU (152 mg, 0.40 mmol) and TEA (28 ⁇ L, 20 mg, 0.20 mmol) in 5 mL of anhydrous DMF.
- 2,2′,2′′-triaminotriethylamine (302 ⁇ L, 293 mg, 2.0 mmol) in 15 mL of DCM and then coupled to unit 11c (158 mg, 0.20 mmol) using HBTU (152 mg, 0.40 mmol) and TEA (28 ⁇ L, 20 mg, 0.20 mmol) in 5 mL of anhydrous DMF.
- depsipeptide 16a (269 mg, 0.17 mmol) was deprotected using 20% palladium hydroxide-on-carbon (200 mg) in 8 mL of 4:1 ethyl acetate/methanol and then cyclized employing PyBroP (317 mg, 0.68 mmol) and TEA (94 ⁇ L, 69 mg, 0.68 mmol) in 170 mL of anhydrous DCM.
- depsipeptide 16b (220 mg, 0.13 mmol) was deprotected using 20% palladium hydroxide-on-carbon (200 mg) in 8 mL of 4:1 ethyl acetate/methanol and then cyclized with PyBroP (250 mg, 0.54 mmol) and TEA (74 ⁇ L, 54 mg, 0.54 mmol) in 134 mL of anhydrous DCM. Isolation by column chromatography yielded 17b as a colorless solid.
- cyclodepsipeptide 17a 80 mg, 64 ⁇ mol was deprotected with TFA (250 ⁇ L) in 1 mL of anhydrous DCM. After separation by column chromatography 18a (silstatin 7) was obtained as a colorless solid.
- cyclodepsipeptide 17b (30 mg, 23 ⁇ mol) was deprotected with TFA (250 ⁇ L) in 1 mL of anhydrous DCM. Separation by column chromatography led to 18b (silstatin 8) as a colorless solid.
- intermediate 26 (130 mg, 0.17 mmol) was dissolved in 3 mL of anhydrous DCM and compound 18a (167 mg, 0.14 mmol) was added followed by DMAP (5 mg, 0.04 mmol) and DCC (31 mg, 0.15 mmol). The reaction mixture was stirred at 23° C. for 16 h. The solvent was separated by filtration and the filtrate was concentrated under reduced pressure. The crude product was separated by chromatography on a silica gel column. Elution with 3:2 hexanes/ethyl acetate gave the allyl protected prodrug 27 as a colorless solid: yield 51% over two steps (176 mg, 90 ⁇ mol).
- silstatins were evaluated against a mini panel of cancer cell lines (Table 1).
- the introduction of polar groups (hydroxyl) somewhat decreased activity as shown for silstatins 2 and 3 (8a and 8b).
- Introduction of an ⁇ -hydroxy acid with a more lipophilic side chain in place of the three (R)-2-hydroxyisocaproic acid units caused a marked reduction of cancer cell growth inhibition capability as seen in silstatins 4 and 6 (14a and 15b).
- silstatin 5 (15a) showed very high inhibitory activity.
- prodrug 28 was synthesized and evaluated against the same mini panel of cancer cell lines (Table 1). The use of glucuronide prodrugs has been validated by in vivo studies showing superior therapeutic efficacy compared to the parent drug. 17
- prodrug 28 that proved to be a prodrug that should have greatly reduced toxicity during transport to the tumor where a glucuronidase would release silstatin 7.
- Evidence of that expected result was obtained as follows.
- the cancer cell growth inhibition activity for prodrug 28 was found to be decreased 16-52 times with respect to the parent silstatin 7.
- prodrug 28 was tested against two normal cell lines and compared to the parent drug (18a) (Table 2) and, as presumed, the prodrug 28 normal cell growth inhibition activity was decreased 62.5 and 12.5 times with respect to the parent silstatin 7 drug (18a) in MCF-10A and CRL-2221 cell lines, respectively.
- prodrug 28 displayed in cancer and normal cell lines might be attributed to the fact that the prodrug could be crossing the cell membrane and releasing the drug (18a).
- the difference in cell growth inhibition activity of prodrug 28, as shown in Table 2, could be due to the level of ⁇ -glucuronidase expression in each cell line.
- a doxorubicin glucuronide prodrug capable of binding albumin through a maleamide moiety was synthesized. The effects of this capability lead to a relatively non-toxic prodrug with higher accumulation in the tumor (more selective) as compared to the glucuronide prodrug without the maleamide moiety.
- test compounds are reconstituted in a small volume of sterile DMSO and diluted in the appropriate media immediately prior to susceptibility experiments. 1
- the MIC is defined as the lowest concentration inhibiting visible growth of the microorganism.
Abstract
Description
- This invention was made with government support under R01 CA090441 awarded by the National Institutes of Health. The government has certain rights in the invention.
- In 2009 Pettit et al. reported the isolation and structures of two very potent cancer cell growth inhibitors, cyclodepsipeptides designated bacillistatins 1 and 21.2 from Bacillus silvestris carried by a South Pacific (Chile) crab. Subsequently, Pettit et al. completed the total synthesis of bacillistatin 2.2 Meanwhile, the promise of marine derived microorganisms as productive sources of new anticancer and antiproliferative drugs continues to expand. Recent examples includes discoveries of marine microorganisms containing small molecule cancer cell growth inhibitors,3a-h antibiotics from bacteria,4a-f antibiotics from fungi,5a-f various inhibitors from cyanobacteria6a-c and the increasing potential of deep-sea microorganisms.7a-d Structurally, the bacillistatins are similar to valinomycin, a well-known antibiotic and cytotoxic cyclodepsipeptide that acts as a carrier-type potassium ionophore (
FIG. 1 ). Another cyclic depsipeptide that resembles the structures of valinomycin and bacillistatins is cereulide, a toxin isolated in 1995 from Bacillus cereus. 8 - The cancer cell growth inhibition values for these molecules are in the order of 10−4-10−5 μg/mL which makes them good candidates as therapeutic agents for cancer treatment and specially when linked to monoclonal antibodies. That is a powerful technique to reduce side effects and increase selectivity as well as other targeting systems that allow the release of the drug, from a non-toxic precursor (prodrug), in the solid tumors microenvironment or inside the cancer cells. One of the major obstacles for this approach with the bacillistatins is the lack of easily derivatizable groups (e.g. —NH2, —SH, —OH, —COOH, etc) necessary for conjugation of these K+ ionophores.
- Accordingly, there is a need to provide new bacillistatin compounds (designated Silstatin compounds) that have suitable cancer cell growth inhibition values and antibacterial activities and that contain an easily derivatizable group for conjugation to monoclonal antibodies.
- Citation of any reference in this section is not to be construed as an admission that such reference is prior art to the present disclosure.
- The present disclosure relates to Silstatin compounds, pharmaceutical compositions comprising such compounds, kits, and methods for using such compounds or pharmaceutical compositions. The compounds of the present disclosure contain an easily derivatizable group for conjugation to monoclonal antibodies. The compounds have, or are believed to have, suitable cancer cell growth inhibition values and antibacterial activities.
- In a first embodiment, the present disclosure provides a compound of formula (I):
- or a pharmaceutically acceptable salt thereof, wherein
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently selected from —(C1-C6)alkyl, —(C2-C6)alkenyl and —(C2-C6)alkynyl, -
- wherein the alkyl, alkenyl or alkynyl are unsubstituted or substituted with a substituent selected from —OH, —NH2, —NHR′, —NHR′R″, —SH, —SR′, —C(O)OH, —C(O)NH2, —C(O)NHR′, —C(O)NR′R″, —NHC(═NH)NH2, —(C6-C14)aryl, —(C6-C14)aryl substituted with OH, -(5- or 6-membered monocyclic heteroaryl), -(9- or 10-membered bicyclic heteroaryl) and —(C3-C7)cycloalkyl, wherein R′ and R″ are independently selected from —(C1-C6)alkyl, —(C2-C6)alkenyl and (C2-C6)alkynyl; or
- wherein the alkyl, taken together with an adjacent N, forms a (5- or 6-membered)heterocyclyl;
X1, X2, X3, X4, X5 and X6 are independently selected from —H, (C1-C5)alkyl, —(C2-C5)alkenyl and —(C2-C6)alkynyl;
and
aa1 is an amino acid, wherein the amino acid is unsubstituted or substituted with a protecting group or a Linking Unit.
- In a second embodiment, the present disclosure provides a compound of formula (II),
- or a pharmaceutically acceptable salt thereof, wherein
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently selected from —(C1-C6)alkyl, —(C2-C6)alkenyl and —(C2-C6)alkynyl, -
- wherein the alkyl, alkenyl or alkynyl are unsubstituted or substituted with a substituent selected from —OH, —NH2, —NHR′, —NHR′R″, —SH, —SR′, —C(O)OH, —C(O)NH2, —C(O)NHR′, —C(O)NR′R″, —NHC(═NH)NH2, —(C6-C14)aryl, —(C6-C14)aryl substituted with OH, -(5- or 6-membered monocyclic heteroaryl), -(9- or 10-membered bicyclic heteroaryl) and —(C3-C7)cycloalkyl, wherein R′ and R″ are independently selected from —(C1-C6)alkyl, —(C2-C6)alkenyl and (C2-C6)alkynyl; or
- wherein the alkyl, taken together with an adjacent N, forms a (5- or 6-membered)heterocyclyl;
X1, X2, X3, X4, X5 and X6 are independently selected from —H, (C1-C6)alkyl, —(C2-C6)alkenyl and —(C2-C6)alkynyl;
aa2 is an amino acid, wherein the amino acid is unsubstituted or substituted with a protecting group or a Linking Unit.
-
FIG. 1 shows the structures of valinomycin, cereulide, bacillistatin 1 and bacillistatin 2. - The invention includes the following:
-
- (1.) A compound of formula (I),
- or a pharmaceutically acceptable salt thereof, wherein
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently selected from —(C1-C6)alkyl, —(C2-C6)alkenyl and —(C2-C6)alkynyl, -
- wherein the alkyl, alkenyl or alkynyl are unsubstituted or substituted with a substituent selected from —OH, —NH2, —NHR′, —NHR′R″, —SH, —SR′, —C(O)OH, —C(O)NH2, —C(O)NHR′, —C(O)NR′R″, —NHC(═NH)NH2, —(C6-C14)aryl, —(C6-C14)aryl substituted with OH, -(5- or 6-membered monocyclic heteroaryl), -(9- or 10-membered bicyclic heteroaryl) and —(C3-C7)cycloalkyl, wherein R′ and R″ are independently selected from —(C1-C6)alkyl, —(C2-C6)alkenyl and (C2-C6)alkynyl; or
- wherein the alkyl, taken together with an adjacent N, forms a (5- or 6-membered)heterocyclyl;
X1, X2, X3, X4, X5 and X6 are independently selected from —H, (C1-C6)alkyl, —(C2-C6)alkenyl and —(C2-C6)alkynyl;
and
aa1 is an amino acid, wherein the amino acid is unsubstituted or substituted with a protecting group or a Linking Unit. - (2.) A compound of formula (II),
- or a pharmaceutically acceptable salt thereof, wherein
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently selected from —(C1-C6)alkyl, —(C2-C6)alkenyl and —(C2-C6)alkynyl, -
- wherein the alkyl, alkenyl or alkynyl are unsubstituted or substituted with a substituent selected from —OH, —NH2, —NHR′, —NHR′R″, —SH, —SR′, —C(O)OH, —C(O)NH2, —C(O)NHR′, —C(O)NR′R″, —NHC(═NH)NH2, —(C6-C14)aryl, —(C6-C14)aryl substituted with OH, -(5- or 6-membered monocyclic heteroaryl), -(9- or 10-membered bicyclic heteroaryl) and —(C3-C7)cycloalkyl, wherein R′ and R″ are independently selected from —(C1-C6)alkyl, —(C2-C6)alkenyl and (C2-C6)alkynyl; or
- wherein the alkyl, taken together with an adjacent N, forms a (5- or 6-membered)heterocyclyl;
X1, X2, X3, X4, X5 and X6 are independently selected from —H, (C1-C6)alkyl, —(C2-C6)alkenyl and —(C2-C6)alkynyl;
aa2 is an amino acid, wherein the amino acid is unsubstituted or substituted with a protecting group or a Linking Unit. - (3.) The compound of the above (1.) or (2.), wherein at least one of R1, R4, and R8 is (C1-C6)alkyl.
- (4.) The compound of the above (1.) or (2.), wherein at least two of R1, R4, and R8 are (C1-C6)alkyl.
- (5.) The compound of the above (1.) or (2.), wherein each of R1, R4, and R8 is (C1-C6)alkyl.
- (6.) The compound of the above (1.) or (2.), wherein at least one of R1, R4, and R8 is (C1-C4)alkyl.
- (7.) The compound of the above (1.) or (2.), wherein at least two of R1, R4, and R8 are (C1-C4)alkyl.
- (8.) The compound of the above (1.) or (2.), wherein each of R1, R4, and R8 is (C1-C4)alkyl.
- (9.) The compound of the above (1.) or (2.), wherein at least one of R1, R4, and R8 is (C4)alkyl.
- (10.) The compound of the above (1.) or (2.), wherein at least two of R1, R4, and R8 are (C4)alkyl.
- (11.) The compound of the above (1.) or (2.), wherein each of R1, R4, and R8 is (C4)alkyl.
- (12.) The compound of the above (1.) or (2.), wherein at least one of R1, R4, and R8 is (C1-C6)alkyl substituted with (C3-C7)cycloalkyl.
- (13.) The compound of the above (1.) or (2.), wherein at least two of R1, R4, and R8 are (C1-C6)alkyl substituted with (C3-C7)cycloalkyl.
- (14.) The compound of the above (1.) or (2.), wherein each of R1, R4, and R8 is (C1-C6)alkyl substituted with (C3-C7)cycloalkyl.
- (15.) The compound of the above (1.) or (2.), wherein at least one of R1, R4, and R8 is (C1-C3)alkyl substituted with (C3-C7)cycloalkyl.
- (16.) The compound of the above (1.) or (2.), wherein at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C3-C7)cycloalkyl.
- (17.) The compound of the above (1.) or (2.), wherein each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C3-C7)cycloalkyl.
- (18.) The compound of the above (1.) or (2.), wherein at least one of R1, R4, and R8 is (C1)alkyl substituted with (C3-C7)cycloalkyl.
- (19.) The compound of the above (1.) or (2.), wherein at least two of R1, R4, and R8 are (C1)alkyl substituted with (C3-C7)cycloalkyl.
- (20.) The compound of the above (1.) or (2.), wherein each of R1, R4, and R8 is (C1)alkyl substituted with (C3-C7)cycloalkyl.
- (21.) The compound of the above (1.) or (2.), wherein at least one of R1, R4, and R8 is (C1-C6)alkyl substituted with (C6)cycloalkyl.
- (22.) The compound of the above (1.) or (2.), wherein at least two of R1, R4, and R8 are (C1-C6)alkyl substituted with (C6)cycloalkyl.
- (23.) The compound of the above (1.) or (2.), wherein each of R1, R4, and R8 is (C1-C6)alkyl substituted with (C6)cycloalkyl.
- (24.) The compound of the above (1.) or (2.), wherein at least one of R1, R4, and R8 is (C1-C3)alkyl substituted with (C6)cycloalkyl.
- (25.) The compound of the above (1.) or (2.), wherein at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C6)cycloalkyl.
- (26.) The compound of the above (1.) or (2.), wherein each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C6)cycloalkyl.
- (27.) The compound of the above (1.) or (2.), wherein at least one of R1, R4, and R8 is (C1)alkyl substituted with (C6)cycloalkyl.
- (28.) The compound of the above (1.) or (2.), wherein at least two of R1, R4, and R8 are (C1)alkyl substituted with (C6)cycloalkyl.
- (29.) The compound of the above (1.) or (2.), wherein each of R1, R4, and R8 is (C1)alkyl substituted with (C6)cycloalkyl.
- (30.) The compound of any one of the above (1.) to (29.), wherein each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl.
- (31.) The compound of any one of the above (1.) to (30.), wherein each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl.
- (32.) The compound of the above (31.), wherein each of X1, X2, X3, X4, X5 and X6 is H.
- (33.) The compound of any one of the above (1.) to (32.), wherein one of aa1 or aa2 is valine.
- (34.) The compound of any one of the above (1.) to (32.), wherein one of aa1 or aa2 is threonine optionally substituted with a protecting group or a Linking Unit.
- (35.) The compound of any one of the above (1.) to (32.), wherein one of aa1 or aa2 is tyrosine optionally substituted with a protecting group or a Linking Unit.
- (36.) The compound of the above (34.) or (35.), wherein the Linking Unit comprises a cleavable linker.
- (37.) The compound of the above (36.), wherein the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage.
- (38.) The compound of the above (37.), wherein the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond.
- (39.) The compound of the above (35.), wherein the cleavable linker comprises glucuronide.
- (40.) The compound of the above (36.), wherein the Linking Unit is represented by formula (III):
-
Aa-Ww—Yy (III), - wherein:
- a is or 1,
each —W— is independently an Amino Acid Unit,
w is an integer ranging from 0 to 12, - y is 0, 1 or 2.
-
- (41.) The compound of the above (40.), wherein Aa is maleimidocaproyl.
- (42.) The compound of the above (40.) or (41.), wherein Ww is Valine-Citrulline.
- (43.) The compound of any one of the above (40.) to (42.), wherein Yy is p-aminobenzyloxycarbonyl.
- (44.) The compound of any one of the above (34.) to (36.) and (40.) to (43.), wherein the Linking Unit comprises a monoclonal antibody.
- (45.) The compound of the above (1.), wherein the compound has formula (Ia):
- or a pharmaceutically acceptable salt thereof, wherein
aa1 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit. -
- (46.) The compound of the above (45.), wherein aa1 is valine.
- (47.) The compound of the above (45.), wherein aa1 is threonine optionally substituted with a protecting group or a Linking Unit.
- (48.) The compound of the above (45.), wherein aa1 is tyrosine optionally substituted with a protecting group or a Linking Unit.
- (49.) The compound of the above (47.) or (48.), wherein the Linking Unit comprises a cleavable linker.
- (50.) The compound of the above (49.), wherein the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage.
- (51.) The compound of the above (49.), wherein the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond.
- (52.) The compound of the above (49.), wherein the cleavable linker comprises glucuronide.
- (53.) The compound of the above (43.), wherein the Linking Unit is represented by formula (II):
-
Aa-Ww—Yy (III), - wherein:
- a is 0 or 1,
each —W— is independently an Amino Acid Unit,
w is an integer ranging from 0 to 12, - y is 0, 1 or 2.
-
- (54.) The compound of the above (53.), wherein Aa is maleimidocaproyl.
- (55.) The compound of the above (53.) or (54.), wherein Ww is Valine-Citrulline.
- (56.) The compound of any one of the above (53.) to (55.), wherein Yy is para-aminobenzyloxycarbonyl.
- (57.) The compound of any one of the above (45.), (47.) to (49.) and (53.) to (56.), wherein the Linking Unit comprises a monoclonal antibody.
- (58.) The compound of the above (1.), wherein the compound has formula (Ib):
- or a pharmaceutically acceptable salt thereof, wherein
aa1 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit. -
- (59.) The compound of the above (58.), wherein aa1 is valine.
- (60.) The compound of the above (58.), wherein aa1 is threonine optionally substituted with a protecting group or a Linking Unit.
- (61.) The compound of the above (58.), wherein aa1 is tyrosine optionally substituted with a protecting group or a Linking Unit.
- (62.) The compound of the above (60.) or (61.), wherein the Linking Unit comprises a cleavable linker.
- (63.) The compound of the above (62.), wherein the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage.
- (64.) The compound of the above (62.), wherein the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond.
- (65.) The compound of the above (62.), wherein the cleavable linker comprises glucuronide.
- (66.) The compound of the above (58.), wherein the Linking Unit is represented by formula (III):
-
Aa-Ww—Yy (III), - wherein:
- a is 0 or 1,
each —W— is independently an Amino Acid Unit,
w is an integer ranging from 0 to 12, - y is 0, 1 or 2.
-
- (67.) The compound of the above (66.), wherein Aa is maleimidocaproyl.
- (68.) The compound of the above (66.) or (67.), wherein Ww is Valine-Citrulline.
- (69.) The compound of any one of the above (66.) to (68.), wherein Yy is para-aminobenzyloxycarbonyl.
- (70.) The compound of any one of the above (58.), (60.) to (62.) and (66.) to (69.), wherein the Linking Unit comprises a monoclonal antibody.
- (71.) The compound of the above (1.), wherein the compound has formula (Ic):
- or a pharmaceutically acceptable salt thereof, wherein
aa1 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit. -
- (72.) The compound of the above (71.), wherein aa1 is valine.
- (73.) The compound of the above (71.), wherein aa1 is threonine optionally substituted with a protecting group or a Linking Unit.
- (74.) The compound of the above (71.), wherein aa1 is tyrosine optionally substituted with a protecting group or a Linking Unit.
- (75.) The compound of the above (73.) or (74.), wherein the Linking Unit comprises a cleavable linker.
- (76.) The compound of the above (75.), wherein the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage.
- (77.) The compound of the above (75.), wherein the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond.
- (78.) The compound of the above (75.), wherein the cleavable linker comprises glucuronide.
- (79.) The compound of the above (71.), wherein the Linking Unit is represented by formula (III):
-
Aa-Ww—Yy (III), - wherein:
- a is 0 or 1,
each —W— is independently an Amino Acid Unit,
w is an integer ranging from 0 to 12, - y is 0, 1 or 2.
-
- (80.) The compound of the above (79.), wherein Aa is maleimidocaproyl.
- (81.) The compound of the above (79.) or (80.), wherein Ww is Valine-Citrulline.
- (82.) The compound of any one of the above (79.) to (81.), wherein Yy is para-aminobenzyloxycarbonyl.
- (83.) The compound of any one of the above (71.), (73.) to (75.) and (79.) to (82.), wherein the Linking Unit comprises a monoclonal antibody.
- (84.) The compound of the above (2.), wherein the compound has formula (IIa):
- or a pharmaceutically acceptable salt thereof, wherein
aa2 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit. -
- (85.) The compound of the above (84), wherein aa2 is valine.
- (86.) The compound of the above (84.), wherein aa2 is threonine optionally substituted with a protecting group or a Linking Unit.
- (87.) The compound of the above (84.), wherein aa2 is tyrosine optionally substituted with a protecting group or a Linking Unit.
- (88.) The compound of the above (86.) or (87.), wherein the Linking Unit comprises a cleavable linker.
- (89.) The compound of the above (88.), wherein the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage.
- (90.) The compound of the above (88.), wherein the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond.
- (91.) The compound of the above (88.), wherein the cleavable linker comprises glucuronide.
- (92.) The compound of the above (84.), wherein the Linking Unit is represented by formula (II):
-
Aa-Ww—Yy (III), - wherein:
- a is 0 or 1,
each —W— is independently an Amino Acid Unit,
w is an integer ranging from 0 to 12, - y is 0, 1 or 2.
-
- (93.) The compound of the above (92.), wherein Aa is maleimidocaproyl.
- (94.) The compound of the above (92.) or (93.), wherein Ww is Valine-Citrulline.
- (95.) The compound of any one of the above (92.) to (94.), wherein Yy is para-aminobenzyloxycarbonyl.
- (96.) The compound of any one of the above (83.), (86.) to (88.) and (92.) to (95.), wherein the Linking Unit comprises a monoclonal antibody.
- (97.) The compound of the above (1.), wherein the compound has formula (IIb):
- or a pharmaceutically acceptable salt thereof, wherein
aa2 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit. -
- (98.) The compound of the above (97.), wherein aa2 is valine.
- (99.) The compound of the above (97.), wherein aa2 is threonine optionally substituted with a protecting group or a Linking Unit.
- (100.) The compound of the above (97.), wherein aa2 is tyrosine optionally substituted with a protecting group or a Linking Unit.
- (101.) The compound of the above (99.) or (100.), wherein the Linking Unit comprises a cleavable linker.
- (102.) The compound of the above (101.), wherein the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage.
- (103.) The compound of the above (101.), wherein the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond.
- (104.) The compound of the above (101.), wherein the cleavable linker comprises glucuronide.
- (105.) The compound of the above (97.), wherein the Linking Unit is represented by formula (III):
-
Aa-Ww—Yy (III), - wherein:
- a is 0 or 1,
each —W— is independently an Amino Acid Unit,
w is an integer ranging from 0 to 12, - y is 0, 1 or 2.
-
- (106.) The compound of the above (105.), wherein Aa is maleimidocaproyl.
- (107.) The compound of the above (105.) or (106.), wherein Ww is Valine-Citrulline.
- (108.) The compound of any one of the above (105.) to (107.), wherein Yy is para-aminobenzyloxycarbonyl.
- (109.) The compound of any one of the above (97.), (99.) to (101.) and (105.) to (108.), wherein the Linking Unit comprises a monoclonal antibody.
- (110.) The compound of the above (2.), wherein the compound has formula (IIc):
- or a pharmaceutically acceptable salt thereof, wherein
aa2 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit. -
- (111.) The compound of the above (110.), wherein aa2 is valine.
- (112.) The compound of the above (110.), wherein aa2 is threonine optionally substituted with a protecting group or a Linking Unit.
- (113.) The compound of the above (110.), wherein aa2 is tyrosine optionally substituted with a protecting group or a Linking Unit.
- (114.) The compound of the above (112.) or (113.), wherein the Linking Unit comprises a cleavable linker.
- (115.) The compound of the above (114.), wherein the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage.
- (116.) The compound of the above (114.), wherein the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond.
- (117.) The compound of the above (114.), wherein the cleavable linker comprises glucuronide.
- (118.) The compound of the above (110.), wherein the Linking Unit is represented by formula (III):
-
Aa-Ww—Yy (III), - wherein:
- a is 0 or 1,
each —W— is independently an Amino Acid Unit,
w is an integer ranging from 0 to 12, - y is 0, 1 or 2.
-
- (119.) The compound of the above (18.), wherein Aa is maleimidocaproyl.
- (120.) The compound of the above (118.) or (119.), wherein Ww is Valine-Citrulline.
- (121.) The compound of any one of the above (118.) to (120.), wherein Yy is para-aminobenzyloxycarbonyl.
- (122.) The compound of any one of the above (110.), (112.) to (114.) and (118.) to (121.), wherein the Linking Unit comprises a monoclonal antibody.
- (123.) A compound selected from the group consisting of:
- pharmaceutically acceptable salts thereof.
-
- (124.) A compound, which is:
- and a pharmaceutically acceptable salt thereof.
-
- (125.) A pharmaceutical composition comprising a compound of any one of the above (1.) to (124.) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- (126.) A pharmaceutical composition comprising a combination of compounds of any one of the above (1.) to (124.) or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.
- (127.) The pharmaceutical composition of the above (125.) or (126.), further comprising a therapeutically effective amount of chemotherapeutic agent selected from the group consisting of a tubulin-forming inhibitor, a topoisomerase inhibitor, and a DNA binder.
- (128.) A method for killing or inhibiting the proliferation of tumor cells or cancer cells comprising treating tumor cells or cancer cells with a compound of any of the above (1.) to (124.), or a pharmaceutical composition of any one of the above (125.) to (127.), in an amount effective to kill or inhibit the proliferation of the tumor cells or cancer cells.
- (129.) A method for treating cancer in a patient in need thereof comprising administering to the patient a compound of any of the above (1.) to (124.), or a pharmaceutical composition of any one of the above (125.) to (127.), wherein the compound or pharmaceutical composition is administered in an amount effective to treat cancer.
- (130.) The method of the above (129.), further comprising administering an effective amount of a second therapeutic agent.
- (131.) A method of determining inhibition of cellular proliferation by a compound, comprising contacting cells in a cell culture medium with the compound of any of the above (1.) to (124.) and measuring the cytotoxic activity of the compound, whereby proliferation of the cells is inhibited.
- (132.) A method of inhibiting the growth of tumor cells that overexpress a tumor-associated antigen comprising administering to a patient the compound of any of the above (1.) to (124.) conjugated to an antibody that is specific for said tumor-associated antigen, and optionally a second therapeutic agent wherein the compound and said second therapeutic agent are each administered in amounts effective to inhibit growth of tumor cells in the patient.
- (133.) The method of the above (132.), wherein the compound sensitizes the tumor cells to said second therapeutic agent.
- (134.) The method of the above (132.), wherein the compound induces cell death.
- (135.) The method of the above (132.), wherein the compound induces apoptosis.
- (136.) The method of the above (132.), wherein the cancer is selected from the group consisting of breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon, colorectal, thyroid, pancreatic, prostate and bladder cancer.
- (137.) A use of the compound of any of the above (1.) to (124.) in the manufacture of a medicament for treating cancer.
- (138.) An article of manufacture comprising the compound of any of the above (1.) to (124.), a container, and a package insert or label indicating that the compound can be used to treat cancer characterized by the overexpression of at least one tumor-associated antigen.
- (139.) An antibacterial or antifungal composition comprising a compound of any one of the above (1.) to (124.) or a pharmaceutically acceptable salt thereof in an amount effective to inhibit bacterial or fungal growth and a pharmaceutically acceptable carrier.
- (140.) A method of inhibiting bacterial or fungal growth in a sample, comprising exposing the sample to a compound of any one of the above (1.) to (124.) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any one of the above (125.) to (127.).
- (141.) A method for treating a bacterial or fungal infection in a patient in need thereof comprising administering to the patient a compound of any of the above (1.) to (124.), or a pharmaceutical composition of any one of the above (125.) to (127.), wherein the compound or pharmaceutical composition is administered in an amount effective to treat the infection.
- (142.) The method of the above (141.), wherein the infection is caused by vancomycin-resistant Enterococcus faecalis, Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, penicillin-resistant Streptococcus pneumoniae, multi-drug-resistant Streptococcus pneumoniae, Streptococcus pyogenes, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Cryptococcus neoformans or Candida albicans.
- (143.) The method of the above (141.), wherein the infection is caused by Streptococcus pneumoniae, penicillin-resistant Streptococcus pneumoniae, multi-drug-resistant Streptococcus pneumoniae, or Streptococcus pyogenes.
- (144.) A use of the compound of any of the above (1.) to (124.) in the manufacture of a medicament for treating a bacterial or fungal infection.
- (145.) An article of manufacture comprising the compound of any of the above (1.) to (124.), a container, and a package insert or label indicating that the compound can be used to treat a bacterial or fungal infection.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as those commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. The materials, methods and examples are illustrative only, and are not intended to be limiting. All publications, patents and other documents mentioned herein are incorporated by reference in their entirety.
- Throughout this specification, the word “comprise” or variations such as “comprises” or “comprising” will be understood to imply the inclusion of a stated integer or groups of integers but not the exclusion of any other integer or group of integers.
- The term “a” or “an” may mean more than one of an item.
- The terms “and” and “or” may refer to either the conjunctive or disjunctive and mean “and/or”.
- The term “about” means within plus or minus 10% of a stated value. For example, “about 100” would refer to any number between 90 and 110.
- The phrase “pharmaceutically acceptable salt,” as used herein, refers to pharmaceutically acceptable organic or inorganic salts of a compound of the disclosure. Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)) salts.
- The term “pharmaceutically acceptable carrier” refers to a diluent, adjuvant or excipient, with which a compound of the disclosure may be administered. Pharmaceutically acceptable carriers include any and all solvents, diluents, or other liquid vehicles, dispersions or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the disclosure such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this disclosure. Examples of pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols, such a propylene glycol or polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
- The term “therapeutically effective amount” refers to an amount of a compound of the disclosure effective to treat a disease or disorder in a patient. In the case of cancer, the therapeutically effective amount of the compound may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. To the extent the compound may inhibit the growth of and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic. For cancer therapy, efficacy can, for example, be measured by assessing the time to disease progression (TTP) and/or determining the response rate (RR). In the case of bacterial or fungal infections, the therapeutically effect amount of the compound may reduce or inhibit the growth of bacteria or fungus.
- The terms “treat” or “treatment” refer to therapeutic treatment and prophylactic measures to obtain a beneficial or desired result. For purposes of this disclosure, beneficial or desired results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, remission (whether partial or total), whether detectable or undetectable and prevention of relapse. “Treatment” can also include prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already having the condition or disorder as well as those prone to have the condition or disorder.
- In the context of cancer, the term “treating” includes any or all of inhibiting growth of tumor cells, cancer cells, or of a tumor; inhibiting replication of tumor cells or cancer cells, lessening of overall tumor burden or decreasing the number of cancerous cells, and ameliorating one or more symptoms associated with the disease.
- In the context of infections, the term “treating” includes inhibiting the growth of bacteria or fungus, preventing the growth of bacteria or fungus and ameliorating one or more symptoms associated with the infection.
- The term “patient,” as used herein, includes, but is not limited to, a human, rat, mouse, guinea pig, monkey, pig, goat, cow, horse, dog, cat, bird and fowl. In some embodiments, the patient is a human.
- The terms “cancer” and “cancerous” refer to or describe the physiological condition or disorder in mammals that is typically characterized by unregulated cell growth. A “tumor” comprises one or more cancerous cells.
- Exemplary cancers include, but not limited to, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer, ovarian cancer, prostate cancer, esophogeal cancer, stomach cancer, oral cancer, nasal cancer, throat cancer, central nervous system cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, uterine cancer, testicular cancer, small cell lung carcinoma, bladder carcinoma, lung cancer, epithelial carcinoma, glioma, glioblastoma multiforme, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, skin cancer, melanoma, neuroblastoma, retinoblastoma, acute lymphoblastic leukemia (ALL), acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute myeloblastic leukemia (AML), acute promyelocytic leukemia (APL), acute monoblastic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia, acute myelomonocytic leukemia, acute nonlymphocyctic leukemia, acute undifferentiated leukemia, chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), hairy cell leukemia, multiple myeloma, Hodgkin's disease, non-Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, heavy chain disease and polycythemia vera.
- The term “cytotoxic activity” refers to a cell-killing, a cytostatic or an anti-proliferative effect of a compound of the disclosure. Methods for measuring cytotoxic activity are well-known in the art. Cytotoxic activity may be expressed as the IC50 value, which is the concentration (molar or mass) per unit volume at which half the cells survive.
- The term “(C1-C6)alkyl” refers to saturated linear and branched hydrocarbon structures having 1, 2, 3, 4, 5, or 6 carbon atoms. When an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed; thus, for example, “propyl” includes n-propyl and iso-propyl and “butyl” includes n-butyl, sec-butyl, iso-butyl and tert-butyl. Examples of (C1-C6)alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, tert-butyl, n-pentyl, n-hexyl, and the like.
- The term “(C1-C4)alkyl” refers to saturated linear and branched hydrocarbon structures having 1, 2, 3 or 4 carbon atoms. When an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed; thus, for example, “propyl” includes n-propyl and iso-propyl and “butyl” includes n-butyl, sec-butyl, iso-butyl and tert-butyl. Examples of (C1-C4)alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, tert-butyl and the like.
- The term “(C1-C3)alkyl” refers to saturated linear and branched hydrocarbon structures having 1, 2 or 3 carbon atoms. When an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed; thus, for example, “propyl” includes n-propyl and iso-propyl. Examples of (C1-C3)alkyl groups include methyl, ethyl, n-propyl and iso-propyl.
- The term “(C2-C6)alkenyl” refers to a straight-chain or branched unsaturated hydrocarbon radical having 2, 3, 4, 5 or 6 carbon atoms and a double bond in any position, e.g., ethenyl, 1 propenyl, 2 propenyl (allyl), 1-butenyl, 2-butenyl, 3-butenyl, 1-methylethenyl, 1-methyl-1 propenyl, 2 methyl-2-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 2-methyl-2-pentenyl, 4-methyl-2-pentenyl, 4-methyl-1-pentenyl, 3-methyl-1-pentenyl, and the like.
- The term “(C2-C6)alkynyl” refers to a straight chain or branched hydrocarbon having 2, 3, 4, 5 or 6 carbon atoms and including at least one carbon-carbon triple bond. Examples of (C2-C6)alkynyls include ethynyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-methyl-2-pentynyl and the like.
- The term “(C6-C14)aryl” refers to a monovalent aromatic hydrocarbon group which may be monocyclic, bicyclic or tricyclic, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3, 4, 5, 6 or 7 ring members. Examples of (C6-C14)aryl groups include without limitation phenyl, naphthyl, indanyl, indenyl, tetralinyl, anthryl and phenanthryl.
- The term “(5- or 6-membered)heteroaryl” refers to a monocyclic aromatic heterocycle ring of 5 or 6 members, i.e., a monocyclic aromatic ring comprising at least one ring heteroatom, e.g., 1, 2, 3, or 4 ring heteroatoms, each independently selected from nitrogen, oxygen, and sulfur. A (5- or 6-membered)heteroaryl group can be attached to the parent structure through a carbon or heteroatom. Examples of (5- or 6-membered)heteroaryls include pyridyl, pyrrolyl, pyrazolyl, furyl, imidazolyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, 1,2,3 oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5 oxadiazolyl, 1,2,3-triazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidyl, pyrazinyl, 1,2,3 thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,5 triazinyl, and thiophenyl.
- The term “(5-membered)heteroaryl” refers to a monocyclic aromatic heterocycle ring of 5 members, i.e., a monocyclic aromatic ring comprising at least one ring heteroatom, e.g., 1, 2, 3, or 4 ring heteroatoms, each independently selected from nitrogen, oxygen, and sulfur. A (5-membered)heteroaryl group can be attached to the parent structure through a carbon or heteroatom. Examples of (5-membered)heteroaryls include pyrrolyl, pyrazolyl, furyl, imidazolyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, 1,2,3 oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5 oxadiazolyl, 1,2,3-triazolyl, pyrazolyl, isothiazolyl, 1,2,3 thiadiazolyl, 1,3,4-thiadiazolyl and 1,2,5-thiadiazolyl.
- The term “(6-membered)heteroaryl” refers to a monocyclic aromatic heterocycle ring of 6 members, i.e., a monocyclic aromatic ring comprising at least one ring heteroatom, e.g., 1, 2, 3, or 4 ring heteroatoms, each independently selected from nitrogen, oxygen, and sulfur. A (6-membered)heteroaryl group can be attached to the parent structure through a carbon or heteroatom. Examples of (6-membered)heteroaryls include pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, 1,3,5 triazinyl, and thiophenyl.
- The term “9- or 10-membered bicyclic heteroaryl” refers to a bicyclic aromatic heterocycle ring of 9 or 10 members, i.e., a bicyclic aromatic ring comprising at least one ring heteroatom, e.g., 1, 2, 3, or 4 ring heteroatoms, each independently selected from nitrogen, oxygen, and sulfur. A (9- or 10-membered)heteroaryl group can be attached to the parent structure through a carbon or heteroatom. Examples of (9- or 10-membered)heteroaryl include benzofuran, benzothiophene, benzoxazole, benzothiazzole, indole, indazole, benzotriazole, benzoimidazole, quinolone, cinnoline, benzotriazine, quinazoline, quinoxaline and the like.
- The term “(C3-C7)cycloalkyl” refers to a saturated cyclic hydrocarbon containing 3, 4, 5, 6 or 7 ring carbon atoms. Examples of (C3-C7)cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
- The term “(5- or 6-membered)heterocyclyl” refers to a 5- or 6-membered, saturated or partially unsaturated, monocyclic-heterocycle containing 1, 2, or 3 ring heteroatoms, each independently selected from nitrogen, oxygen, and sulfur, wherein said nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. Examples of “(5- or 6-membered)heterocyclyl groups include pyrrolidinyl, piperidinyl, piperazinyl, tetrahydro-oxazinyl, tetrahydrofuran, thiolane, dithiolane, pyrroline, pyrrolidine, pyrazoline, pyrazolidine, imidazoline, imidazolidine, tetrahydrofuranone, γ-butyrolactone, 2H-pyran, 4H-pyran, dioxolane, tetrahydropyran, dioxane, dihydrothiophene, piperazine, morpholine, thiomorpholine, oxazine, tetrahydro-oxazinyl, and the like.
- The term “(C6)heterocycloalkyl” refers to a 6-membered, saturated or partially unsaturated, bridged, mono- or bicyclic-heterocycle containing 1, 2, or 3 ring heteroatoms each independently selected from nitrogen, oxygen, and sulfur, wherein said nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. A heterocycloalkyl group can be attached to the parent structure through a carbon or heteroatom. Examples of (C6)heterocycloalkyl groups include piperidinyl, piperazinyl, tetrahydro-oxazinyl, tetrahydropyran, dioxane, morpholine, thiomorpholine, and the like.
- The term “amino acid” refers to both natural and unnatural amino acids. Examples of amino acids include alanine, β-alanine, N-methyl alanine, N-ethyl alanine, N-methyl-β-alanine, N-ethyl-β-alanine, arginine, asparagine, aspartic acid, cysteine, homocysteine, cystine, glutamic acid, glutamine, glycine, N-ethyl glycine, N-propyl glycine, N-isopropyl glycine, phenylalanine, 4-aminophenylalanine, 3-aminophenylalanine, 2-aminophenylalanine, histidine, isoleucine, alloisoleucine, lysine, ornithine, citrulline, leucine, norleucine, t-leucine, methionine, proline, pipecolic acid, serine, homoserine, isoserine, threonine, allothreonine, valine, norvaline, isovaline, α-methylnorvaline, tryptophan, tyrosine, γ-aminobutyric acid, δ-aminolevulinic acid, 4-aminobenzoic acid, α-aminoisobuyric acid, dehydroalanine, cystathionine, lanthionine, djenkolic acid, diaminopimelic acid, α-amino-n-heptanoic acid, α, β-diaminopropionic acid, α,γ-diaminopropionic acid, β-amino-n-butyric acid, β-aminoisobutyric acid, sarcosine, α-hydroxy-γ-aminobutyric acid and the like.
- The term “Protecting Group” refers to any group that is capable of reversibly protecting another functional group from undergoing an undesired reaction. Suitable protecting groups, as well as suitable conditions for protection and deprotection are well-known in the art and are described e.g., in T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis”, Third edition, Wiley, New York 1999, and references cited therein.
- The term “antibody” as used herein includes whole antibodies, monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments that exhibit the desired biological activity. An antibody may be of any type or class (e.g., IgG, IgE, IgM, IgD, and IgA) or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2). The antibody may be derived from any suitable species. In some embodiments, the antibody is of human or murine origin. An antibody may be, for example, human, humanized or chimeric.
- The term “monoclonal antibodies” as used herein refers to antibodies produced by a single clone of cells or cell line and comprising identical antibody molecules. The term “polyclonal antibodies” refers to antibodies produced by more than one type of cell or cell line and comprising different antibody molecules.
- A compound of the disclosure can contain one, two, or more asymmetric centers and thus can give rise to enantiomers, diastereomers, and other stereoisomeric forms. The disclosure encompasses compounds with all such possible forms, as well as their racemic and resolved forms or any mixture thereof, unless specifically otherwise indicated. When a compound of the disclosure contains an olefinic double bond, a C═N double bond, or any other center of geometric asymmetry, it is intended to include all “geometric isomers”, e.g., both Z and E geometric isomers, unless specifically otherwise indicated. All “tautomers”, e.g., amine-imine, enamine-enimine, enamine-imine, urea-isourea, ketone-enol, amide-imidic acid, lactam-lactim, are intended to be encompassed by the disclosure as well unless specifically otherwise indicated.
- In one embodiment, the present disclosure provides a compound of formula (I),
- or a pharmaceutically acceptable salt thereof, wherein
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently selected from —(C1-C6)alkyl, —(C2-C6)alkenyl and —(C2-C6)alkynyl, -
- wherein the alkyl, alkenyl or alkynyl are unsubstituted or substituted with a substituent selected from —OH, —NH2, —NHR′, —NHR′R″, —SH, —SR′, —C(O)OH, —C(O)NH2, —C(O)NHR′, —C(O)NR′R″, —NHC(═NH)NH2, —(C6-C14)aryl, —(C6-C14)aryl substituted with OH, -(5- or 6-membered monocyclic heteroaryl), -(9- or 10-membered bicyclic heteroaryl) and —(C4-C7)cycloalkyl, wherein R′ and R″ are independently selected from —(C1-C6)alkyl, —(C2-C6)alkenyl and (C2-C6)alkynyl; or
- wherein the alkyl, taken together with an adjacent N, forms a (5- or 6-membered)heterocyclyl;
X1, X2, X3, X4, X5 and X6 are independently selected from —H, (C1-C6)alkyl, —(C2-C6)alkenyl and —(C2-C6)alkynyl;
and
aa1 is an amino acid, wherein the amino acid is unsubstituted or substituted with a protecting group or a Linking Unit.
- In some embodiments, the compound of formula (I) is conjugated directly or indirectly to an antibody. In one embodiment, the compound of formula (I) is conjugated directly to an antibody. In another embodiment, the compound of formula (I) is conjugated to an antibody through a Linker Unit. The compound may be conjugated to an antibody through a Linker Unit at aa1. The Linker Unit can operate to provide a suitable release of the compound of formula (I). The preparation of antibody drug conjugates is known to those of skill in the art.
- In embodiments in which the compound of formula (I) is conjugated to an antibody through a Linker Unit, the Linker Unit may comprise a cleavable linker in one embodiment and a non-cleavable linker in another embodiment.
- In embodiments in which the Linker Unit comprises a cleavable linker, the cleavable linker may be cleaved by methods known in the art. In one embodiment, the cleavable linker may be cleaved by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage. In one embodiment, the cleavage method is selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage. In another embodiment, the cleavage method is selected from the group consisting of glycosidase-induced cleavage, peptidase-induced cleavage, and esterase-induced cleavage. In another embodiment, the cleavage method is selected from glycosidase-induced cleavage or peptidase-induced cleavage. In another embodiment, the cleavage method is selected from glycosidase-induced cleavage or esterase-induced cleavage. In another embodiment, the cleavage method is selected from peptidase-induced cleavage or esterase-induced cleavage.
- In embodiments in which the Linker Unit comprises a cleavable linker, the cleavable linker may comprise a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond. In one embodiment, the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, or an ester bond. In one embodiment, the cleavable linker comprises a glycosidic bond, a hydrazone, or a cathepsin-B-cleavable peptide. In one embodiment, the cleavable linker comprises a glycosidic bond, a hydrazone, or an ester bond. In one embodiment, the cleavable linker comprises a glycosidic bond, a cathepsin-B-cleavable peptide, or an ester bond. In one embodiment, the cleavable linker comprises a hydrazone, a cathepsin-B-cleavable peptide, or an ester bond.
- In one embodiment, the cleavable linker comprises a glycosidic bond. In one embodiment, the cleavable linker comprises glucuronide.
- The compounds of formula (I) may be conjugated to any antibody, e.g., an antibody that binds to a tumor associated antigen. In one embodiment, the antibody used in the antibody drug conjugate of the disclosure is a monoclonal antibody. In another embodiment, the antibody used in the antibody drug conjugate of the disclosure binds at least one of CD19, CD20, CD30, CD33, CD70, BCMA, Glypican-3, Liv-1 and Lewis Y antigen.
- When present, the Linker Unit is a bifunctional moiety that can be used to conjugate a compound of formula (I) to an antibody. Such bifuncitional moieties are known in the art and include, but are not limited to, alkyldiyl, an aryldiyl, a heteroaryldiyl, moieties such as: repeating units of alkyloxy (e.g., polyethylenoxy, PEG, polymethyleneoxy) and alkylamino (e.g., polyethyleneamino, Jeffamine™); and diacid ester and amides including succinate, succinamide, diglycolate, malonate, and caproamide. See, e.g., U.S. Pat. Nos. 6,214,345 and 7,745,394, the contents of both of which are incorporated by reference in their entireties.
- In some embodiments, the Linker Unit is as described in U.S. Pat. Nos. 6,214,345 and 7,745,394 and has formula:
-
AaWwYy, - wherein A is a Stretcher Unit,
a is 0 or 1,
each —W— is independently an Amino Acid Unit,
w is an integer ranging from 0 to 12, - y is 0, 1 or 2.
- The Stretcher Unit (-A-), when present, is capable of linking an antibody to an Amino Acid Unit (—W—). The antibody has a functional group that can form a bond with a functional group of a Stretcher. Useful functional groups that can be present on an antibody, either naturally or via chemical manipulation include, but are not limited to, sulfhydryl, amino, hydroxyl, carboxy, the anomeric hydroxyl group of a carbohydrate, and carboxyl. In one aspect, the antibody functional groups are sulfhydryl and amino. Sulfhydryl groups can be generated by reduction of an intramolecular disulfide bond of an antibody. Alternatively, sulfhydryl groups can be generated by reaction of an amino group of a lysine moiety of an antibody using 2-iminothiolane (Traut's reagent) or another sulfhydryl generating reagent.
- The Amino Acid Unit (—W—), when present, links the Stretcher Unit to the Spacer Unit if the Spacer Unit is present, links the Stretcher Unit to the compound of formula (I) if the Spacer Unit is absent, and links the antibody to the compound of formula (I) if the Stretcher Unit and Spacer Unit are absent.
- Ww— is a dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide, decapeptide, undecapeptide or dodecapeptide unit. The Amino Acid may be any amino acid. In some embodiments, the Amino Acid Unit comprises natural amino acids. In other embodiments, the Amino Acid Unit comprises non-natural amino acids.
- The Spacer Unit (—Y—), when present, links an Amino Acid Unit to the compound of formula (I) when an Amino Acid Unit is present. Alternately, the Spacer Unit links the Stretcher Unit to the compound of formula (I) when the Amino Acid Unit is absent. The Spacer Unit also links the compound of formula (I) to the antibody when both the Amino Acid Unit and Stretcher Unit are absent.
- Suitable Spacer Units include, but are not limited to a glycine-glycine unit; a glycine unit; p-aminobenzyl alcohol (PAB) unit or aromatic compounds that are electronically similar to the PAB group such as 2-aminoimidazol-5-methanol derivatives (Hay et al. (1999) Bioorg. Med. Chem. Lett. 9:2237) and ortho or para-aminobenzylacetals; spacers that undergo cyclization upon amide bond hydrolysis, such as substituted and unsubstituted 4-aminobutyric acid amides (Rodrigues et al., Chemistry Biology, 1995, 2, 223), appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems (Storm, et al., J. Amer. Chem. Soc., 1972, 94, 5815) and 2-aminophenylpropionic acid amides (Amsberry, et al., J. Org. Chem., 1990, 55, 5867); and a branched bis(hydroxymethyl)styrene (BHMS) unit.
- In some embodiments, at least one of R1, R4, and R8 is (C1-C6)alkyl. In some embodiments, at least two of R1, R4, and R8 are (C1-C6)alkyl. In some embodiments, each of R1, R4, and R8 is (C1-C6)alkyl. In some embodiments, at least one of R1, R4, and R8 is (C1-C4)alkyl. In some embodiments, at least two of R1, R4, and R8 are (C1-C4)alkyl. In some embodiments, each of R1, R4, and R8 is (C1-C4)alkyl. In some embodiments, at least one of R1, R4, and R8 is (C4)alkyl. In some embodiments, at least two of R1, R4, and R8 are (C4)alkyl. In some embodiments, each of R1, R4, and R8 is (C4)alkyl.
- In some embodiments, at least one of R1, R4, and R8 is (C1-C6)alkyl substituted with (C4-C7)cycloalkyl. In some embodiments, at least two of R1, R4, and R8 are (C1-C6)alkyl substituted with (C4-C7)cycloalkyl. In some embodiments, each of R1, R4, and R8 is (C1-C6)alkyl substituted with (C4-C7)cycloalkyl. In some embodiments, at least one of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl. In some embodiments, at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl. In some embodiments, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl. In some embodiments, at least one of R1, R4, and R8 is (C1)alkyl substituted with (C4-C7)cycloalkyl. In some embodiments, at least two of R1, R4, and R8 are (C1)alkyl substituted with (C4-C7)cycloalkyl. In some embodiments, each of R1, R4, and R8 is (C1)alkyl substituted with (C4-C7)cycloalkyl. In some embodiments, at least one of R1, R4, and R8 is (C1-C6)alkyl substituted with (C6)cycloalkyl. In some embodiments, at least two of R1, R4, and R8 are (C1-C6)alkyl substituted with (C6)cycloalkyl. In some embodiments, each of R1, R4, and R8 is (C1-C6)alkyl substituted with (C6)cycloalkyl. In some embodiments, at least one of R1, R4, and R8 is (C1-C3)alkyl substituted with (C6)cycloalkyl. In some embodiments, at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C6)cycloalkyl. In some embodiments, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C6)cycloalkyl. In some embodiments, at least one of R1, R4, and R8 is (C1)alkyl substituted with (C6)cycloalkyl. In some embodiments, at least two of R1, R4, and R8 are (C1)alkyl substituted with (C6)cycloalkyl. In some embodiments, each of R1, R4, and R8 is (C1)alkyl substituted with (C6)cycloalkyl.
- In some embodiments, at least one of R1, R4, and R8 is (C1-C6)alkyl or (C1-C6)alkyl substituted with (C4-C7)cycloalkyl. In another embodiment, one of R1, R4, and R8 is (C1-C4)alkyl and the others are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl. In another embodiment, two of R1, R4, and R8 are (C1-C4)alkyl and the other is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl.
- In some embodiments, each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In some embodiments, each of R2, R5, R7, R9, and R11 is (C3)alkyl. In some embodiments, each of R3, R6, and R10 is (C1)alkyl.
- In some embodiments, each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In some embodiments, each of X1, X2, X3, X4, X5 and X6 is H. In some embodiments, at least one of X1, X2, X3, X4, X5 and X6 is (C1-C6)alkyl and the other are H. In some embodiments, at least one of X1, X2, X3, X4, X5 and X6 is (C1-C3)alkyl and the other are H. In some embodiments, at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H.
- In some embodiments, aa1 is a natural amino acid. In other embodiments, aa1 is an unnatural amino acid. In some embodiments, aa1 comprises a functional group selected from —NH2, —SH, —OH or —COOH. In some embodiments, aa1 comprises —NH2. In some embodiments, aa1 comprises —SH. In some embodiments, aa1 comprises —OH. In some embodiments, aa1 comprises —COOH. In some embodiments, aa1 is valine. In other embodiments, aa1 is threonine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa1 is threonine. In other embodiments, aa1 is threonine substituted with a Protecting Group. In other embodiments, aa1 is threonine substituted with a Linking Unit. In other embodiments, aa1 is tyrosine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa1 is tyrosine. In other embodiments, aa1 is tyrosine substituted with a Protecting Group. In other embodiments, aa1 is tyrosine substituted with a Linking Unit. In some embodiments, aa1 is 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa1 is 4-aminophenylalanine. In other embodiments, aa1 is 4-aminophenylalanine substituted with a Protecting Group. In other embodiments, aa1 is 4-aminophenylalanine substituted with a Linking Unit. In some embodiments, aa1 is 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa1 is 3-aminophenylalanine. In other embodiments, aa1 is 3-aminophenylalanine substituted with a Protecting Group. In other embodiments, aa1 is 3-aminophenylalanine substituted with a Linking Unit. In some embodiments, aa1 is 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa1 is 2-aminophenylalanine. In other embodiments, aa1 is 2-aminophenylalanine substituted with a Protecting Group. In other embodiments, aa1 is 2-aminophenylalanine substituted with a Linking Unit.
- In some embodiments, the Linking Unit comprises a cleavable linker. In some embodiments, the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage. In some embodiments, the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond. In some embodiments, the cleavable linker comprises glucuronide.
- In some embodiments, Aa is maleimidocaproyl.
- In some embodiments, Ww is Valine-Citrulline.
- In some embodiments, Yy is p-aminobenzyloxycarbonyl.
- In some embodiments, Aa is maleimidocaproyl, Ww is Valine-Citrulline and Yy is p-aminobenzyloxycarbonyl.
- In some embodiments, the Linking Unit comprises a monoclonal antibody.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In one embodiment, at least two of R1, R4, and R8 are (C1-C4)alkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In another embodiment, at least one of R1, R4, and R8 is (C4)alkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C4)alkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C4)alkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl and each of R2, R5, R7, R9, and R11 is (C3)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C1-C4)alkyl and each of R2, R5, R7, R9, and R11 is (C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of R2, R5, R7, R9, and R11 is (C3)alkyl. In another embodiment, at least one of R1, R4, and R8 is (C4)alkyl and each of R2, R5, R7, R9, and R11 is (C3)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C4)alkyl and each of R2, R5, R7, R9, and R11 is (C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C4)alkyl and each of R2, R5, R7, R9, and R11 is (C3)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl and each of R3, R6, and R10 is (C1)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C1-C4)alkyl and each of R3, R6, and R10 is (C1)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of R3, R6, and R10 is (C1)alkyl. In another embodiment, at least one of R1, R4, and R8 is (C4)alkyl and each of R3, R6, and R10 is (C1)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C4)alkyl and each of R3, R6, and R10 is (C1)alkyl. In another embodiment, each of R1, R4, and R8 is (C4)alkyl and each of R3, R6, and R10 is (C1)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C3)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C3)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C3)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C3)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R3, R6, and R10 is (C1)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R3, R6, and R10 is (C1)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R3, R6, and R10 is (C1)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl or (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In another embodiment, one of R1, R4, and R8 is (C1-C4)alkyl and the other two are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C6)alkyl. In another embodiment, two of R1, R4, and R8 are (C1-C4)alkyl and the other is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl or (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C3)alkyl. In another embodiment, one of R1, R4, and R8 is (C1-C4)alkyl and the other two are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C3)alkyl. In another embodiment, two of R1, R4, and R8 are (C1-C4)alkyl and the other is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of R2, R5, R7, R9, and R11 is (C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C3)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl or (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R3, R6, and R10 is (C1)alkyl. In another embodiment, one of R1, R4, and R8 is (C1-C4)alkyl and the other two are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R3, R6, and R10 is (C1)alkyl. In another embodiment, two of R1, R4, and R8 are (C1-C4)alkyl and the other is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R3, R6, and R10 is (C1)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of R3, R6, and R10 is (C1)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R3, R6, and R10 is (C1)alkyl.
- In one embodiment, at least two of R1, R4, and R8 are (C1-C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, at least one of R1, R4, and R8 is (C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, each of R1, R4, and R8 is (C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl.
- In one embodiment, at least two of R1, R4, and R8 are (C1-C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, at least one of R1, R4, and R8 is (C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, at least two of R1, R4, and R8 are (C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, each of R1, R4, and R8 is (C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is H.
- In one embodiment, at least two of R1, R4, and R8 are (C1-C4)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, at least one of R1, R4, and R8 is (C4)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, at least two of R1, R4, and R8 are (C4)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, each of R1, R4, and R8 is (C4)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is H.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C)alkyl and the other are H. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl or (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, one of R1, R4, and R8 is (C1-C4)alkyl and the other two are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, two of R1, R4, and R8 are (C1-C4)alkyl and the other is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl or (C1-C3)alkyl substituted with (C4-C7)cycloalkyl 1 and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, one of R1, R4, and R8 is (C1-C4)alkyl and the other two are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, two of R1, R4, and R8 are (C1-C4)alkyl and the other is (C1-C6)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is H.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl or (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, one of R1, R4, and R8 is (C1-C4)alkyl and the other two are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, two of R1, R4, and R8 are (C1-C4)alkyl and the other is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H.
- In one embodiment, each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, each of R2, R5, R7, R9, and R11 is (C3)alkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, each of R3, R6, and R10 is (C1)alkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl.
- In one embodiment, each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, each of R2, R5, R7, R9, and R11 is (C3)alkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, each of R3, R6, and R10 is (C1)alkyl and each of X1, X2, X3, X4, X5 and X6 is H.
- In one embodiment, each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, each of R2, R5, R7, R9, and R11 is (C3)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, each of R3, R6, and R10 is (C1)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H.
- In one embodiment, at least two of R1, R4, and R8 are (C1-C4)alkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, at least one of R1, R4, and R8 is (C4)alkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, at least two of R1, R4, and R8 are (C4)alkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, each of R1, R4, and R8 is (C4)alkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl or (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, one of R1, R4, and R8 is (C1-C4)alkyl and the other two are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, two of R1, R4, and R8 are (C1-C4)alkyl and the other is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- In one embodiment, each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, each of R2, R5, R7, R9, and R11 is (C3)alkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, each of R3, R6, and R10 is (C1)alkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- In one embodiment, each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, each of X1, X2, X3, X4, X5 and X6 is H and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- In some embodiments, the present disclosure provides a compound has formula (Ia):
- or a pharmaceutically acceptable salt thereof, wherein
aa1 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit. - In some embodiments, aa1 is valine. In other embodiments, aa1 is threonine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa1 is threonine. In other embodiments, aa1 is threonine substituted with a Protecting Group. In other embodiments, aa1 is threonine substituted with a Linking Unit. In other embodiments, aa1 is tyrosine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa1 is tyrosine. In other embodiments, aa1 is tyrosine substituted with a Protecting Group. In other embodiments, aa1 is tyrosine substituted with a Linking Unit.
- In some embodiments, the Linking Unit comprises a cleavable linker. In some embodiments, the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage. In some embodiments, the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond. In some embodiments, the cleavable linker comprises glucuronide.
- In some embodiments, Aa is maleimidocaproyl.
- In some embodiments, Ww is Valine-Citrulline.
- In some embodiments, Yy is p-aminobenzyloxycarbonyl.
- In some embodiments, Aa is maleimidocaproyl, Ww is Valine-Citrulline and Yy is p-aminobenzyloxycarbonyl.
- In some embodiments, the Linking Unit comprises a monoclonal antibody.
- In some embodiments, the present disclosure provides a compound has formula (Ib):
- or a pharmaceutically acceptable salt thereof, wherein
aa1 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit. - In some embodiments, aa1 is valine. In other embodiments, aa1 is threonine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa1 is threonine. In other embodiments, aa1 is threonine substituted with a Protecting Group. In other embodiments, aa1 is threonine substituted with a Linking Unit. In other embodiments, aa1 is tyrosine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa1 is tyrosine. In other embodiments, aa1 is tyrosine substituted with a Protecting Group. In other embodiments, aa1 is tyrosine substituted with a Linking Unit.
- In some embodiments, the Linking Unit comprises a cleavable linker. In some embodiments, the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage. In some embodiments, the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond. In some embodiments, the cleavable linker comprises glucuronide.
- In some embodiments, Aa is maleimidocaproyl.
- In some embodiments, Ww is Valine-Citrulline.
- In some embodiments, Yy is p-aminobenzyloxycarbonyl.
- In some embodiments, Aa is maleimidocaproyl, Ww is Valine-Citrulline and Yy is p-aminobenzyloxycarbonyl.
- In some embodiments, the Linking Unit comprises a monoclonal antibody.
- In some embodiments, the present disclosure provides a compound has formula (Ic):
- or a pharmaceutically acceptable salt thereof, wherein
aa1 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit. - In some embodiments, aa1 is valine. In other embodiments, aa1 is threonine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa1 is threonine. In other embodiments, aa1 is threonine substituted with a Protecting Group. In other embodiments, aa1 is threonine substituted with a Linking Unit. In other embodiments, aa1 is tyrosine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa1 is tyrosine. In other embodiments, aa1 is tyrosine substituted with a Protecting Group. In other embodiments, aa1 is tyrosine substituted with a Linking Unit.
- In some embodiments, the Linking Unit comprises a cleavable linker. In some embodiments, the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage. In some embodiments, the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond. In some embodiments, the cleavable linker comprises glucuronide.
- In some embodiments, Aa is maleimidocaproyl.
- In some embodiments, Ww is Valine-Citrulline.
- In some embodiments, Yy is p-aminobenzyloxycarbonyl.
- In some embodiments, Aa is maleimidocaproyl, Ww is Valine-Citrulline and Yy is p-aninobenzyloxycarbonyl.
- In some embodiments, the Linking Unit comprises a monoclonal antibody.
- In another embodiment, the present disclosure provides a compound of formula (II),
- or a pharmaceutically acceptable salt thereof, wherein
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently selected from —(C1-C6)alkyl, —(C2-C6)alkenyl and —(C2-C6)alkynyl, -
- wherein the alkyl, alkenyl or alkynyl are unsubstituted or substituted with a substituent selected from —OH, —NH2, —NHR′, —NHR′R″, —SH, —SR′, —C(O)OH, —C(O)NH2, —C(O)NHR′, —C(O)NR′R″, —NHC(═NH)NH2, —(C6-C14)aryl, —(C6-C14)aryl substituted with OH, -(5- or 6-membered monocyclic heteroaryl), -(9- or 10-membered bicyclic heteroaryl) and —(C4-C7)cycloalkyl, wherein R′ and R″ are independently selected from —(C1-C6)alkyl, —(C2-C6)alkenyl and (C2-C6)alkynyl; or
- wherein the alkyl, taken together with an adjacent N, forms a (5- or 6-membered)heterocyclyl;
X1, X2, X3, X4, X5 and X6 are independently selected from —H, (C1-C6)alkyl, —(C2-C6)alkenyl and —(C2-C6)alkynyl;
aa2 is an amino acid, wherein the amino acid is unsubstituted or substituted with a protecting group or a Linking Unit.
- The Linker Unit is as defined for Compound of Formula (I).
- In some embodiments, the compound of formula (II) is conjugated directly or indirectly to an antibody. In one embodiment, the compound of formula (II) is conjugated directly to an antibody. In another embodiment, the compound of formula (II) is conjugated to an antibody through a Linker Unit. The compound may be conjugated to an antibody through a Linker Unit at aa1. The Linker Unit can operate to provide a suitable release of the compound of formula (II). The preparation of antibody drug conjugates is known to those of skill in the art.
- The compounds of formula (II) may be conjugated to any antibody, e.g., an antibody that binds to a tumor associated antigen. In one embodiment, the antibody used in the antibody drug conjugate of the disclosure is a monoclonal antibody. In another embodiment, the antibody used in the antibody drug conjugate of the disclosure binds at least one of CD19, CD20, CD30, CD33, CD70, BCMA, Glypican-3, Liv-1 and Lewis Y antigen.
- In some embodiments, at least one of R1, R4, and R8 is (C1-C6)alkyl. In some embodiments, at least two of R1, R4, and R8 are (C1-C6)alkyl. In some embodiments, each of R1, R4, and R8 is (C1-C6)alkyl. In some embodiments, at least one of R1, R4, and R8 is (C1-C4)alkyl. In some embodiments, at least two of R1, R4, and R8 are (C1-C4)alkyl. In some embodiments, each of R1, R4, and R8 is (C1-C4)alkyl. In some embodiments, at least one of R1, R4, and R8 is (C4)alkyl. In some embodiments, at least two of R1, R4, and R8 are (C4)alkyl. In some embodiments, each of R1, R4, and R8 is (C4)alkyl.
- In some embodiments, at least one of R1, R4, and R8 is (C1-C6)alkyl substituted with (C4-C7)cycloalkyl. In some embodiments, at least two of R1, R4, and R8 are (C1-C6)alkyl substituted with (C4-C7)cycloalkyl. In some embodiments, each of R1, R4, and R8 is (C1-C6)alkyl substituted with (C4-C7)cycloalkyl. In some embodiments, at least one of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl. In some embodiments, at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl. In some embodiments, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl. In some embodiments, at least one of R1, R4, and R8 is (C1)alkyl substituted with (C4-C7)cycloalkyl. In some embodiments, at least two of R1, R4, and R8 are (C1)alkyl substituted with (C4-C7)cycloalkyl. In some embodiments, each of R1, R4, and R8 is (C1)alkyl substituted with (C4-C7)cycloalkyl. In some embodiments, at least one of R1, R4, and R8 is (C1-C6)alkyl substituted with (C6)cycloalkyl. In some embodiments, at least two of R1, R4, and R8 are (C1-C6)alkyl substituted with (C6)cycloalkyl. In some embodiments, each of R1, R4, and R8 is (C1-C6)alkyl substituted with (C6)cycloalkyl. In some embodiments, at least one of R1, R4, and R8 is (C1-C3)alkyl substituted with (C6)cycloalkyl. In some embodiments, at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C6)cycloalkyl. In some embodiments, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C6)cycloalkyl. In some embodiments, at least one of R1, R4, and R8 is (C1)alkyl substituted with (C6)cycloalkyl. In some embodiments, at least two of R1, R4, and R8 are (C1)alkyl substituted with (C6)cycloalkyl. In some embodiments, each of R1, R4, and R8 is (C1)alkyl substituted with (C6)cycloalkyl.
- In some embodiments, at least one of R1, R4, and R8 is (C1-C6)alkyl or (C1-C6)alkyl substituted with (C4-C7)cycloalkyl. In another embodiment, one of R1, R4, and R8 is (C1-C4)alkyl and the other two are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl. In another embodiment, two of R1, R4, and R8 are (C1-C4)alkyl and the other is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl.
- In some embodiments, each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In some embodiments, each of R2, R5, R7, R9, and R11 is (C3)alkyl. In some embodiments, each of R3, R6, and R10 is (C1)alkyl.
- In some embodiments, each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In some embodiments, each of X1, X2, X3, X4, X5 and X6 is H. In some embodiments, at least one of X1, X2, X3, X4, X5 and X6 is (C1-C6)alkyl and the other are H. In some embodiments, at least one of X1, X2, X3, X4, X5 and X6 is (C1-C3)alkyl and the other are H. In some embodiments, at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H.
- In some embodiments, aa2 is a natural amino acid. In other embodiments, aa2 is an unnatural amino acid. In some embodiments, aa2 comprises a functional group selected from —NH2, —SH, —OH or —COOH. In some embodiments, aa1 comprises —NH2. In some embodiments, aa1 comprises —SH. In some embodiments, aa1 comprises —OH. In some embodiments, aa1 comprises —COOH. In some embodiments, aa2 is valine. In other embodiments, aa2 is threonine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa2 is threonine. In other embodiments, aa2 is threonine substituted with a Protecting Group. In other embodiments, aa2 is threonine substituted with a Linking Unit. In other embodiments, aa2 is tyrosine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa2 is tyrosine. In other embodiments, aa2 is tyrosine substituted with a Protecting Group. In other embodiments, aa2 is tyrosine substituted with a Linking Unit. In some embodiments, aa2 is 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa2 is 4-aminophenylalanine. In other embodiments, aa2 is 4-aminophenylalanine substituted with a Protecting Group. In other embodiments, aa2 is 4-aminophenylalanine substituted with a Linking Unit. In some embodiments, aa2 is 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa2 is 3-aminophenylalanine. In other embodiments, aa2 is 3-aminophenylalanine substituted with a Protecting Group. In other embodiments, aa2 is 3-aminophenylalanine substituted with a Linking Unit. In some embodiments, aa2 is 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa2 is 2-aminophenylalanine. In other embodiments, aa2 is 2-aminophenylalanine substituted with a Protecting Group. In other embodiments, aa2 is 2-aminophenylalanine substituted with a Linking Unit.
- In some embodiments, the Linking Unit comprises a cleavable linker. In some embodiments, the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage. In some embodiments, the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond. In some embodiments, the cleavable linker comprises glucuronide.
- In some embodiments, Aa is maleimidocaproyl.
- In some embodiments, Ww is Valine-Citrulline.
- In some embodiments, Yy is p-aminobenzyloxycarbonyl.
- In some embodiments, Aa is maleimidocaproyl, Ww is Valine-Citrulline and Yy is p-aminobenzyloxycarbonyl.
- In some embodiments, the Linking Unit comprises a monoclonal antibody.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In one embodiment, at least two of R1, R4, and R8 are (C1-C4)alkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In another embodiment, at least one of R1, R4, and R8 is (C4)alkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C4)alkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C4)alkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl and each of R2, R5, R7, R9, and R11 is (C1)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C1-C4)alkyl and each of R2, R1, R7, R9, and R11 is (C1)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of R2, R5, R7, R9, and R11 is (C1)alkyl. In another embodiment, at least one of R1, R4, and R8 is (C4)alkyl and each of R2, R5, R7, R9, and R11 is (C1)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C4)alkyl and each of R2, R5, R7, R9, and R11 is (C1)alkyl. In another embodiment, each of R1, R4, and R8 is (C4)alkyl and each of R2, R5, R7, R9, and R11 is (C1)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl and each of R3, R6, and R10 is (C3)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C1-C4)alkyl and each of R3, R6, and R10 is (C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of R3, R6, and R10 is (C3)alkyl. In another embodiment, at least one of R1, R4, and R8 is (C4)alkyl and each of R3, R6, and R10 is (C3)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C4)alkyl and each of R3, R6, and R10 is (C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C4)alkyl and each of R3, R6, and R10 is (C3)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C1)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C1)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C1)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C1)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C1)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C1)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R3, R6, and R10 is (C3)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R3, R6, and R10 is (C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R3, R6, and R10 is (C3)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl or (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In another embodiment, one of R1, R4, and R8 is (C1-C4)alkyl and the other two are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In another embodiment, two of R1, R4, and R8 are (C1-C4)alkyl and the other is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl or (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C1)alkyl. In another embodiment, one of R1, R4, and R8 is (C1-C4)alkyl and the other two are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C1)alkyl. In another embodiment, two of R1, R4, and R8 are (C1-C4)alkyl and the other is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C1)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of R2, R5, R7, R9, and R11 is (C1)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R2, R5, R7, R9, and R11 is (C1)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl or (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R3, R6, and R10 is (C3)alkyl. In another embodiment, one of R1, R4, and R8 is (C1-C4)alkyl and the other two are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R3, R6, and R10 is (C3)alkyl. In another embodiment, two of R1, R4, and R8 are (C1-C4)alkyl and the other is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R3, R6, and R10 is (C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of R3, R6, and R10 is (C3)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of R3, R6, and R10 is (C3)alkyl.
- In one embodiment, at least two of R1, R4, and R8 are (C1-C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, at least one of R1, R4, and R8 is (C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, each of R1, R4, and R8 is (C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl.
- In one embodiment, at least two of R1, R4, and R8 are (C1-C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, at least one of R1, R4, and R8 is (C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, at least two of R1, R4, and R8 are (C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, each of R1, R4, and R8 is (C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is H.
- In one embodiment, at least two of R1, R4, and R8 are (C1-C4)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, at least one of R1, R4, and R8 is (C4)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, at least two of R1, R4, and R8 are (C4)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, each of R1, R4, and R8 is (C4)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C6)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is H.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C6)alkyl substituted with (C4-C7)cycloalkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C)alkyl and the other are H. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl or (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, one of R1, R4, and R8 is (C1-C4)alkyl and the other two are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, two of R1, R4, and R8 are (C1-C4)alkyl and the other is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl or (C1-C3)alkyl substituted with (C4-C7)cycloalkyl 1 and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, one of R1, R4, and R8 is (C1-C4)alkyl and the other two are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, two of R1, R4, and R8 are (C1-C4)alkyl and the other is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and each of X1, X2, X3, X4, X5 and X6 is H.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl or (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, one of R1, R4, and R8 is (C1-C4)alkyl and the other two are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, two of R1, R4, and R8 are (C1-C4)alkyl and the other is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H.
- In one embodiment, each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, each of R2, R5, R7, R9, and R11 is (C1)alkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl. In another embodiment, each of R3, R6, and R10 is (C3)alkyl and each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl.
- In one embodiment, each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, each of R2, R5, R7, R9, and R11 is (C1)alkyl and each of X1, X2, X3, X4, X5 and X6 is H. In another embodiment, each of R3, R6, and R10 is (C3)alkyl and each of X1, X2, X3, X4, X5 and X6 is H.
- In one embodiment, each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H. In another embodiment, each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl and at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H.
- In one embodiment, at least two of R1, R4, and R8 are (C1-C4)alkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, at least one of R1, R4, and R8 is (C4)alkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, at least two of R1, R4, and R8 are (C4)alkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, each of R1, R4, and R8 is (C4)alkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, at least two of R1, R4, and R8 are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, each of R1, R4, and R8 is (C1-C6)alkyl substituted with (C4-C7)cycloalkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- In one embodiment, at least one of R1, R4, and R8 is (C1-C4)alkyl or (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, one of R1, R4, and R8 is (C1-C4)alkyl and the other two are (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, two of R1, R4, and R8 are (C1-C4)alkyl and the other is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, each of R1, R4, and R8 is (C1-C4)alkyl aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, each of R1, R4, and R8 is (C1-C3)alkyl substituted with (C4-C7)cycloalkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- In one embodiment, each of R2, R3, R5, R6, R7, R9, R10 and R11 is independently (C1-C3)alkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, each of R2, R5, R7, R9, and R11 is (C1)alkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, each of R3, R6, and R10 is (C3)alkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- In one embodiment, each of X1, X2, X3, X4, X5 and X6 is independently H or (C1-C6)alkyl and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, each of X1, X2, X3, X4, X5 and X6 is H and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit. In another embodiment, at least one of X1, X2, X3, X4, X5 and X6 is (C1)alkyl and the other are H and aa1 is valine, threonine optionally substituted with a Protecting Group or a Linking Unit, tyrosine optionally substituted with a Protecting Group or a Linking Unit, 4-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit, 3-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit or 2-aminophenylalanine optionally substituted with a Protecting Group or a Linking Unit.
- In some embodiments, the present disclosure provides a compound of formula (Ia):
- or a pharmaceutically acceptable salt thereof, wherein
aa2 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit. - In some embodiments, aa2 is valine. In other embodiments, aa2 is threonine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa2 is threonine. In other embodiments, aa2 is threonine substituted with a Protecting Group. In other embodiments, aa2 is threonine substituted with a Linking Unit. In other embodiments, aa2 is tyrosine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa2 is tyrosine. In other embodiments, aa2 is tyrosine substituted with a Protecting Group. In other embodiments, aa2 is tyrosine substituted with a Linking Unit.
- In some embodiments, the Linking Unit comprises a cleavable linker. In some embodiments, the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage. In some embodiments, the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond. In some embodiments, the cleavable linker comprises glucuronide.
- In some embodiments, Aa is maleimidocaproyl.
- In some embodiments, Ww is Valine-Citrulline.
- In some embodiments, Yy is p-aminobenzyloxycarbonyl.
- In some embodiments, Aa is maleimidocaproyl, Ww is Valine-Citrulline and Yy is p-aminobenzyloxycarbonyl.
- In some embodiments, the Linking Unit comprises a monoclonal antibody.
- In some embodiments, the present disclosure provides a compound of formula (IIb):
- or a pharmaceutically acceptable salt thereof, wherein
aa2 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit. - In some embodiments, aa2 is valine. In other embodiments, aa2 is threonine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa2 is threonine. In other embodiments, aa2 is threonine substituted with a Protecting Group. In other embodiments, aa2 is threonine substituted with a Linking Unit. In other embodiments, aa2 is tyrosine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa2 is tyrosine. In other embodiments, aa2 is tyrosine substituted with a Protecting Group. In other embodiments, aa2 is tyrosine substituted with a Linking Unit.
- In some embodiments, the Linking Unit comprises a cleavable linker. In some embodiments, the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage. In some embodiments, the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond. In some embodiments, the cleavable linker comprises glucuronide.
- In some embodiments, Aa is maleimidocaproyl.
- In some embodiments, Ww is Valine-Citrulline.
- In some embodiments, Yy is p-aminobenzyloxycarbonyl.
- In some embodiments, Aa is maleimidocaproyl, Ww is Valine-Citrulline and Yy is p-aminobenzyloxycarbonyl.
- In some embodiments, the Linking Unit comprises a monoclonal antibody.
- In some embodiments, the present disclosure provides a compound of formula (IIc):
- or a pharmaceutically acceptable salt thereof, wherein
aa2 is valine, threonine optionally substituted with a protecting group or a Linking Unit, and tyrosine optionally substituted with a protecting group or a Linking Unit. - In some embodiments, aa2 is valine. In other embodiments, aa2 is threonine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa2 is threonine. In other embodiments, aa2 is threonine substituted with a Protecting Group. In other embodiments, aa2 is threonine substituted with a Linking Unit. In other embodiments, aa2 is tyrosine optionally substituted with a Protecting Group or a Linking Unit. In some embodiments, aa2 is tyrosine. In other embodiments, aa2 is tyrosine substituted with a Protecting Group. In other embodiments, aa2 is tyrosine substituted with a Linking Unit.
- In some embodiments, the Linking Unit comprises a cleavable linker. In some embodiments, the cleavable linker is cleavable by a method selected from the group consisting of glycosidase-induced cleavage, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage. In some embodiments, the cleavable linker comprises a glycosidic bond, a hydrazone, a cathepsin-B-cleavable peptide, a disulfide or an ester bond. In some embodiments, the cleavable linker comprises glucuronide.
- In some embodiments, Aa is maleimidocaproyl.
- In some embodiments, Ww is Valine-Citrulline.
- In some embodiments, Yy is p-aminobenzyloxycarbonyl.
- In some embodiments, Aa is maleimidocaproyl, Ww is Valine-Citrulline and Yy is p-aninobenzyloxycarbonyl.
- In some embodiments, the Linking Unit comprises a monoclonal antibody.
- Representative compounds of formulae (I) and (II) include:
- pharmaceutically acceptable salts thereof.
- In one embodiment, the compound is
- and a pharmaceutically acceptable salt thereof.
- The compounds of this disclosure may be prepared by methods known to those skilled in the art, methods of Schemes I through IV, or the synthetic Examples set forth below.
- According to another embodiment, the present disclosure provides a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- The pharmaceutical composition of the disclosure may be formulated for administration in solid or liquid form, including those adapted for administration by oral, nasal, parenteral, rectal, topical, ocular, inhalation and intra-tumor administration. Parenteral administration includes subcutaneous injections, intravenous, intramuscular or intrasternal injection or infusion techniques. In one embodiment, the compositions are administered parenterally. In another embodiment, the compositions are administered intravenously.
- The pharmaceutical composition of the disclosure may be in the form of a liquid, e.g., a solution, emulsion or suspension, pellets, powders, sustained-release formulations, or any other form suitable for use. The pharmaceutical composition may comprise sterile diluents such as water, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono- or digylcerides, which can serve as the solvent or suspending medium, polyethylene glycols, glycerin, cyclodextrin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates, phosphates or amino acids; agents for the adjustment of tonicity such as sodium chloride or dextrose; surfactants; preservatives; wetting agents; dispersing agents; suspending agents; stabilizers; solubilizing agents; local anesthetics, e.g., lignocaine; or isotonic agent.
- It should be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the type of patient (e.g., human), the activity of the specific compound employed, the composition employed, the manner of administration, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the nature and the severity of the particular disorder being treated. The amount of active ingredients will also depend upon the particular compound in the composition. The amount of active ingredient can be determined by standard clinical techniques. In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges.
- Preferably, the compositions are formulated so that a dosage of between about 0.01 to about 20 mg/kg body weight/day of the compound of formula (I) can be administered to a patient receiving the composition. In one embodiment, the dosage administered to the patient is between about 0.01 mg/kg and about 10 mg/kg of the patient's body weight. In another embodiment, the dosage administered to the patient is between about 0.1 mg/kg and about 10 mg/kg of the patient's body weight. In yet another embodiment, the dosage administered to the patient is between about 0.1 mg/kg and about 5 mg/kg of the patient's body weight. In yet another embodiment, the dosage administered is between about 0.1 mg/kg and about 3 mg/kg of the patient's body weight. In yet another embodiment, the dosage administered is between about 1 mg/kg and about 3 mg/kg of the patient's body weight.
- The pharmaceutical compositions comprise an effective amount of a compound described herein such that a suitable dosage will be obtained. Typically, this amount is at least about 0.01% of a compound by weight of the composition. In a preferred embodiment, pharmaceutical compositions are prepared so that a parenteral dosage unit contains from about 0.01% to about 2% by weight of the compound of the disclosure.
- For intravenous administration, the pharmaceutical composition may comprise from about 0.01 to about 100 mg of a compound described herein per kg of the patient's body weight. In one aspect, the composition may include from about 1 to about 100 mg of a compound described herein per kg of the patient's body weight. In another aspect, the amount administered will be in the range from about 0.1 to about 25 mg of a compound described herein per kg of body weight.
- The pharmaceutical compositions of the present disclosure may optionally further comprise a second therapeutic agent in a therapeutically effective amount. The second therapeutic agent includes those that are known and those discovered to be effective in the reatment of cancer, a bacterial infection or a fungal infection. In some embodiments, the second therapeutic agent is selected from the group consisting of a tubulin-forming inhibitor, a topoisomerase inhibitor, and a DNA binder.
- The present disclosure also provides methods of using the compounds described herein or pharmaceutical compositions thereof. The compounds and compositions are useful for killing or inhibiting the proliferation of tumor cells or cancer cells. The compounds and compositions are also useful for treating cancer in a patient. In addition, the compounds and compositions are useful for inhibiting bacterial or fungal growth. The compounds and compositions are useful in treating a bacterial or fungal infection in a patient.
- In some embodiments, the present disclosure provides methods of killing or inhibiting the proliferation of tumor cells or cancer cells. In some embodiments, the method comprises contacting the tumor cells or cancer cells with a compound described herein, or a pharmaceutically acceptable salt thereof, in an amount effective to kill or inhibit the proliferation of the tumor cells or cancer cells. In alternate embodiments, the method comprises contacting the tumor cells or cancer cells with a pharmaceutical composition comprising a compound described herein in an amount effective to kill or inhibit the proliferation of the tumor cells or cancer cells.
- In some embodiments, the method further comprises contacting the cells with an effective amount of a second therapeutic agent or a pharmaceutical composition thereof. In one embodiment, the second therapeutic agent can be selected from the group consisting of a tubulin-forming inhibitor, a topoisomerase inhibitor, and a DNA binder.
- The cells may be contacted with the compound described herein and the second therapeutic agent simultaneously in either the same or different compositions or sequentially in any order. The amounts of compound described herein and the second therapeutic agent and the relative timings of their contact will be selected in order to achieve the desired combined effect.
- In another embodiment, the present disclosure provides a method of determining inhibition of cellular proliferation by a compound described herein. The method comprises contacting cells in a cell culture medium with the compound described herein and measuring the cytotoxic activity of the compound, whereby proliferation of the cells is inhibited. In some embodiments, the method further comprises culturing the cells for a period from about 6 hours to about 5 days.
- Suitable cell lines are known to those skilled in the art and include those used for evaluating other anti-cancer drugs. Such cell lines include, but are not limited to, 786-O (a renal cell carcinoma); Caki-1 (a renal cell carcinoma): L428 (Hodgkin's disease); UMRC-3 (renal cell carcinoma); LP-1 (human myeloma); U251 (glioblastoma cell line); BXPC-3 (pancreas); MCF-7 (breast); SF-268 (CNS); NCI-H460 (lung); KM20L2 (colon); and DU-145 (prostate). In some embodiments, the cells are obtained from a patient having a disease to be treated (e.g., cancer) or from a relevant cell line.
- In another embodiment, the present disclosure provides a method of measuring cell viability in the presence of a compound described herein. The method comprises contacting cells in a cell culture medium with the compound of described herein, culturing the cells for a period from about 6 hours to about 5 days, preferably 96 hours; and measuring cell viability. In some embodiments, the cells are obtained from a patient having a disease to be treated (e.g., cancer) or from a relevant cell line.
- In another embodiment, the present disclosure provides a method for treating cancer in a patient. In some embodiments, the method comprises administering to the patient a compound described herein, or a pharmaceutically acceptable salt thereof, in an amount effective to treat cancer. In other embodiments, the method comprises administering to the patient a composition comprising a compound described herein in an amount effective to treat cancer.
- In some embodiments, the patient receives an additional treatment, such as radiation therapy, surgery, chemotherapy with another chemotherapeutic agent or combinations thereof. In some embodiments, the compound of the disclosure is administered concurrently with the chemotherapeutic agent or with radiation therapy or with surgery. In other embodiments, the chemotherapeutic agent or radiation therapy or surgery is administered or performed prior or subsequent to administration of a compound of the disclosure.
- In some embodiments, the method for treating cancer further comprises administering to the patient an effective amount of a second therapeutic agent, e.g., a chemotherapeutic agent. Any one or a combination of the chemotherapeutic agents, such a standard of care chemotherapeutic agent(s), can be administered. In some embodiments, the chemotherapeutic agent may be selected from the group consisting of a tubulin-forming inhibitor, a topoisomerase inhibitor, and a DNA binder.
- The compound described herein and the chemotherapeutic agent may be administered simultaneously in either the same or different pharmaceutical composition or sequentially in any order. The amounts of compound described herein and the chemotherapeutic agent and the relative timings of their administration will be selected in order to achieve the desired combined effect.
- In another embodiment, the present disclosure provides a method of inhibiting the growth of tumor cells that overexpress a tumor-associated antigen in a patient. In some embodiments, the method comprises administering to the patient a compound described herein conjugated to an antibody that is specific for said tumor-associated antigen, wherein the compound described herein is administered in amount effective to inhibit growth of tumor cells in the patient. In alternate embodiments, the method comprises administering to the patient a pharmaceutical composition comprising a compound described herein conjugated to an antibody that is specific for said tumor-associated antigen, wherein the compound described herein is administered in amount effective to inhibit growth of tumor cells in the patient. The method may optionally further comprises administering to the patient a chemotherapeutic agent, or a pharmaceutical composition thereof, in an amount effective to inhibit the growth of tumor cells in the patient.
- In some embodiments, the compound sensitizes the tumor cells to the chemotherapeutic agent.
- In some embodiments, the compound induces cell death. In other embodiments, the compound induces apoptosis.
- In some embodiments, the tumor cells are associated with a cancer selected from the group consisting of breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon, colorectal, thyroid, pancreatic, prostate, central nervous system and bladder cancer.
- In some embodiments, the compound described herein is conjugated to an antibody selected from the group consisting of CD19, CD20, CD30, CD33, CD70, BCMA, Glypican-3, Liv-1 and Lewis Y.
- In some embodiments, the present disclosure provides methods of inhibiting bacterial or fungal growth in a sample. In some embodiments, the method comprises contacting the sample with a compound described herein, or a pharmaceutically acceptable salt thereof, in an amount effective to inhibit growth of bacteria or fungus in the sample. In alternate embodiments, the method comprises contacting the sample with a pharmaceutical composition comprising a compound described herein in an amount effective to inhibit the growth of bacteria or fungus in the sample.
- In some embodiments, the present disclosure provides methods of treating a bacterial or fungal infection in a patient. In some embodiments, the method comprises administering to the patient a compound described herein, or a pharmaceutically acceptable salt thereof, in an amount effective to treat the bacterial or fungal infection. In other embodiments, the method comprises administering to the patient a composition comprising a compound described herein in an amount effective to the bacterial or fungal infection.
- The compounds of the present disclosure may be used in methods for inhibiting bacterial or fungal growth and in methods for treating bacterial or fungal infections. The compounds are used in a method for inhibiting bacterial growth in one embodiment, in a method for treating a bacterial infection in a second embodiment, in a method for inhibiting fungal growth in a third embodiment, and in a method for treating a fungal infection in a four embodiment. In each embodiment of this paragraph in which the compounds inhibit bacterial growth or treat a bacterial infection, the bacteria is selected from gram-negative bacteria or gram-positive bacteria. In some embodiments, the bacteria or fungi is selected from vancomycin-resistant Enterococcus faecalis, Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, multi-drug-resistant Streptococcus pneumoniae, Streptococcus pyogenes, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Cryptococcus neoformans and Candida albicans. In one embodiment, the bacteria is Streptococcus pneumoniae (including a penicillin-resistant strain and a multi-drug resistant strain) or Streptococcus pyogenes.
- In some embodiments, the method for treating a bacterial or fungal infection further comprises administering to the patient an effective amount of a second therapeutic agent. Any one or a combination of the second therapeutic agent, such a standard of care therapeutic agent(s) for bacterial or fungal infections, can be administered.
- Any compound or pharmaceutical composition described herein may be used in the methods of the present disclosure.
- In some of the above methods, the compound described herein is administered to a patient in a composition comprising a pharmaceutically acceptable carrier. In some of these embodiments, the composition is administered intravenously. In certain embodiments, the compound is formulated in a unit dosage injectable form.
- In preferred embodiments of each of the above methods, the patient is a human.
- In an additional embodiment, the present disclosure provides the use of a compound of described herein in the manufacture of a medicament for the treatment of any of the above mentioned conditions. In one embodiment, the medicament is useful for the treatment of any of the above mentioned cancers. In another embodiment, the medicament is useful for the treatment of a bacterial or fungal infection. It will be appreciated that a compound described herein and one or more second therapeutic agents may be used in the manufacture of the medicament.
- In additional embodiments, the present disclosure provides an article of manufacture comprising a compound described herein, a container, and a package insert or label indicating that the compound can be used to treat cancer characterized by the overexpression of at least one tumor-associated antigen.
- In additional embodiments, the present disclosure provides an article of manufacture comprising a compound described herein, a container, and a package insert or label indicating that the compound can be used to treat a bacterial or fungal infection.
- The term “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products that contain information about the indication(s), usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products.
- In order that this invention be more fully understood, the following examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.
- Reagents and anhydrous solvents were purchased from Sigma-Aldrich Chemical Company and Alfa-Aesar Inc, and were used as received. Degussa type E101 NE/W was employed for 20% palladium hydroxide on carbon. The reactions were carried out under an atmosphere of nitrogen unless specified otherwise. Column chromatography was conducted using silica gel (E. Merck 60 Å, 230-400 mesh), applying a low-pressure stream of nitrogen. Analytical thin layer chromatography separations were carried out on glass plates coated with silica gel (Analtech, GHLF uniplates). The TLC chromatograms were visualized using UV (short wave) lamp irradiation or by immersing the plates in ceric ammonium molybdate (CAM) staining solution followed by heating with a heat gun.
- Melting points are uncorrected and were determined with a Fischer-Johns melting point apparatus. Optical rotations were measured by use of a Perkin-Elmer 241 polarimeter, and the [α]D values are given in 10−1 deg cm2 g−1. 1H and 13C NMR spectra were recorded on a Varian Unity INOVA 400 instrument with deuterated solvents; 1H NMR chemical shifts were recorded relative to residual CHCl3 at 7.26 ppm, or MeOH 3.31 ppm; 13C NMR chemical shifts were reported relative to residual CHCl3 at 77.16 ppm, or MeOH 49.00 ppm. High resolution mass spectra were obtained in the Arizona State University CLAS High Resolution Mass Spectrometry Laboratory.
- Compounds 7a, 8a and 8b were synthesized according to the method depicted in Scheme 1.
- To a stirred solution containing Boc-D-Val (1.00 g, 4.60 mmol) and benzyl L-lactate (638 mg, 3.54 mmol) in 20 mL of anhydrous DCM at 0° C. was added DMAP (86 mg, 0.71 mmol) followed by DCC (840 mg, 4.07 mmol). The reaction mixture was stirred at 23° C. for 4 h. The mixture was filtered to remove most of the DCU and the filtrate was diluted with 80 mL of DCM. The organic solution was washed with 50 mL of 0.3 N HCl, 50 mL of satd aq NaHCO3 and 50 mL of brine. The organic solution was dried over MgSO4 and concentrated under reduced pressure. The residue was dissolved in 50 mL of cold acetonitrile and the formed precipitate was filtered. The filtrate was concentrated under reduced pressure to afford 1 as a colorless oil: yield 97% (1.32 g, 3.47 mmol); [α]24 D−3.43 (c 0.18, ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 7.25 (5H, m), 5.06 (4H, m), 4.22 (1H, m), 2.11 (1H, m), 1.42 (3H, d, J=7.2 Hz), 1.37 (9H, s), 0.90 (3H, d, J=6.8 Hz) and 0.83 (3H, d, J=6.8 Hz); 13C NMR (CDCl3, 101 MHz) δ 171.3, 169.9, 155.4, 135.1, 128.4, 128.5, 128.0, 79.5, 69.0, 66.9, 58.5, 31.0, 28.2, 18.8, 17.4 and 16.8; HRMS (APCI), m/z 380.2067 [M+H]+ (calcd for C20H30NO6, 380.2073).
- To a stirred solution containing ester 1 (4.12 g, 10.9 mmol) in 60 mL of anhydrous DCM was added TFA (15 mL). The reaction mixture was stirred at 23° C. for 5 h and then concentrated under reduced pressure. The residue was dissolved in 140 mL of DCM and washed with two 100-mL portions of satd aq NaHCO3 and 100 mL of brine. The organic solution was dried over MgSO4 and concentrated under reduced pressure. The residue was dissolved in 60 mL of anhydrous DCM and cooled to 0° C. Next, (R)-2-hydroxyisocaproic acid (1.44 g, 10.9 mmol) was added followed by HOBt (2.22 g, 16.4 mmol), TEA (2.27 mL, 1.66 g, 16.4 mmol) and EDCI hydrochloride (3.14 g, 16.4 mmol). The reaction mixture was stirred at 23° C. for 18 h. The solution was diluted with 140 mL of DCM and washed with 100 mL of 0.3 N HCl, 100 mL of satd aq NaHCO3 and 100 mL of brine. The organic solution was dried over MgSO4 and concentrated under reduced pressure. The residue was separated by chromatography on a silica gel column. Elution with 1:2 ethyl acetate/hexanes gave 2 as a colorless oil: yield 86% (3.68 g, 9.35 mmol); TLC Rf 0.40 (1:2 ethyl acetate/hexanes); [α]24 D+12.8 (c 0.18, ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 7.33 (5H, m), 6.93 (1H, d, J=9.2 Hz), 5.14 (3H, m), 4.64 (1H, dd, J=9.2 Hz, 4.8 Hz), 4.14 (1H, m), 2.66 (1H, d, J=4.8 Hz), 2.21 (1H, m), 1.84 (1H, m), 1.65 (1H, m), 1.53 (4H, m) and 0.93 (12H, m); 13C NMR (CDCl3, 101 MHz) δ 174.4, 171.2, 170.2, 135.3, 128.8, 128.6, 128.3, 71.1, 69.5, 67.3, 56.7, 44.0, 31.4, 24.7, 23.6, 21.5, 19.1, 17.7 and 17.1; HRMS (APCI), m/z 394.2239 [M+H]+ (calcd for C21H32NO6, 394.2230).
- To a stirred solution containing unit 2 (3.58 g, 9.10 mmol), Fmoc-Val (3.70 g, 10.9 mmol) and DMAP (334 mg, 2.73 mmol) in 100 mL of anhydrous DCM at 0° C. was added DCC (2.06 g, 10.0 mmol). The reaction mixture was stirred at 23° C. for 2 h. The solution was filtered and the filtrate was concentrated under reduced pressure. The crude product was separated by chromatography on a silica gel column. Elution with 1:4 ethyl acetate/hexanes gave 3a as a colorless solid: yield 77% (5.0 g, 6.98 mmol); TLC Rf 0.40 (1:4 ethyl acetate/hexanes); mp 43-47° C.; [α]24 D+6.59 (c 0.43, ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 7.74 (2H, d, J=7.2 Hz), 7.58 (2H, d, J=7.6 Hz), 7.39 (2H, m), 7.33 (7H, m), 6.76 (1H, d, J=8.4 Hz), 5.39 (1H, d, J=8.8 Hz), 5.24 (1H, m), 5.09 (3H, m), 4.55 (1H, m), 4.41 (1H, m), 4.25 (3H, m), 2.28 (1H, m), 2.15 (1H, m), 1.74 (3H, m), 1.42 (3H, d, J=6.8 Hz) and 0.95 (18H, m); 13C NMR (CDCl3, 101 MHz) δ 171.6, 170.6, 170.1, 170.0, 156.5, 144.0, 143.8, 141.4, 135.3, 128.6, 128.4, 128.2, 127.8, 127.1, 125.2, 120.1, 120.0, 73.6, 69.3, 67.4, 67.1, 59.8, 57.4, 47.2, 40.8, 30.8, 30.7, 24.5, 23.3, 21.5, 19.2, 19.1, 18.0 and 16.8; HRMS (APCI), m/z 715.3586 [M+H]+ (calcd for C41H51N2O9, 715.3594).
- Using the strategy followed for the preparation and purification of 3a, unit 2 (492 mg, 1.25 mmol) was coupled to Fmoc-Thr(tBu) (596 mg, 1.50 mmol) using DMAP (46 mg, 0.38 mmol) and DCC (285 mg, 1.38 mmol) in 15 mL of anhydrous DCM. After separation by column chromatography 3b was obtained as a colorless solid. Yield 83% (800 mg, 1.04 mmol); TLC Rf 0.40 (1:3 ethyl acetate/hexanes); mp 40-44° C.; [α]24 D+10.8 (c 0.42, ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 7.74 (2H, d, J=7.6 Hz), 7.58 (2H, t, J=7.2 Hz), 7.38 (2H, t, J=7.6 Hz), 7.29 (7H, m), 6.77 (1H, d, J=8.4 Hz), 5.69 (1H, d, J=8.4 Hz), 5.18 (1H, m), 5.09 (3H, m), 4.55 (1H, dd, J=8.8 Hz, 5.6 Hz), 4.35 (3H, m), 4.21 (2H, m), 2.27 (1H, m), 1.79 (3H, m), 1.45 (3H, d, J=6.8 Hz), 1.23 (3H, d, J=6.4 Hz), 1.18 (9H, s) and 0.95 (12H, m); 13C NMR (CDCl3, 101 MHz) δ 170.51, 170.50, 169.99, 169.72, 156.57, 144.03, 143.75, 141.32, 135.22, 128.60, 128.43, 128.18, 127.75, 127.10, 125.23, 120.01, 74.44, 73.87, 69.28, 67.42, 67.13, 67.07, 60.06, 57.23, 47.16, 40.89, 30.95, 28.55, 24.32, 23.08, 21.92, 20.53, 18.99, 17.93 and 16.85; HRMS (APCI), m/z 773.4015 [M+H]+ (calcd for C44H57N2O10, 773.4013).
- Using the procedure followed for the preparation and purification of 3a, unit 2 (492 mg, 1.25 mmol) was coupled to Fmoc-Tyr(tBu) (584 mg, 1.27 mmol) using DMAP (39 mg, 0.32 mmol) and DCC (241 mg, 1.17 mmol) in 15 mL of anhydrous DCM. After separation by column chromatography 3c was obtained as a colorless solid. Yield 94% (830 mg, 0.99 mmol); TLC Rf 0.40 (1:3 ethyl acetate/hexanes); mp 45-50° C.; [α]24 D+6.04 (c 0.27, ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 7.74 (2H, d, J=7.6 Hz), 7.55 (2H, m), 7.38 (2H, t, J=7.6 Hz), 7.26 (7H, m), 7.08 (2H, d, J=8.4 Hz), 6.95 (1H, d, J=8.8 Hz), 6.90 (2H, d, J=8.4 Hz), 5.55 (1H, d, J=7.2 Hz), 5.22 (1H, m), 5.07 (3H, m), 4.55 (2H, m), 4.35 (1H, m), 4.28 (1H, m), 4.15 (1H, t, J=7.2 Hz), 3.13 (1H, m), 3.04 (1H, m), 2.31 (1H, m), 1.71 (2H, m), 1.50 (1H, m), 1.45 (3H, d, J=7.2 Hz), 1.31 (9H, s), 0.97 (6H, m) and 0.87 (6H, m); 13C NMR (CDCl3, 101 MHz) δ 171.19, 170.51, 170.11, 170.06, 156.01, 154.68, 143.81, 143.67, 141.26, 135.18, 130.17, 129.66, 128.54, 128.36, 128.11, 127.74, 127.05, 125.07, 124.12, 119.97, 78.34, 73.66, 69.16, 67.31, 67.01, 57.40, 55.67, 47.01, 40.70, 36.93, 30.58, 28.84, 24.37, 23.14, 21.55, 19.05, 18.10 and 16.79; HRMS (APCI), m/z 835.4176 [M+H]+ (calcd for C49H59N2O10, 835.4169).
- To a stirred solution containing compound 3a (300 mg, 0.42 mmol) in 10 mL of anhydrous DCM was added 2,2′,2″-triaminotriethylamine (633 μL, 614 mg, 4.20 mmol). The reaction mixture was stirred at 23° C. for 2 h. The solution was diluted with 10 mL of DCM and washed with two 10-mL portions of phosphate buffer (25.3 g of K2HPO4/12.3 g of KH2PO4 in 250 mL of water) and 10 mL of brine. The organic solution was dried over MgSO4 and concentrated under reduced pressure. The residue was dissolved in 5 mL of anhydrous DMF and unit 4a (262 mg, 0.42 mmol) was added followed by TEA (58 μL, 42 mg, 0.42 mmol) and HBTU (319 mg, 0.84 mmol). The solution was stirred at 23° C. for 16 h and then diluted with 50 mL of ethyl acetate and washed with 50 mL of brine. The organic solution was dried over MgSO4 and concentrated under reduced pressure. The mixture was separated by chromatography on a silica gel column. Elution with 1:4 ethyl acetate/hexanes gave 5 as a colorless solid: yield 83% (384 mg, 0.35 mmol); TLC Rf 0.20 (1:4 ethyl acetate/hexanes); mp 59-64° C.; [α]24 D+6.27 (c 0.26, ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 7.74 (2H, d, J=7.2 Hz), 7.58 (2H, dd, J=13.2 Hz, 7.6 Hz), 7.39 (3H, m), 7.33 (7H, m), 7.20 (1H, d, J=7.2 Hz), 7.16 (1H, d, J=8.8 Hz), 5.51 (1H, d, J=7.6 Hz), 5.27 (2H, m), 5.23 (1H, m), 5.09 (3H, m), 4.42 (2H, m), 4.33 (1H, m), 4.20 (2H, m), 4.11 (1H, t, J=7.6 Hz), 4.04 (1H, t, J=7.6 Hz), 2.27 (3H, m), 2.15 (1H, m), 1.74 (6H, m), 1.41 (6H, d, J=6.4 Hz) and 0.95 (36H, m); 13C NMR (CDCl3, 101 MHz) δ 171.99, 171.04, 170.91, 170.85, 170.52, 170.41, 170.28, 170.21, 156.89, 143.87, 143.62, 141.28, 135.29, 128.48, 128.24, 128.12, 127.72, 127.02, 125.02, 119.97, 73.15, 73.07, 70.43, 69.12, 67.46, 66.92, 60.40, 59.02, 57.80, 47.03, 40.68, 40.44, 34.64, 31.56, 30.38, 30.08, 29.72, 29.42, 25.25, 24.41, 23.19, 22.62, 21.42, 21.37, 19.17, 19.06, 19.01, 18.89, 18.79, 18.55, 18.32, 17.42 and 16.75; HRMS (APCI), m/z 1099.586 [M+H]+ (calcd for C60H82N4O15, 1099.585).
- By means of the strategy followed for the preparation and purification of 5, unit 5 (345 mg, 0.31 mmol) was deprotected with 2,2′,2″-triaminotriethylamine (467 μL, 453 mg, 3.10 mmol) in 10 mL of DCM and then coupled to unit 4a (194 mg, 0.31 mmol) using HBTU (235 mg, 0.62 mmol) and TEA (43 μL, 31 mg, 0.42 mmol) in 5 mL of anhydrous DMF. After separation by column chromatography 6a was obtained as a colorless solid. Yield 62% (284 mg, 0.19 mmol); TLC Rf 0.35 (1:2 ethyl acetate/hexanes); mp 59-63° C.; [α]24 D+3.56 (c 0.23, ethanol); 1H NMR (CDCl3, 400 MHz) δ 7.74 (2H, d, J=7.6 Hz), 7.66 (2H, m), 7.58 (2H, dd, J=14.8 Hz, 7.2 Hz), 7.51 (1H, d, J=6.0 Hz), 7.39 (3H, m), 7.33 (8H, m), 5.74 (1H, d, J=7.2 Hz), 5.34 (1H, m), 5.20 (4H, m), 5.10 (3H, m), 4.38 (3H, m), 4.22 (1H, t, J=7.2 Hz), 4.13 (2H, m), 4.04 (1H, t, J=6.4 Hz), 3.95 (2H, m), 2.27 (5H, m), 1.99 (1H, m), 1.74 (9H, m), 1.41 (9H, d, J=6.8 Hz) and 0.95 (54H, m); 13C NMR (CDCl3, 101 MHz) 172.54, 171.69, 171.55, 171.40, 170.96, 170.70, 170.68, 170.59, 170.58, 170.41, 170.38, 170.36, 157.20, 144.16, 143.78, 141.44, 135.49, 128.60, 128.35, 127.85, 127.19, 125.25, 120.10, 73.35, 73.10, 72.68, 70.54, 70.17, 69.21, 67.64, 67.04, 60.77, 60.04, 59.82, 59.66, 59.08, 58.16, 47.19, 40.94, 40.59, 40.51, 34.79, 31.71, 30.42, 30.08, 29.77, 29.47, 29.29, 29.18, 25.40, 24.57, 24.53, 24.50, 23.38, 23.35, 22.77, 21.68, 21.49, 21.40, 19.48, 19.35, 19.30, 19.26, 19.19, 19.16, 19.06, 18.88, 18.64, 17.56, 17.35 and 16.91; HRFTMS (ESI), m/z 1505.788 [M+Na]+ (calcd for C79H114N6O21Na, 1505.793).
- With the procedure followed for the preparation and purification of 5, unit 5 (300 mg, 0.27 mmol) was deprotected with 2,2′,2″-triaminotriethylamine (407 μL, 395 mg, 2.70 mmol) in 12 mL of DCM and then coupled to unit 4b (184 mg, 0.27 mmol) using HBTU (205 mg, 0.54 mmol) and TEA (37 μL, 27 mg, 0.27 mmol) in 5 mL of anhydrous DMF. After separation by column chromatography 6b was obtained as a colorless solid. Yield 74% (308 mg, 0.20 mmol); TLC Rf 0.35 (1:2 ethyl acetate/hexanes); mp 62-65° C.; [α]24 D+13.0 (c 0.10, ethanol); 1H NMR (CDCl3, 400 MHz) δ 7.73 (2H, d, J=7.6 Hz), 7.70 (1H, d, J=6.0 Hz), 7.56 (4H, m), 7.51 (2H, t, J=7.6 Hz), 7.33 (8H, m), 7.17 (1H, d, J=6.4 Hz), 5.68 (1H, d, J=7.2 Hz), 5.23 (5H, m), 5.10 (3H, m), 4.35 (3H, m), 4.22 (1H, t, J=7.2 Hz), 4.04 (6H, m), 2.27 (5H, m), 1.74 (9H, m), 1.41 (9H, m), 1.22 (3H, d, J=5.6 Hz), 1.18 (9H, s) and 0.95 (48H, m); 13C NMR (CDCl3, 101 MHz) δ 171.34, 171.27, 171.25, 170.89, 170.83, 170.81, 170.63, 170.59, 170.45, 170.44, 170.29, 170.27, 156.80, 143.84, 143.58, 141.25, 135.35, 128.46, 128.21, 128.14, 127.72, 127.04, 125.05, 119.98, 74.62, 73.22, 72.99, 72.54, 70.19, 70.08, 69.07, 67.50, 66.88, 66.83, 60.19, 59.91, 59.80, 59.46, 59.26, 58.05, 47.03, 40.79, 40.33, 34.62, 30.23, 29.65, 29.57, 29.33, 28.51, 28.46, 25.23, 24.36, 24.33, 24.21, 23.22, 23.02, 21.71, 21.40, 21.33, 20.54, 19.34, 19.22, 19.19, 19.15, 19.11, 19.09, 19.04, 18.97, 18.93, 18.52, 17.25, 17.12 and 16.74; HRFTMS (ESI), m/z 1563.833 [M+Na]+ (calcd for C82H120N6O22Na, 1563.835).
- Employing the strategy followed for the preparation and purification of 5, unit 5 (630 mg, 0.57 mmol) was deprotected with 2,2,2′,2″-triaminotriethylamine (850 μL, 834 mg, 5.70 mmol) in 20 mL of DCM and then coupled to unit 4c (425 mg, 0.57 mmol) using HBTU (434 mg, 1.14 mmol) and TEA (79 μL, 58 mg, 0.57 mmol) in 5 mL of anhydrous DMF. After separation by column chromatography 6c was obtained as a colorless solid. Yield 81% (744 mg, 0.46 mmol); TLC Rf 0.35 (1:2 ethyl acetate/hexanes); mp 62-65° C.; [α]24 D+5.71 (c 0.28, ethanol); 1H NMR (CDCl3, 400 MHz) δ 7.78 (1H, d, J=7.6 Hz), 7.74 (2H, d, J=7.6 Hz), 7.67 (1H, m), 7.62 (1H, d, J=6.4 Hz), 7.52 (2H, m), 7.44 (1H, m), 7.37 (3H, m), 7.30 (7H, m), 7.06 (2H, d, J=8.0 Hz), 6.89 (2H, d, J=8.4 Hz), 5.73 (1H, d, J=6.4 Hz), 5.18 (8H, m), 4.35 (4H, m), 4.19 (1H, t, J=6.8 Hz), 4.06 (3H, m), 3.95 (1H, t, J=6.4 Hz), 3.03 (2H, m), 2.25 (5H, m), 1.74 (8H, m), 1.59 (1H, m), 1.41 (9H, m), 1.30 (9H, s) and 0.95 (48H, m); 13C NMR (CDCl3, 101 MHz) δ 171.92, 171.59, 171.45, 171.42, 171.21, 170.97, 170.88, 170.72, 170.64, 170.53, 170.44, 170.43, 156.72, 154.89, 144.01, 143.74, 141.36, 135.51, 130.70, 129.76, 128.61, 128.35, 128.31, 127.89, 127.17, 125.21, 124.24, 120.13, 80.72, 73.45, 73.14, 72.74, 70.46, 70.28, 69.26, 67.68, 67.05, 59.95, 59.92, 59.70, 59.24, 58.24, 56.19, 47.14, 40.93, 40.52, 36.61, 36.59, 30.40, 29.83, 29.79, 29.55, 29.47, 29.38, 29.26, 29.19, 28.99, 24.53, 24.51, 24.34, 23.39, 23.23, 21.65, 21.49, 19.46, 19.43, 19.31, 19.30, 19.27, 19.21, 19.12, 19.09, 18.68, 17.49, 17.44 and 16.91; HRFTMS (ESI), m/z 1625.844 [M+Na]+ (calcd for C87H122N6O22Na, 1625.850).
- To a stirred solution containing depsipeptide 6a (250 mg, 0.17 mmol) in 5 mL of 4:1 ethyl acetate/methanol was added 20% palladium hydroxide-on-carbon (125 mg). The mixture was stirred under a hydrogen atmosphere (1 atm) at 23° C. for 7 h and then filtered through Celite. The filtrate was concentrated under reduced pressure and the residue was dissolved in 125 mL of anhydrous DCM. TEA (24 μL, 17 mg, 0.17 mmol) was added followed by PyBroP (238 mg, 0.51 mmol) and the reaction mixture was stirred at 23° C. for 24 h. The solution was filtered through a silica gel plug and the filtrated was concentrated under reduced pressure. The residue was separated by chromatography on a silica gel column. Elution with 1:4 ethyl acetate/hexanes gave 7a (silstatin 1) as a colorless solid: yield 28% (54 mg, 47 μmol); TLC Rf 0.42 (1:4 ethyl acetate/hexanes); mp 137-138° C.; [α]24 D+30.9 (c 0.11, ethanol); 1H NMR (CDCl3, 400 MHz) δ 7.78 (3H, d, J=7.6 Hz), 7.73 (3H, d, J=6.4 Hz), 5.21 (3H, m), 5.13 (3H, m), 4.06 (3H, dd, J=9.6 Hz, 8.0 Hz), 3.93 (3H, dd, J=9.6 Hz, 6.4 Hz), 2.23 (6H, m), 1.74 (9H, m), 1.44 (9H, d, J=7.2 Hz), 1.04 (18H, m) and 0.95 (36H, m); 13C NMR (CDCl3, 101 MHz) δ 172.4, 172.0, 171.6, 170.4, 73.5, 70.6, 60.3, 59.1, 40.8, 28.7, 28.5, 24.6, 23.4, 21.4, 19.8, 19.6, 19.3, 19.2 and 17.2; HRMS (APCI), m/z 1153.685 [M+H]+ (calcd for C57H97N6O18, 1153.686).
- By the method followed for the preparation and purification of 7a, depsipeptide 6b (300 mg, 0.20 mmol) was deprotected using 20% palladium hydroxide-on-carbon (300 mg) in 10 mL of 4:1 ethyl acetate/methanol and then cyclized with PyBroP (373 mg, 0.80 mmol) and TEA (111 μL, 81 mg, 0.80 mmol) in 200 mL of anhydrous DCM. After separation by column chromatography 7b was obtained as a colorless solid. Yield 33% (81 mg, 67 μmol); TLC Rf 0.5 (1:3 ethyl acetate/hexanes); mp 75-78° C.; [α]24 D+23.3 (c 0.06, ethanol); 1H NMR (CDCl3, 400 MHz) δ 7.83 (1H, d, J=8.0 Hz), 7.74 (1H, d, J=7.2 Hz), 7.66 (1H, d, J=8.4 Hz), 7.49 (1H, d, J=8.0 Hz), 7.45 (1H, d, J=5.6 Hz), 7.37 (1H, d, J=4.8 Hz), 5.20 (6H, m), 4.29 (1H, t, J=8.4 Hz), 4.17 (2H, m), 4.05 (3H, m), 3.85 (1H, dd, J=10 Hz, 6.0 Hz), 2.23 (5H, m), 1.74 (9H, m), 1.41 (9H, m), 1.20 (9H, s), 1.17 (3H, d, J=6.4 Hz), 1.10 (18H, m) and 0.90 (30H, m); 13C NMR (CDCl3, 101 MHz) δ 172.33, 172.32, 172.14, 172.12, 171.81, 171.80, 171.13, 171.12, 170.35, 170.27, 170.19, 169.88, 74.76, 73.88, 73.37, 73.11, 70.91, 70.84, 70.64, 66.54, 60.82, 59.81, 59.12, 59.08, 58.53, 57.72, 40.96, 40.77, 40.71, 34.77, 29.64, 29.23, 28.78, 28.54, 28.53, 28.46, 25.38, 24.58, 24.55, 23.51, 23.50, 23.45, 21.47, 21.32, 21.20, 19.92, 19.86, 19.54, 19.53, 19.41, 19.38, 19.32, 19.04, 18.72, 18.45, 17.54, 17.13 and 17.05; HRMS (APCI), m/z 1211.723 [M+H]+ (calcd for C60H103N6O19, 1211.728).
- Using the strategy followed for the preparation and purification of 7a, depsipeptide 6c (700 mg, 0.44 mmol) was deprotected using 20% palladium hydroxide-on-carbon (300 mg) in 10 mL of 4:1 ethyl acetate/methanol and then cyclized with PyBroP (373 mg, 0.80 mmol) and TEA (111 μL, 81 mg, 0.80 mmol) in 200 mL of anhydrous DCM. After separation by column chromatography 7c was obtained as a colorless solid. Yield 11% (66 mg, 52 μmol); TLC Rf 0.20 (1:4 ethyl acetate/hexanes); mp 64-67° C.; [α]24 D+25.7 (c 0.14, ethanol); 1H NMR (CDCl3, 400 MHz) δ 7.94 (1H, d, J=7.2 Hz), 7.85 (2H, m), 7.76 (1H, d, J=8.0 Hz), 7.68 (1H, d, J=7.2 Hz), 7.65 (1H, d, J=6.0 Hz), 7.09 (2H, d, J=8.8 Hz), 6.86 (2H, d, J=8.4 Hz), 5.20 (4H, m), 5.05 (2H, m), 4.53 (q, J=7.6 Hz, 1H), 4.13 (1H, t, J=8.8 Hz), 4.02 (11H, dd, J=9.6 Hz, 7.6 Hz), 3.95 (1H, dd, J=9.6 Hz, 7.2 Hz), 3.89 (2H, dd, J=10 Hz, 6.0 Hz), 3.10 (2H, m), 2.23 (51H, m), 1.74 (7H, m), 1.55 (2H, t, J=6.8 Hz), 1.42 (6H, d, J=6.8 Hz), 1.36 (3H, d, J=6.8 Hz), 1.30 (9H, s), 1.05 (18H, m), 0.92 (24H, m), 0.75 (3H, d, J=6.8 Hz) and 0.71 (3H, d, J=6.4 Hz); 13C NMR (CDCl3, 101 MHz) δ 172.49, 172.37, 172.10, 172.00, 171.71, 171.69, 171.53, 171.43, 170.59, 170.52, 170.27, 170.03, 154.31, 131.01, 129.66, 123.91, 78.11, 73.61, 73.18, 70.71, 70.50, 70.07, 60.41, 60.37, 59.39, 59.28, 58.39, 54.57, 40.73, 40.63, 40.61, 40.48, 35.27, 30.32, 29.65, 28.80, 28.58, 28.53, 28.46, 28.40, 24.45, 24.16, 23.71, 23.31, 22.88, 21.80, 21.24, 21.08, 19.73, 19.46, 19.35, 19.33, 19.17, 19.14, 19.11, 19.06, 19.04, 18.84, 17.19, 17.09 and 16.81; HRMS (APCI), m/z 1273.744 [M+H]+ (calcd for C65H105N6O19, 1273.743).
- To a stirred solution containing cyclodepsipeptide 7b (70 mg, 58 μmol) in 1 mL of anhydrous DCM was added TFA (250 μL). The reaction mixture was stirred at 23° C. for 2 h. The solution was concentrated under reduced pressure and the residue was separated by chromatography on a silica gel column. Elution with 1:3 ethyl acetate/hexanes gave 8a (silstatin 2) as a colorless solid: yield 94% (63 mg, 55 μmol); TLC Rf 0.25 (1:3 ethyl acetate/hexanes); mp 75-78° C.; [α]24 D+25.9 (c 0.19, ethanol); 1H NMR (CDCl3, 400 MHz) δ 7.99 (1H, d, J=7.2 Hz), 7.91 (1H, d, J=7.2 Hz), 7.81 (3H, m), 7.57 (1H, d, J=6.4 Hz), 5.28 (2H, m), 5.17 (3H, m), 5.05 (1H, m), 4.87 (1H, br s), 4.14 (1H, t, J=9.2 Hz), 3.95 (6H, m), 2.23 (4H, m), 2.12 (1H, m), 1.74 (9H, m), 1.41 (9H, m), 1.20 (3H, d, J=5.6 Hz), 1.10 (18H, m) and 0.90 (30H, m); 13C NMR (CDCl3, 101 MHz) δ 173.51, 172.82, 172.39, 172.32, 172.20, 171.92, 171.53, 171.20, 171.00, 170.92, 170.29, 169.97, 74.49, 73.29, 73.16, 70.76, 70.70, 70.42, 66.19, 60.84, 60.47, 60.14, 59.89, 59.60, 58.52, 40.84, 40.70, 40.62, 28.72, 28.67, 28.55, 28.49, 28.21, 24.67, 24.57, 23.49, 23.37, 23.35, 23.33, 21.53, 21.36, 21.35, 19.70, 19.60, 19.53, 19.48, 19.47, 19.46, 19.45, 19.41, 19.37, 19.35, 18.98, 17.53, 17.10 and 17.03; HRMS (APCI), m/z 1155.664 [M+H]+ (calcd for C56H95N6O19, 1155.665).
- Using the strategy followed for the preparation and purification of 8a, cyclodepsipeptide 7c (7 mg, 5.5 μmol) was deprotected with TFA (250 μL) in 1 mL of anhydrous DCM. After separation by column chromatography 8b (silstatin 3) was obtained as a colorless solid. Yield 75% (5 mg, 4.1 μmol); TLC Rf 0.25 (1:3 ethyl acetate/hexanes); mp 65-68° C.; [α]24 D+35.0 (c 0.10, ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 7.77 (6H, m), 7.04 (2H, d, J=8.4 Hz), 6.73 (2H, d, J=8.4 Hz), 5.20 (5H, m), 4.96 (1H, t, J=6.0 Hz), 4.43 (1H, q, J=7.6 Hz), 4.10 (3H, m), 3.95 (2H, m), 3.10 (2H, m), 2.23 (5H, m), 1.65 (9H, m), 1.42 (6H, d, J=6.8 Hz), 1.36 (3H, d, J=7.2 Hz), 1.04 (18H, m), 0.92 (24H, m), 0.71 (3H, d, J=6.4 Hz) and 0.71 (3H, d, J=6.8 Hz); 13C NMR (CDCl3, 101 MHz) 172.50, 172.38, 172.23, 172.04, 171.98, 171.94, 171.81, 171.53, 171.43, 170.36, 170.28, 170.20, 155.19, 130.57, 127.82, 115.78, 73.90, 73.58, 73.43, 70.73, 70.64, 60.57, 60.22, 59.01, 58.81, 58.80, 55.29, 40.94, 40.80, 40.68, 35.44, 29.85, 29.81, 29.08, 28.79, 28.73, 28.63, 24.68, 24.64, 24.28, 23.49, 23.20, 22.84, 21.66, 21.41, 21.31, 19.83, 19.71, 19.59, 19.55, 19.47, 19.38, 19.37, 19.12, 18.98, 18.83, 17.42, 17.18 and 17.04; HRMS (APCI), m/z 1217.681 [M+H]+ (calcd for C61H97N6O19, 1217.681).
- Compounds 14a, 15 and 15b were synthesized according to the method depicted in Scheme 2.
- Using the strategy followed for the preparation and purification of 2, unit 1 (2.52 g, 6.64 mmol) was deprotected with TFA (7.5 mL) in 30 mL of anhydrous DCM and then coupled to (2R)-2-hydroxy-3-cyclohexylpropionic acid (1.23 g, 7.14 mmol) using HOBt (1.35 g, 9.96 mmol), TEA (1.38 mL, 1.10 g, 9.96 mmol) and EDCI hydrochloride (1.91 g, 9.96 mmol) in 30 mL of anhydrous DCM. After separation by column chromatography 9 was obtained as a colorless oil (solidifies upon standing). Yield 63% (1.80 g, 4.15 mmol); TLC Rf 0.30 (1:3 ethyl acetate/hexanes); mp 55-57° C.; [α]24 D+19.1 (c 0.32, ethanol); 1H NMR (CDCl3, 400 MHz) δ 7.34 (5H, m), 6.90 (11H, d, J=9.2 Hz), 5.18 (2H, m), 4.64 (1H, dd, J=9.2 Hz, 4.8 Hz), 4.14 (1H, m), 2.62 (1H, br s), 2.21 (1H, m), 1.78 (1H, d, J=12.8 Hz), 1.66 (5H, m), 1.50 (5H, m), 1.20 (3H, m) and 0.93 (8H, m); 13C NMR (CDCl3, 101 MHz) δ 174.5, 171.1, 170.1, 135.3, 128.8, 128.6, 128.3, 70.5, 69.5, 67.3, 56.7, 42.7, 34.3, 34.1, 32.3, 31.4, 26.6, 26.4, 26.2, 19.1, 17.7 and 17.1; HRMS (APCI), m/z 434.2542 [M+H]+ (calcd for C24H36NO6, 434.2543).
- By the procedure followed for the preparation and purification of 3a, unit 9 (1.80 g, 4.15 mmol) was coupled to Fmoc-Val (1.55 g, 4.57 mmol) using DCC (943 mg, 4.57 mmol) and DMAP (152 mg, 1.25 mmol) in 50 mL of anhydrous DCM. After separation by column chromatography 10a was obtained as a colorless solid. Yield 82% (2.56 g, 3.39 mmol); TLC Rf 0.25 (1:4 ethyl acetate/hexanes); mp 49-53° C.; [α]24 D+0.45 (c 0.22, chloroform); 1H NMR (CDCl3, 400 MHz) δ 7.74 (2H, d, J=7.6 Hz), 7.57 (2H, d, J=7.6 Hz), 7.39 (2H, m) 7.33 (7H, m), 6.74 (1H, d, J=8.8 Hz), 5.34 (1H, d, J=8.4 Hz), 5.28 (1H, m), 5.09 (3H, m), 4.55 (1H, m), 4.41 (1H, m), 4.25 (2H, m), 4.18 (1H, m), 2.28 (1H, m), 2.15 (1H, m), 1.74 (7H, m), 1.41 (4H, m), 1.16 (3H, m) and 0.95 (14H, m); 13C NMR (CDCl3, 101 MHz) δ 171.63, 170.59, 170.13, 170.08, 156.50, 144.02, 143.81, 141.40, 135.29, 128.67, 128.49, 128.26, 127.84, 127.17, 125.20, 120.09, 73.02, 69.32, 67.44, 67.16, 59.84, 57.38, 47.21, 39.43, 33.94, 33.89, 32.16, 30.87, 30.82, 26.41, 26.34, 26.07, 19.22, 19.11, 18.09, 18.06 and 16.89; HRMS (APCI), m/z 755.3901 [M+H]+ (calcd for C44H55N2O9, 755.3907).
- With the method followed for the preparation and purification of 3a, unit 9 (1.80 g, 4.15 mmol) was coupled to Fmoc-Thr(OtBu) (381 mg, 0.96 mmol) using DCC (198 mg, 0.96 mmol) and DMAP (32 mg, 0.26 mmol) in 10 mL of anhydrous DCM. After separation by column chromatography 10b was obtained as a colorless solid. Yield 79% (561 mg, 0.69 mmol); TLC Rf 0.27 (1:4 ethyl acetate/hexanes); mp 50-54° C.; [α]24 D+2.97 (c 0.37, chloroform); 1H NMR (CDC3, 400 MHz) δ 7.74 (2H, d, J=7.6 Hz), 7.57 (2H, t, J=7.6 Hz), 7.39 (2H, t, J=7.2 Hz), 7.33 (7H, m), 6.79 (1H, d, J=8.8 Hz), 5.70 (1H, d, J=8.0 Hz), 5.22 (1H, t, J=6.8 Hz), 5.09 (3H, m), 4.55 (1H, dd, J=8.4 Hz, 5.2 Hz), 4.35 (3H, m), 4.20 (3H, m), 2.28 (1H, m), 1.74 (7H, m), 1.41 (4H, m), 1.16 (15H, m) and 0.95 (8H, m); 13C NMR (CDCl3, 101 MHz) 170.50, 170.48, 169.95, 169.78, 156.51, 143.99, 143.71, 141.28, 135.19, 128.56, 128.38, 128.13, 127.72, 127.06, 125.20, 119.97, 74.40, 73.37, 69.25, 67.39, 67.10, 67.02, 60.05, 57.21, 47.12, 39.43, 33.70, 33.49, 32.53, 30.91, 28.54, 26.33, 26.14, 25.96, 20.52, 18.94, 17.91 and 16.82; HRMS (APCI), m/z 813.4324 [M+H]+ (calcd for C47H61N2O10, 813.4326).
- Using the strategy followed for the preparation and purification of 3a, unit 9 (376 mg, 0.87 mmol) was coupled to Fmoc-Tyr(OtBu) (441 mg, 0.96 mmol) using DCC (198 mg, 0.96 mmol) and DMAP (32 mg, 0.26 mmol) in 10 mL of anhydrous DCM. After separation by column chromatography 10b was obtained as a colorless solid. Yield 90% (688 mg, 0.79 mmol): TLC Rf 0.25 (1:4 ethyl acetate/hexanes); mp 52-56° C.; [α]24 D+11.2 (c 0.17, chloroform); 1H NMR (CDCl3, 400 MHz) δ 7.74 (2H, d, J=7.6 Hz), 7.57 (2H, t, J=7.6 Hz), 7.39 (2H, t, J=7.2 Hz), 7.33 (7H, m), 7.06 (2H, d, J=8.4 Hz), 6.90 (2H, d, J=8.4 Hz), 6.83 (1H, d, J=8.4 Hz), 5.45 (1H, d, J=7.6 Hz), 5.23 (1H, t, J=6.4 Hz), 5.09 (3H, m), 4.55 (2H, m), 4.35 (1H, m), 4.26 (1H, m), 4.15 (1H, m), 3.17 (1H, m), 3.02 (1H, m), 2.28 (1H, m), 1.74 (7H, m), 1.42 (4H, m), 1.31 (12H, m), 1.15 (3H, m) and 0.95 (8H, m); 13C NMR (CDCl3, 101 MHz) δ 171.1, 170.6, 170.2, 170.1, 156.0, 154.7, 143.7, 141.3, 135.2, 130.3, 129.7, 128.6, 128.4, 128.2, 127.8, 127.1, 125.1, 124.2, 120.0, 78.5, 73.3, 69.3, 67.3, 67.1, 57.3, 55.5, 47.1, 39.4, 36.9, 33.8, 33.7, 32.4, 30.8, 28.9, 26.4, 26.1, 26.0, 19.1, 18.0 and 16.9; HRMS (APCI), m/z 875.4487 [M+H]+ (calcd for C52H63N2O10, 875.4482).
- Application of the experimental strategy followed for the preparation and purification of 5, unit 10a (300 mg, 0.40 mmol) was deprotected with 2,2′,2″-triaminotriethylamine (605 μL, 588 mg, 4.00 mmol) in 10 mL of DCM and then coupled to unit 11a (266 mg, 0.40 mmol) using HBTU (303 mg, 0.80 mmol) and TEA (55 μL, 40 mg, 0.40 mmol) in 5 mL of anhydrous DMF. After separation by
column chromatography 12 was obtained as a colorless solid. Yield 76% (360 mg, 0.31 mmol); TLC Rf 0.28 (1:4 ethyl acetate/hexanes); mp 60-65° C.; [α]24 D+17.1 (c 0.25, chloroform); 1H NMR (CDCl3, 400 MHz) δ 7.74 (2H, d, J=7.2 Hz), 7.58 (2H, dd, J=14 Hz, 7.6 Hz), 7.39 (3H, m) 7.33 (7H, m), 7.21 (1H, d, J=7.2 Hz), 7.16 (1H, d, J=8.4 Hz), 5.50 (1H, d, J=7.6 Hz), 5.26 (3H, m), 5.09 (3H, m), 4.42 (2H, m), 4.33 (1H, m), 4.22 (2H, m), 4.11 (1H, t, J=7.6 Hz), 4.02 (1H, t, J=7.6 Hz), 2.27 (3H, m), 2.15 (1H, m), 1.74 (14H, m), 1.41 (8H, m), 1.16 (6H, m) and 0.95 (28H, m); 13C NMR (CDCl3, 101 MHz) δ 172.17, 171.33, 171.06, 171.01, 170.66, 170.54, 170.52, 170.35, 157.04, 144.01, 143.75, 141.41, 135.44, 128.60, 128.36, 128.25, 127.85, 127.19, 125.16, 120.10, 72.65, 72.58, 70.52, 69.24, 67.61, 67.04, 60.58, 59.18, 57.98, 47.16, 39.32, 39.13, 34.77, 33.94, 33.83, 33.81, 32.18, 32.11, 31.69, 30.49, 30.22, 29.85, 29.49, 26.47, 26.42, 26.39, 26.34, 26.10, 26.05, 25.39, 19.21, 19.16, 19.03, 18.94, 18.74, 18.47, 17.56 and 16.88; HRMS (APCI): m/z 1179.645 [M+H]+ (calcd for C66H91N4O15, 1179.648). - Again using the procedure followed for the preparation and purification of 5, unit 12 (320 mg, 0.27 mmol) was deprotected with 2,2′,2″-triaminotriethylamine (281 μL, 273 mg, 2.16 mmol) in 6 mL of DCM and then coupled to unit 11a (179 mg, 0.27 mmol) using HBTU (205 mg, 0.54 mmol) and TEA (37 μL, 27 mg, 0.27 mmol) in 5 mL of anhydrous DMF. After separation by column chromatography 13a was obtained as a colorless solid. Yield 70% (304 mg, 0.19 mmol); TLC Rf 0.30 (1:4 ethyl acetate/hexanes); mp 60-64° C.; [α]24 D+20.9 (c 0.11, chloroform); 1H NMR (CDCl3, 400 MHz) δ 7.73 (2H, d, J=7.2 Hz), 7.66 (7.6 Hz, 2H, J=4.4 Hz, 2H), 7.58 (3H, d, J=15.6 Hz), 7.51 (1H, d, J=6.0 Hz), 7.36 (3H, m), 7.29 (8H, m), 5.79 (1H, d, J=7.2 Hz), 5.24 (5H, m), 5.10 (3H, m), 4.38 (3H, m), 4.21 (1H, t, J=7.2 Hz), 4.13 (2H, m), 4.02 (11H, m), 3.93 (2H, m), 2.27 (5H, m), 1.99 (1H, m), 1.74 (21H, m), 1.41 (12H, m) and 1.02 (51H, m); 13C NMR (CDCl3, 101 MHz) δ 172.44, 171.71, 171.39, 171.38, 171.29, 170.88, 170.68, 170.52, 170.46, 170.42, 170.26, 170.18, 157.07, 144.03, 143.63, 141.27, 135.35, 128.43, 128.17, 128.13, 127.69, 127.02, 124.99, 119.94, 72.57, 72.29, 71.86, 70.35, 69.94, 69.04, 67.49, 66.86, 60.67, 59.95, 59.66, 59.64, 58.92, 58.08, 47.03, 39.31, 38.96, 34.63, 33.85, 33.81, 33.69, 33.66, 33.61, 32.15, 32.03, 31.94, 31.86, 30.20, 29.92, 29.54, 29.26, 29.15, 29.02, 28.97, 26.33, 26.31, 26.26, 26.21, 25.95, 25.92, 25.24, 20.67, 19.35, 19.19, 19.15, 19.14, 19.11, 19.06, 19.02, 18.96, 18.91, 18.79, 18.54, 17.42, 17.15 and 16.74; HRFTMS (ESI), m/z 1625.885 [M+Na]+ (calcd for C88H126N6O21Na, 1625.887).
- By the procedure followed for the preparation and purification of 5, unit 12 (500 mg, 0.42 mmol) was deprotected with 2,2′,2″-triaminotriethylamine (633 μL, 614 mg, 4.2 mmol) in 15 mL of DCM and then coupled to unit 11b (306 mg, 0.42 mmol) using HBTU (319 mg, 0.84 mmol) and TEA (58 μL, 42 mg, 0.42 mmol) in 7 mL of anhydrous DMF. After separation by column chromatography 13b was obtained as a colorless solid. Yield 64% (448 mg, 0.23 mmol); TLC Rf 0.40 (1:2 ethyl acetate/hexanes); mp 62-66° C.; [α]24 D+10.6 (c 0.18, chloroform); 1H NMR (CDCl3, 400 MHz) δ 7.73 (2H, d, J=7.2 Hz), 7.66 (4H, m), 7.36 (3H, m), 7.29 (8H, m), 7.14 (1H, d, J=6.4 Hz), 5.66 (1H, d, J=7.2 Hz), 5.24 (5H, m), 5.10 (3H, m), 4.38 (3H, m), 4.22 (1H, t, J=7.2 Hz), 4.13 (4H, m), 4.02 (1H, m), 3.93 (1H, m), 2.27 (4H, m), 2.08 (1H, m), 1.74 (21H, m), 1.41 (12H, m), 1.21 (21H, m) and 1.02 (36H, m); 13C NMR (CDCl3, 101 MHz) δ 171.45, 171.44, 171.41, 171.01, 170.98, 170.84, 170.79, 170.56, 170.54, 170.42, 170.41, 156.89, 143.98, 143.73, 141.39, 135.51, 130.57, 128.59, 128.33, 127.86, 127.18, 125.20, 120.11, 74.76, 72.86, 72.48, 72.01, 70.30, 70.14, 69.19, 67.64, 66.99, 60.36, 60.08, 59.98, 59.69, 59.39, 58.25, 47.17, 39.42, 39.05, 39.00, 34.76, 33.97, 33.80, 33.77, 33.71, 33.55, 32.50, 32.16, 32.08, 31.68, 30.30, 29.79, 29.75, 29.69, 29.48, 29.43, 28.63, 26.47, 26.45, 26.40, 26.38, 26.35, 26.23, 26.07, 26.03, 26.00, 25.38, 20.73, 19.47, 19.37, 19.27, 19.24, 19.18, 19.08, 19.05, 18.69, 17.33, 17.23 and 16.87; HRFTMS (ESI), m/z 1683.927 [M+Na]+ (calcd for C91H132N6O22Na, 1683.929).
- By employing the procedure followed for the preparation and purification of 5, unit 12 (500 mg, 0.42 mmol) was deprotected with 2,2′,2″-triaminotriethylamine (633 μL, 614 mg, 4.2 mmol) in 15 mL of DCM and then condensed to unit 11c (329 mg, 0.42 mmol) using HBTU (319 mg, 0.84 mmol) and TEA (58 μL, 42 mg, 0.42 mmol) in 7 mL of anhydrous DMF. Following separation by column chromatography 13c was obtained as a colorless solid. Yield 74% (534 mg, 0.31 mmol); TLC Rf 0.40 (1:2 ethyl acetate/hexanes); mp 61-65° C.; [α]24 D+14.3 (c 0.30, chloroform); 1H NMR (CDCl3, 400 MHz) δ 7.73 (2H, d, J=7.6 Hz), 7.69 (1H, d, J=6.0 Hz), 7.65 (1H, d, J=6.0 Hz), 7.53 (3H, m), 7.38 (4H, m), 7.29 (7H, m), 7.06 (2H, d, J=8.4 Hz), 6.90 (2H, d, J=8.4 Hz), 5.74 (1H, d, J=6.4 Hz), 5.26 (5H, m), 5.09 (3H, m), 4.38 (4H, m), 4.20 (1H, m), 4.11 (2H, m), 4.00 (1H, m), 3.94 (1H, m), 3.09 (2H, m), 2.28 (5H, m), 1.65 (21H, m), 1.41 (12H, m), 1.21 (18H, m) and 1.02 (36H, m); 13C NMR (CDCl3, 101 MHz) 171.67, 171.54, 171.63, 171.52, 171.45, 171.02, 170.93, 170.82, 170.59, 170.47, 170.42, 170.40, 156.64, 154.77, 143.92, 143.69, 141.37, 135.47, 130.19, 129.69, 128.54, 128.25, 127.82, 127.17, 125.15, 124.22, 120.06, 78.42, 72.95, 72.45, 72.03, 70.36, 70.15, 69.20, 67.58, 66.98, 59.95, 59.93, 59.73, 59.21, 58.26, 56.03, 47.09, 39.39, 39.08, 39.04, 39.03, 36.46, 34.74, 33.96, 33.95, 33.75, 33.70, 33.67, 33.63, 32.46, 32.18, 32.05, 31.66, 30.27, 29.69, 29.36, 29.27, 29.13, 28.94, 26.45, 26.39, 26.36, 26.06, 25.92, 25.35, 20.78, 19.41, 19.33, 19.30, 19.25, 19.24, 19.18, 19.05, 18.69, 17.38, 17.34, 16.83, 14.19 and 11.51; HRFTMS (ESI): m/z 1745.941 [M+Na]+ (calcd for C96H134N6O22Na, 1745.944).
- Using the strategy followed for the preparation and purification of 7a, depsipeptide 13a (193 mg, 0.12 mmol) was deprotected using 20% palladium hydroxide-on-carbon (100 mg) in 8 mL of 4:1 ethyl acetate/methanol and then cyclized with PyBroP (224 mg, 0.48 mmol) and TEA (35 μL, 24 mg, 0.24 mmol) in 120 mL of anhydrous DCM. After separation by column chromatography silstatin 4 (14a) was obtained as a colorless solid. Yield 23% (35 mg, 27 μmol); TLC Rf 0.5 (1:4 ethyl acetate/hexanes); mp 52-56° C.; [α]24 D+35.0 (c 0.06, chloroform); 1H NMR (CDCl3, 400 MHz) δ 7.79 (3H, d, J=8.0 Hz), 7.73 (3H, d, J=6.4 Hz), 5.23 (3H, m), 5.17 (8.0 Hz, dd), 3.93 (3H, dd, J=9.6 Hz, 6.0 Hz), 2.23 (6H, m), 1.74 (21H, m), 1.46 (12H, m) and 1.02 (51H, m); 13C NMR (CDCl3, 101 MHz) δ 172.4, 172.1, 171.5, 170.4, 72.9, 70.6, 60.3, 59.1, 39.4, 34.0, 33.9, 32.1, 28.7, 28.6, 26.6, 26.4, 26.1, 19.8, 19.6, 19.4, 19.2 and 17.3; HRMS (APCI), m/z 1273.779 [M+H]+ (calcd for C66H109N6O18, 1273.780).
- Using the strategy followed for the preparation and purification of 7a, depsipeptide 13b (530 mg, 0.26 mmol) was deprotected using 20% palladium hydroxide-on-carbon (200 mg) in 10 mL of 4:1 ethyl acetate/methanol and then cyclized with PyBroP (485 mg, 1.04 mmol) and TEA (144 μL, 105 mg, 1.04 mmol) in 260 mL of anhydrous DCM. After separation by column chromatography 14b was obtained as a colorless solid. Yield 29% (100 mg, 75 μmol); TLC Rf 0.4 (1:4 ethyl acetate/hexanes); mp 61-65° C.; [α]24 D+27.1 (c 0.09, chloroform); 1H NMR (CDCl3, 400 MHz) δ7.77 (1H, d, J=8.4 Hz), 7.69 (1H, d, J=7.2 Hz), 7.62 (1H, d, J=8.4 Hz), 7.42 (1H, d, J=8.0 Hz), 7.40 (1H, d, J=6.0 Hz), 7.29 (1H, d, J=5.2 Hz), 5.23 (5H, m), 5.13 (1H, dd, J=9.2 Hz, 3.6 Hz), 4.29 (1H, t, J=8.0 Hz), 4.23 (1H, t, J=8.0 Hz), 4.05 (4H, m), 3.85 (1H, dd, J=10 Hz, 5.6 Hz), 2.23 (5H, m), 1.74 (21H, m), 1.41 (12H, m), 1.21 (21H, m) and 1.02 (36H, m); 13C NMR (CDCl3, 101 MHz) δ 172.29, 172.16, 172.08, 172.01, 171.78, 171.65, 171.17, 171.02, 170.19, 170.13, 169.94, 169.93, 74.84, 73.29, 72.77, 72.47, 71.04, 70.81, 70.70, 66.64, 60.82, 59.76, 59.10, 58.94, 58.23, 57.81, 39.50, 39.47, 39.43, 39.21, 36.77, 34.79, 34.13, 34.09, 34.03, 33.90, 33.83, 33.80, 32.22, 31.93, 31.83, 29.91, 29.35, 28.98, 28.68, 28.64, 28.59, 28.57, 28.52, 26.52, 26.42, 26.35, 26.09, 24.82, 20.15, 19.91, 19.53, 19.51, 19.42, 19.36, 19.29, 18.95, 18.58, 18.46, 17.50, 17.21 and 17.13; HRFTMS (ESI), m/z 1353.805 [M+Na]+ (calcd for C69H114N6O19Na, 1353.803).
- By means of the strategy followed for the preparation and purification of 7a, depsipeptide 13c (502 mg, 0.29 mmol) was deprotected using 20% palladium hydroxide-on-carbon (200 mg) in 8 mL of 4:1 ethyl acetate/methanol and then cyclized with PyBroP (541 mg, 1.16 mmol) and TEA (160 μL, 118 mg, 1.17 mmol) in 290 mL of anhydrous DCM. After separation by column chromatography cyclodepsipeptide 14c was obtained as a colorless solid. Yield 34% (145 mg, 0.10 mmol); TLC Rf 0.4 (1:4 ethyl acetate/hexanes); mp 68-72° C.; [α]24 D+31.3 (c 0.12, chloroform); 1H NMR (CDCl3, 400 MHz) δ 7.97 (1H, d, J=7.2 Hz), 7.93 (1H, d, J=6.0 Hz), 7.85 (1H, d, J=6.8 Hz), 7.75 (1H, d, J=8.4 Hz), 7.63 (1H, d, J=6.8 Hz), 7.58 (1H, d, J=5.6 Hz), 7.11 (2H, d, J=8.4 Hz), 6.88 (2H, d, J=8.0 Hz), 5.23 (3H, m), 5.13 (3H, m), 4.57 (q, J=7.2 Hz, 1H, J=9.2 Hz, 4.0 Hz, dd), 4.07 (3H, dd, J=9.2 Hz), 4.16 (1H, t, J=8.8 Hz), 3.99 (1H, dd, J=9.6 Hz, 7.2 Hz), 3.88 (3H, m), 3.11 (2H, m), 2.23 (5H, m) and 1.90-0.80 (87H, m); 13C NMR (CDCl3, 101 MHz) δ 172.79, 172.76, 172.42, 172.15, 171.92, 171.75, 171.62, 171.55, 170.77, 170.45, 170.34, 170.10, 154.34, 131.42, 129.84, 124.13, 78.28, 73.37, 73.20, 72.54, 70.98, 70.71, 70.03, 60.76, 60.63, 59.69, 59.64, 58.33, 54.29, 39.50, 39.44, 39.25, 39.24, 35.29, 34.06, 33.89, 33.85, 33.69, 33.46, 32.88, 31.95, 31.85, 29.80, 29.02, 28.96, 28.76, 28.69, 28.67, 28.64, 28.61, 28.50, 26.52, 26.45, 26.39, 26.10, 26.07, 26.02, 19.96, 19.64, 19.49, 19.47, 19.40, 19.35, 19.32, 19.25, 18.92, 17.41, 17.27, 16.86 and 14.22; HRFTMS (ESI), m/z 1415.822 [M+Na]+ (calcd for C74H116N6O19Na, 1415.819).
- By the experimental route followed for the preparation and isolation of 8a, cyclodepsipeptide 14b (80 mg, 60 μmol) was deprotected with TFA (250 μL) in 2 mL of anhydrous DCM. After isolation by column chromatography yielded cyclodepsipeptide 15a (silstatin 5) as a colorless solid. Yield 91% (70 mg, 55 μmol); TLC Rf 0.27 (1:3 ethyl acetate/hexanes); mp 58-63° C.; [α]D 24+32.0 (c 0.10, chloroform); 1H NMR (CDCl3, 400 MHz) δ 7.96 (1H, d, J=6.8 Hz), 7.88 (1H, d, J=7.2 Hz), 7.76 (3H, m), 7.57 (1H, d, J=6.0 Hz), 5.20 (5H, m), 5.05 (1H, dd, J=9.2 Hz, 4.4 Hz), 4.12 (1H, t, J=9.2 Hz), 4.03 (4H, m), 3.88 (2H, m), 2.23 (4H, m), 2.11 (1H, m), 1.70 (21H, m), 1.41 (12H, m) and 1.21-0.90 (48H, m); 13C NMR (CDCl3, 101 MHz) δ 173.36, 172.42, 172.26, 172.01, 171.96, 171.56, 171.36, 170.91, 170.61, 170.60, 170.28, 169.84, 73.80, 72.45, 72.34, 70.65, 70.60, 70.23, 66.01, 60.45, 60.36, 60.11, 59.60, 59.24, 58.37, 39.33, 39.07, 39.02, 34.62, 33.86, 33.75, 33.70, 33.65, 32.02, 31.96, 31.79, 28.61, 28.56, 28.47, 28.35, 28.11, 26.37, 26.35, 26.27, 26.22, 26.15, 25.97, 25.95, 25.93, 25.23, 19.62, 19.41, 19.40, 19.36, 19.34, 19.31, 19.30, 19.28, 19.27, 19.17, 19.15, 18.83, 17.35, 16.92 and 16.85; HRMS (APCI), m/z 1275.757 [M+H]+ (calcd for C65H107N6O19, 1275.759).
- Again by the procedure followed for the preparation and purification of 8a, cyclodepsipeptide 14c (130 mg, 93 μmol) was deprotected with TFA (250 μL) in 2 mL of anhydrous DCM. After separation by column chromatography cyclodepsipeptide 15b (silstatin 6) was obtained as a colorless solid, yield 96% (120 mg, 90 μmol); TLC Rf 0.28 (1:3 ethyl acetate/hexanes); mp 76-80° C.; [α]24 D+26.2 (c 0.21, chloroform); 1H NMR (CDCl3, 400 MHz) δ 7.84 (1H, d, J=7.2 Hz), 7.81 (1H, d, J=5.6 Hz), 7.77 (1H, d, J=8.4 Hz), 7.69 (1H, d, J=6.4 Hz), 7.63 (1H, d, J=6.0 Hz), 7.59 (1H, d, J=7.2 Hz), 7.02 (2H, d, J=8.8 Hz), 6.73 (2H, d, J=8.4 Hz), 5.23 (3H, m), 5.10 (3H, m), 4.50 (q. J=8.0 Hz, 1H), 4.15 (1H, t, J=8.8 Hz), 3.99 (2H, m), 3.88 (2H, m), 3.11 (2H, m), 2.23 (5H, m) and 1.90-0.80 (78H, m); 13C NMR (CDCl3, 101 MHz) δ 172.65, 172.62, 172.32, 172.15, 171.92, 171.79, 171.76, 171.43, 170.84, 170.53, 170.35, 170.09, 155.46, 130.45, 127.60, 115.75, 73.49, 73.10, 72.57, 70.90, 70.76, 70.28, 60.75, 60.36, 59.17, 59.15, 58.56, 54.59, 39.45, 39.42, 39.40, 39.25, 39.24, 35.30, 34.79, 34.07, 33.88, 33.63, 33.57, 32.57, 31.92, 31.84, 31.70, 28.95, 28.91, 28.75, 28.74, 28.69, 26.51, 26.41, 26.12, 26.07, 25.96, 25.40, 22.77, 19.91, 19.79, 19.60, 19.46, 19.40, 19.30, 19.28, 19.27, 19.11, 18.97, 18.94, 17.39, 17.06 and 16.99; HRFTMS (ESI), m/z 1359.755 [M+Na]+ (calcd for C70H108N6O19Na, 1359.756).
- Compounds 18a and 18b were synthesized according to the method depicted in Scheme 3.
- Application of the method followed for the preparation and isolation of 5, unit 5 (264 mg, 0.24 mmol) was deprotected with 2,2′,2″-triaminotriethylamine (362 μL, 351 mg, 2.4 mmol) in 15 mL of DCM and then coupled to unit 11b (170 mg, 0.24 mmol) using HBTU (182 mg, 0.48 mmol) and TEA (33 μL, 24 mg, 0.24 mmol) in 5 mL of anhydrous DMF. Separation by column chromatography provided 16a which was obtained as a colorless solid. Yield 74% (281 mg, 0.18 mmol); TLC Rf 0.50 (1:2 ethyl acetate/hexanes); mp 56-60° C.; [α]24 D+7.62 (c 0.11, chloroform); 1H NMR (CDC3, 400 MHz) δ 7.74 (2H, d, J=7.2 Hz), 7.70 (1H, d, J=6.0 Hz), 7.55 (4H, m), 7.39 (2H, m) 7.29 (8H, m), 7.14 (1H, d, J=6.4 Hz), 5.65 (1H, d, J=7.2 Hz), 5.24 (5H, m), 5.10 (3H, m), 4.38 (3H, m), 4.22 (1H, t, J=7.2 Hz), 4.13 (4H, m), 3.98 (1H, m), 3.92 (1H, m), 2.27 (5H, m), 1.74 (13H, m), 1.41 (10H, m), 1.09 (15H, m) and 0.98 (44H, m); 13C NMR (CDCl3, 101 MHz) δ 171.45, 171.38, 171.34, 171.03, 170.96, 170.91, 170.76, 170.69, 170.53, 170.48, 170.37, 170.36, 156.88, 143.95, 143.71, 141.38, 135.48, 128.58, 128.32, 128.26, 127.84, 127.16, 125.17, 120.09, 74.75, 73.10, 72.82, 72.62, 70.27, 70.18, 69.17, 67.63, 66.98, 66.94, 64.43, 60.35, 60.07, 59.97, 59.61, 59.42, 58.17, 47.15, 40.90, 40.43, 39.04, 33.80, 33.53, 32.47, 30.34, 29.76, 29.64, 29.44, 29.43, 28.61, 26.38, 26.21, 25.98, 24.48, 24.44, 23.33, 21.51, 21.44, 20.71, 19.47, 19.37, 19.31, 19.26, 19.23, 19.20, 19.15, 19.08, 19.06, 18.63, 17.36, 17.23 and 16.85; HRFTMS (ESI), m/z 1603.867 [M+Na]+ (calcd for C85H124N6O22Na, 1603.866).
- By following the experimental used for the synthesis and purification of 5, that unit (5) (221 mg, 0.20 mmol) was deprotected with 2,2′,2″-triaminotriethylamine (302 μL, 293 mg, 2.0 mmol) in 15 mL of DCM and then coupled to unit 11c (158 mg, 0.20 mmol) using HBTU (152 mg, 0.40 mmol) and TEA (28 μL, 20 mg, 0.20 mmol) in 5 mL of anhydrous DMF. After isolation by column chromatography afforded 16b as a colorless solid in a 71% yield (232 mg, 0.14 mmol); TLC Rf 0.45 (1.2 ethyl acetate/hexanes); mp 58-62° C.; [α]24 D+15.3 (c 0.09, chloroform); 1H NMR (CDCl3, 400 MHz) δ 7.74 (3H, m), 7.65 (1H, d, J=7.2 Hz), 7.55 (3H, m), 7.30 (11H, m), 7.06 (2H, d, J=8.0 Hz), 6.89 (2H, d, J=8.4 Hz), 5.79 (1H, d, J=6.8 Hz), 5.24 (5H, m), 5.08 (3H, m), 4.38 (3H, m), 4.05 (5H, m), 3.03 (2H, m), 2.25 (5H, m), 1.70 (13H, m), 1.41 (10H, m), 1.32 (9H, s), 1.09 (3H, m) and 0.98 (44H, m); 13C NMR (CDCl3, 101 MHz) δ 171.68, 171.57, 171.54, 171.42, 171.38, 170.93, 170.72, 170.58, 170.45, 170.43, 170.42, 170.38, 156.64, 154.73, 143.89, 143.67, 141.35, 135.42, 129.67, 128.54, 128.29, 128.23, 127.81, 127.15, 125.13, 124.21, 120.05, 78.43, 73.08, 72.92, 72.66, 70.22, 69.21, 67.55, 66.99, 59.91, 59.89, 59.87, 59.86, 59.60, 59.21, 58.18, 56.01, 47.07, 40.86, 40.47, 39.07, 36.44, 34.72, 33.66, 33.61, 32.43, 31.64, 30.33, 29.73, 29.40, 29.36, 29.28, 29.11, 28.92, 26.37, 26.04, 25.90, 25.34, 24.46, 24.44, 23.32, 23.31, 21.52, 21.41, 19.39, 19.30, 19.26, 19.23, 19.19, 19.14, 19.05, 18.62, 17.37 and 16.83; HRFTMS (ESI), m/z 1665.877 [M+Na]+ (calcd for C90H126N6O22Na, 1665.882).
- By employing the route followed for obtaining 7a, depsipeptide 16a (269 mg, 0.17 mmol) was deprotected using 20% palladium hydroxide-on-carbon (200 mg) in 8 mL of 4:1 ethyl acetate/methanol and then cyclized employing PyBroP (317 mg, 0.68 mmol) and TEA (94 μL, 69 mg, 0.68 mmol) in 170 mL of anhydrous DCM. Separation by column chromatography provided 17a as a colorless solid in 48% yield (102 mg, 81 μmol); TLC Rf 0.3 (1:4 ethyl acetate/hexanes); mp 58-62° C.; [α]24 D+17.3 (c 0.08, chloroform); 1H NMR (CDCl3, 400 MHz) δ 7.78 (1H, d, J=8.0 Hz), 7.71 (1H, d, J=7.2 Hz), 7.62 (1H, d, J=8.4 Hz), 7.43 (2H, m), 7.33 (1H, d, J=4.8 Hz), 5.18 (6H, m), 4.28 (1H, t, J=8.0 Hz), 4.22 (1H, t, J=8.0 Hz), 4.05 (4H, m), 3.85 (1H, dd, J=10 Hz, 5.6 Hz), 2.23 (5H, m), 1.74 (13H, m), 1.43 (10H, m) and 1.25-0.9 (59H, m); 13C NMR (CDCl3, 101 MHz) δ 172.31, 172.21, 172.06, 171.97, 171.69, 171.20, 171.09, 170.24, 170.22, 170.14, 169.99, 169.94, 74.80, 73.41, 73.28, 73.12, 70.99, 70.79, 70.68, 66.61, 60.79, 59.77, 59.12, 58.97, 58.27, 57.84, 40.94, 40.69, 39.46, 34.03, 33.77, 32.20, 29.83, 29.80, 29.29, 28.91, 28.65, 28.56, 28.49, 26.49, 26.33, 26.07, 24.60, 24.55, 23.50, 21.29, 21.18, 20.12, 19.87, 19.53, 19.51, 19.40, 19.37, 19.33, 19.29, 18.96, 18.60, 18.47, 17.48, 17.19 and 17.12; HRMS (APCI), m/z 1251.760 [M+H]+ (calcd for C63H107N6O19, 1251.759).
- Cyclo-{Tyr(tBu)-D-Hcha-D-Val-Lac-[Val-D-Hica-D-Val-Lac]2} (17b)
- The preceding method followed for synthesis and isolation of 7a, depsipeptide 16b (220 mg, 0.13 mmol) was deprotected using 20% palladium hydroxide-on-carbon (200 mg) in 8 mL of 4:1 ethyl acetate/methanol and then cyclized with PyBroP (250 mg, 0.54 mmol) and TEA (74 μL, 54 mg, 0.54 mmol) in 134 mL of anhydrous DCM. Isolation by column chromatography yielded 17b as a colorless solid. Yield 22% (38 mg, 29 μmol); TLC Rf 0.3 (1:4 ethyl acetate/hexanes); mp 55-59° C.; [α]24 D+24.3 (c 0.07, chloroform); 1H NMR (CDCl3, 400 MHz) δ 7.98 (1H, d, J=7.2 Hz), 7.94 (1H, d, J=5.6 Hz), 7.85 (1H, d, J=7.2 Hz), 7.74 (1H, d, J=8.8 Hz), 7.63 (1H, d, J=6.8 Hz), 7.59 (1H, d, J=5.6 Hz), 7.12 (2H, d, J=8.4 Hz), 6.88 (2H, d, J=8.4 Hz), 5.23 (5H, m), 5.13 (1H, m), 4.58 (q, J=7.6 Hz, 1H), 4.18 (1H, t, J=8.8 Hz), 4.01 (1H, dd, J=10 Hz, 7.6 Hz), 3.88 (3H, m), 3.11 (2H, m), 2.23 (5H, m) and 1.90-0.80 (73H, m); 13C NMR (CDCl3, 101 MHz) δ 172.64, 172.53, 172.29, 172.02, 171.78, 171.60, 171.52, 171.31, 170.57, 170.35, 170.10, 169.92, 154.19, 131.28, 129.68, 123.97, 78.15, 73.78, 73.18, 73.08, 70.81, 70.58, 69.86, 60.55, 59.58, 59.47, 58.13, 54.12, 40.73, 40.58, 39.29, 35.10, 35.09, 33.51, 33.33, 32.73, 29.66, 28.82, 28.62, 28.56, 28.49, 28.45, 28.33, 26.35, 25.91, 25.86, 24.46, 24.45, 23.35, 23.32, 21.15, 21.03, 19.82, 19.80, 19.50, 19.35, 19.31, 19.27, 19.18, 19.16, 18.75, 17.27, 17.15 and 16.68; HRMS (APCI), m/z 1313.777 [M+H]+ (calcd for C68H109N6O19, 1313.775).
- By using the procedure used for the synthesis and isolation of 8a, cyclodepsipeptide 17a (80 mg, 64 μmol) was deprotected with TFA (250 μL) in 1 mL of anhydrous DCM. After separation by column chromatography 18a (silstatin 7) was obtained as a colorless solid. Yield 92% (70 mg, 59 μmol); TLC Rf 0.27 (1:3 ethyl acetate/hexanes); mp 75-79° C.; [α]24 D+18.8 (c 0.09, chloroform); 1H NMR (CDCl3, 400 MHz) δ 7.97 (1H, d, J=6.8 Hz), 7.88 (1H, d, J=7.2 Hz), 7.76 (3H, m), 7.57 (1H, d, J=6.0 Hz), 5.20 (5H, m), 5.05 (1H, dd, J=8.8 Hz, 4.0 Hz), 4.75 (1H, br s), 4.12 (1H, t, J=8.8 Hz), 3.95 (6H, m), 2.23 (4H, m), 2.11 (1H, m), 1.74 (13H, m), 1.43 (10H, m) and 1.25-0.9 (50H, m); 13C NMR (CDCl3, 101 MHz) δ 173.4, 172.65, 172.30, 172.23, 172.13, 171.75, 171.57, 171.07, 170.94, 170.80, 170.40, 170.00, 73.91, 73.31, 73.19, 70.79, 70.72, 70.43, 66.16, 60.69, 60.48, 60.21, 59.86, 59.44, 58.59, 40.82, 40.73, 39.16, 34.00, 33.87, 32.12, 28.73, 28.68, 28.62, 28.52, 28.26, 26.50, 26.30, 26.10, 24.59, 24.58, 23.46, 23.34, 21.54, 21.34, 19.76, 19.58, 19.53, 19.49, 19.48, 19.47, 19.46, 19.45, 19.42, 19.32, 19.02, 17.50 and 17.05; HRMS (APCI), m/z 1195.696 [M+H]+ (calcd for C59H99N6O19, 1195.697).
- By using the general procedure for the preparation and isolation of 8a, cyclodepsipeptide 17b (30 mg, 23 μmol) was deprotected with TFA (250 μL) in 1 mL of anhydrous DCM. Separation by column chromatography led to 18b (silstatin 8) as a colorless solid. Yield 87% (25 mg, 20 μmol); TLC Rf 0.27 (1:3 ethyl acetate/hexanes); mp 78-82° C.; [α]24 D+21.3 (c 0.08, chloroform); 1H NMR (CDCl3, 400 MHz) δ 7.80 (3H, m), 7.67 (2H, m), 7.61 (1H, d, J=7.2 Hz), 7.05 (2H, d, J=8.0 Hz), 6.74 (2H, d, J=8.0 Hz), 6.03 (1H, br s), 5.23 (3H, m), 5.09 (3H, m), 4.48 (q, J=7.4 Hz, 1H), 4.14 (1H, t, J=8.8 Hz), 4.05 (2H, m), 3.93 (2H, m), 3.05 (2H, m), 2.23 (5H, m), 1.77 (7H, m), 1.60 (7H, m), 1.45 (6H, d, J=6.8 Hz), 1.36 (3H, d, J=6.8 Hz) and 1.11-0.80 (47H, m); 13C NMR (CDCl3, 101 MHz) δ 172.60, 172.44, 172.34, 172.22, 171.88, 171.78, 171.69, 171.49, 170.99, 170.45, 170.36, 170.14, 155.25, 130.52, 127.80, 115.81, 73.75, 73.54, 73.26, 70.86, 70.72, 70.38, 60.75, 60.31, 59.04, 59.01, 58.69, 54.69, 40.91, 40.74, 39.41, 35.32, 33.64, 33.62, 32.54, 29.85, 29.04, 28.91, 28.75, 28.72, 28.67, 26.53, 26.09, 25.97, 24.66, 24.63, 23.50, 23.49, 21.33, 21.21, 19.91, 19.76, 19.62, 19.50, 19.42, 19.36, 19.35, 19.07, 18.99, 18.89, 17.44 and 17.06; HRMS (APCI), m/z 1257.713 [M+H]+ (calcd for C64H101N6O19, 1257.712).
- Employing the strategy presented by Duimstra et al.,11 1-bromo-2,3,4-tri-O-acetyl-α-D-glucuronate (2.32 g, 5.84 mmol) was coupled to 4-hydroxy-3-nitrobenzaldehyde (1.66 g, 9.93 mmol) using Ag2O (6.14 g, 26.5 mmol) in 20 ml of anhydrous acetonitrile. Yield 93% (2.62 g, 5.42 mmol); 1H NMR (CDCl3, 400 MHz) δ 9.98 (1H, s), 8.32 (1H, d, J=1.6 Hz), 8.10 (1H, dd, J=8.0 Hz, 1.6 Hz), 7.52 (1H, d, J=8.8 Hz), 5.43 (2H, m), 5.31 (2H, m), 4.34 (1H, d, J=8.8 Hz), 3.71 (3H, s), 2.13 (3H, s), 2.09 (3H, s) and 2.08 (3H, s); 13C NMR (CDCl3, 101 MHz) δ 188.7, 170.0, 169.4, 169.2, 166.8, 153.4, 141.2, 134.4, 131.6, 126.8, 118.9, 98.7, 72.8, 70.3, 69.9, 68.2, 53.2, 20.7 and 20.7.
- Compound 28 was synthesized according to the method depicted in Scheme 4.
- By means of the synthesis presented by Duimstra et al.,11 glucuronate 19 (2.60 g, 5.38 mmol) was reduced with sodium borohydride (305 mg, 8.07 mmol) in the presence of silica (1.08 g) in 65 mL of 1:5 isopropanol/chloroform and then silyl protected using TBDMS-CL (1.22 g, 8.07 mmol) and imidazole (549 mg, 8.07 mmol) in 30 mL of anhydrous DCM. After separation by column chromatography 21 was obtained as a colorless solid. Yield 80% (2.58 g, 4.30 mmol); TLC Rf 0.25 (1:2 ethyl acetate/hexanes); 1H NMR (CDCl3, 400 MHz) δ 7.75 (1H, d, J=2.4 Hz), 7.45 (1H, dd, J=8.8 Hz, 2.4 Hz), 7.32 (1H, d, J=8.4 Hz), 5.31 (3H, m), 5.17 (1H, d, J=7.2 Hz), 4.72 (2H, s), 4.19 (1H, d, J=9.2 Hz), 3.75 (3H, s), 2.13 (3H, s), 2.06 (3H, s), 2.05 (3H, s), 0.94 (9H, s) and 0.11 (6H, s); 13C NMR (CDCl3, 101 MHz) δ 170.16, 169.44, 169.43, 166.87, 147.92, 141.45, 138.24, 131.19, 122.56, 120.35, 100.23, 72.75, 71.37, 70.39, 68.97, 63.53, 53.18, 26.01, 20.74, 20.71, 20.65 and −5.18.
- By employing the procedure recorded by Grinda et al.,12 glucuronate 21 (1.58 g, 2.63 mmol) was deacetylated with 0.5 N sodium methoxide in methanol (5.26 mL, 2.63 mmol) in 50 mL of anhydrous methanol and then transesterified with a sodium allylate solution (prepared by dissolving sodium (12 mg, 0.53 mmol) in 5 m L of allyl alcohol). By means of separation by column chromatography 22 was obtained as a colorless solid. Yield 51% (671 mg, 1.34 mmol); TLC Rf 0.25 (1:1 acetone/hexanes); 1H NMR (CDCl3, 400 MHz) δ 7.71 (1H, d, J=2.4 Hz), 7.42 (1H, dd, J=8.4 Hz, 2.0 Hz), 7.29 (1H, d, J=8.4 Hz), 5.87 (1H, m), 5.32 (1H, m), 5.20 (1H, m), 5.02 (1H, d, J=7.2 Hz), 4.81 (1H, br s), 4.66 (4H, m), 4.39 (1H, br s), 4.28 (1H, br s), 4.11 (1H, d, J=9.6 Hz), 3.92 (1H, m), 3.78 (1H, m), 0.91 (9H, s) and 0.07 (6H, s); 13C NMR (CDCl3, 101 MHz) 168.4, 149.1, 140.3, 137.0, 131.8, 131.4, 122.9, 119.1, 118.8, 102.3, 75.1, 74.8, 72.9, 71.0, 66.6, 63.5, 26.0, 18.5 and −5.2.
- Application of the experimental recommended by Grinda et al.,12 the free hydroxyl groups of glucuronate 22 (200 mg, 0.40 mmol) were protected using allyl chloroformate (1.28 mL, 1.45 g, 12.0 mmol) in 2 mL of anhydrous pyridine and following separation by column chromatography 23 was obtained as a colorless oil. Yield 72% (216 mg, 0.29 mmol); TLC Rf 0.4 (1:3 ethyl acetate/hexanes); 1H NMR (CDCl3, 400 MHz) δ 7.72 (1H, d, J=2.4 Hz), 7.45 (1H, dd, J=8.8 Hz, 2.4 Hz), 7.29 (1H, d, J=8.4 Hz), 5.87 (4H, m), 5.33 (3H, m), 5.20 (7H, m), 4.68 (4H, m), 4.59 (6H, m), 4.31 (1H, m), 0.91 (9H, s) and 0.07 (6H, s); 13C NMR (CDCl3, 101 MHz) δ 165.73, 154.03, 153.55, 153.54, 147.96, 140.99, 137.99, 131.31, 131.22, 131.15, 131.04, 130.97, 122.68, 119.38, 119.35, 119.32, 119.27, 119.05, 99.83, 75.15, 74.07, 72.49, 72.26, 69.54, 69.33, 69.18, 66.94, 63.42, 25.94, 18.41 and −5.24.
- Again following the procedure presented by Grinda et al.,12 compound 23 (409 mg, 0.54 mmol) was deprotected using a 7:3 HF/Pyridine solution (2.05 mL) in 10 mL of anhydrous tetrahydrofuran. Column chromatography using ethyl acetate/hexanes gave 24 as a colorless oil. Yield 92% (316 mg, 0.50 mmol); TLC Rf 0.20 (1:3 ethyl acetate/hexanes); 1H NMR (CDCl3, 400 MHz) δ 7.76 (1H, d, J=2.0 Hz), 7.45 (1H, dd, J=8.4 Hz, 2.0 Hz), 7.29 (1H, d, J=8.4 Hz), 5.87 (4H, m), 5.33 (4H, m), 5.20 (8H, m), 4.67 (10H, m) and 4.35 (1H, d, J=8.8 Hz); 13C NMR (CDCl3, 101 MHz) 165.80, 154.04, 153.58, 153.56, 148.16, 140.75, 137.52, 132.11, 131.24, 131.10, 131.00, 130.92, 123.33, 119.44, 119.37, 119.34, 119.12, 119.09, 99.54, 75.15, 74.07, 72.45, 72.07, 69.61, 69.36, 69.22, 67.01 and 63.25.
- Following the procedure presented by Grinda et al.,12 compound 24 (316 mg, 0.50 mmol) was activated using 4-nitrophenyl chloroformate (202 mg, 1.00 mmol) and pyridine (101 μL, 99 mg, 1.25 mmol) in 10 mL of anhydrous dichloromethane. After separation by column chromatography 25 was obtained as a colorless oil. Yield 89% (356 mg, 0.44 mmol). TLC Rf 0.4 (2:3 ethyl acetate/hexanes); 1H NMR (CDCl3, 400 MHz) δ 8.27 (2H, d, J=8.8 Hz), 7.87 (1H, d, J=2.0 Hz), 7.58 (1H, dd, J=8.4 Hz, 2.0 Hz), 7.29 (3H, m), 5.84 (4H, m), 5.33 (14H, m), 4.65 (8H, m) and 4.35 (1H, d, J=9.2 Hz); 13C NMR (CDCl3, 101 MHz) δ 165.70, 155.36, 154.04, 153.55, 153.51, 152.39, 149.50, 145.60, 140.87, 134.20, 131.20, 131.11, 130.99, 130.90, 130.36, 125.68, 125.44, 121.86, 119.52, 119.45, 119.42, 119.22, 119.13, 99.35, 74.89, 73.93, 72.31, 72.30, 69.65, 69.40, 69.27, 68.93 and 67.05.
- To a stirred solution containing 4-(methylamino)butyric acid (38 mg, 0.32 mmol) in 1 mL of anhydrous DMF was added potassium carbonate (88 mg, 0.64 mmol) followed by compound 25 (256 mg, 0.32 mmol). The reaction mixture was stirred at 23° C. for 30 min, diluted with 60 mL of ethyl acetate, washed with 20 mL of 6% aq citric acid, 25 mL of brine, dried over MgSO4 and concentrated under reduced pressure. The residue was partially separated using a short silica gel plug to remove the 4-nitrophenol and afford intermediate 26 as a colorless oil; crude yield 80% (200 mg). Next, intermediate 26 (130 mg, 0.17 mmol) was dissolved in 3 mL of anhydrous DCM and compound 18a (167 mg, 0.14 mmol) was added followed by DMAP (5 mg, 0.04 mmol) and DCC (31 mg, 0.15 mmol). The reaction mixture was stirred at 23° C. for 16 h. The solvent was separated by filtration and the filtrate was concentrated under reduced pressure. The crude product was separated by chromatography on a silica gel column. Elution with 3:2 hexanes/ethyl acetate gave the allyl protected prodrug 27 as a colorless solid: yield 51% over two steps (176 mg, 90 μmol). TLC Rf 0.25 (2:3 ethyl acetate/hexanes); mp 76-79° C.; [α]24 D+12.0 (c 0.03, chloroform); 1H NMR (CDCl3, 400 MHz) δ 7.93 (1H, m), 7.77 (6H, m), 7.53 (1H, dd, J=8.8 Hz, 2.0 Hz), 7.33 (1H, d, J=8.8 Hz), 5.84 (4H, m), 5.25 (16H, m), 5.09 (4H, m), 4.65 (8H, m), 4.69 (8H, m), 4.48 (1H, dd, J=8.4 Hz, 6.4 Hz), 4.33 (1H, d, J=8.8 Hz), 4.08 (5H, m), 3.90 (1H, m), 3.47 (2H, m), 3.32 (3H, m), 2.92 (3H, s), 2.26 (5H, m), 1.77 (15H, m), 1.36 (13H, m), 1.08 (20H, m) and 0.94 (27H, m); 13C NMR (CDCl3, 101 MHz) 172.32, 172.26, 172.06, 172.03, 172.01, 171.84, 171.69, 171.57, 171.49, 170.46, 170.28, 170.08, 165.54, 156.71, 153.89, 153.41, 153.40, 148.68, 140.87, 133.38, 131.12, 131.00, 130.88, 130.79, 124.74, 119.89, 119.34, 119.26, 119.24, 119.21, 118.97, 99.54, 74.87, 73.83, 73.40, 73.27, 73.15, 72.27, 72.22, 70.47, 70.41, 70.37, 69.45, 69.22, 69.11, 68.50, 66.86, 65.17, 60.52, 59.88, 58.74, 58.63, 57.62, 49.10, 40.63, 40.57, 39.15, 34.62, 33.92, 33.73, 33.69, 32.12, 31.54, 28.62, 28.53, 28.49, 26.30, 26.16, 25.92, 25.58, 25.23, 24.90, 24.45, 24.41, 23.45, 23.23, 22.62, 22.61, 21.24, 20.95, 20.66, 19.71, 19.43, 19.39, 19.29, 19.24, 19.03, 18.92, 18.87, 17.21, 16.98, 16.88 and 14.07; HRFTMS (ESI), m/z 1979.8054 [M+Na]+ (calcd for C93H136N8O37Na, 1979.8899).
- To a stirred solution containing protected prodrug 27 (24 mg, 12 μmol) in 1 mL of anhydrous tetrahydrofuran was added a solution containing formic acid (1.4 μL, 1.7 mg, 36 μmol) and TEA (8.3 μL, 6.1 mg, 60 μmol) of in 100 μL of anhydrous tetrahydrofuran. The reaction mixture was stirred at 23° C. for 10 min, then Pd(PPh3)4 (1.4 mg, 1.2 μmol) was added, the mixture was stirred at 23° C. for 2.5 h and then concentrated under reduced pressure. The crude product was separated by reverse phase HPLC. Column: Phenomenex Luna C8(2), 250×10 mm, 5 μm. Flow rate: 3.5 mL/min. Solvents: A) 50 mM NH4OAc (pH=3.5); B) ACN. Isocratic elution with 20% A in B from 0 to 10 min; next, gradient elution from 20% A in B to 1% A in B from min 10 to
min 12; finally, isocratic elution with 1% A in B frommin 12 to min 18. Retention time: 15.5 min. To provide a colorless solid: yield 50% (10 mg, 6 μmol); mp 133-136° C.; [α]24 D+8.57 (c 0.04, chloroform); 1H NMR (CD3OD, 400 MHz) δ 7.84 (1H, m), 7.61 (1H, dd, J=8.4 Hz, 1.6 Hz), 7.48 (1H, d, J=8.8 Hz), 5.44 (1H, m), 5.12 (9H, m), 4.99 (1H, m), 4.39 (2H, d, J=6.8 Hz), 4.25 (3H, m), 3.85 (1H, d, J=9.6 Hz), 3.52 (3H, m), 3.36 (2H, m), 2.94 (3H, s), 2.30 (7H, m), 1.74 (15H, m), 1.41 (10H, m) 1.29 (6H, m) and 0.95 (44H, m); 13C NMR (CD3OD, 101 MHz) δ 175.10, 173.42, 173.40, 173.29, 173.16, 172.82, 172.77, 172.74, 172.12, 172.10, 172.01, 171.99, 171.97, 170.56, 157.75, 151.12, 141.73, 134.57, 132.65, 125.51, 119.06, 102.39, 77.66, 76.57, 74.87, 74.49, 74.44, 73.18, 71.95, 71.86, 71.79, 66.75, 60.00, 59.86, 59.80, 59.72, 57.24, 49.28, 41.97, 40.85, 40.83, 35.67, 34.99, 34.94, 34.90, 34.46, 33.37, 32.15, 32.12, 31.50, 31.40, 31.22, 31.07, 31.02, 27.43, 27.24, 27.04, 26.19, 25.70, 24.20, 23.75, 23.68, 23.61, 21.71, 21.60, 19.68, 19.63, 19.62, 19.61, 19.60, 19.28, 19.16, 18.93, 18.85, 18.78, 18.08, 18.03 and 17.19; HRFTMS (ESI), m/z 1687.7934 [M+Na]+ (calcd for C78H120N8O31Na, 1687.7952). - Inhibition of human cancer cell growth was assessed using the National Cancer Institute's standard sulforhodamine B assay as previously described.19 In summary, cells in a 5% fetal bovine serum/RPM 1640 medium were inoculated in 96-well plates and incubated for 24 hrs. Next, serial dilutions of the compounds were added. After 48 h, the plates were fixed with trichloroacetic acid, stained with sulforhodamine B, and read with an automated microplate reader. A growth inhibition of 50% (GI50 or the drug concentration causing a 50% reduction in the net protein increase) was calcd from optical density data with Immunosoft software. Normal cells were treated in identical conditions. Normal human prostate CRL-2221 (PZ-HPV-7) was grown in MEM 10% FBS and normal human breast MCF-10A in MEGM kit.
- The growth inhibition property of the silstatins and some intermediates were evaluated against a mini panel of cancer cell lines (Table 1). An overall observation pointed to small modifications on the structure of the bacillistatin, while keeping the overall lipophilicity as shown for silstatin 1 (7a), did not affect its high potency. However, the introduction of polar groups (hydroxyl) somewhat decreased activity as shown for silstatins 2 and 3 (8a and 8b). Introduction of an α-hydroxy acid with a more lipophilic side chain in place of the three (R)-2-hydroxyisocaproic acid units caused a marked reduction of cancer cell growth inhibition capability as seen in silstatins 4 and 6 (14a and 15b). In contrast, silstatin 5 (15a) showed very high inhibitory activity.
- In order to maximize the activity displayed versus lipophilicity, only one (R)-2-hydroxyisocaproic acid residue was interchanged with (2R)-2-hydroxy-3-cyclohexylpropionic acid thereby rescuing the activity as cancer cell growth inhibitors of the structures containing a hydroxyl group as shown by silstatins 7 and 8 (18a and 18b); although, without reaching the activity shown by silstatins 1 (7a) or the bacillistatins.
-
TABLE 1 Growth inhibition of human cancer cell lines (GI50 μg/mL). Cell linea BXPC3 MCF-7 SF268 NCI-H460 KM20L2 DU145 Bacillistatin 11 0.00095 0.00061 0.00045 0.0023 0.00087 0.0015 Bacillistatin 21 0.00034 0.00031 0.0018 0.00045 0.00026 0.00086 Silstatin 1 (7a) 0.0008 0.00011 0.00021 0.0007 0.00016 0.00042 7c 0.03 0.0042 0.0025 0.029 0.0048 0.011 Silstatin 2 (8a) 0.004 0.0022 0.0031 0.0032 0.0033 0.006 Silstatin 3 (8b) 0.005 0.0016 0.004 0.0037 0.0011 0.0051 Silstatin 4 (14a) 0.5 0.18 0.081 0.4 0.18 0.22 14b 0.18 0.075 0.075 0.32 0.08 0.12 14c >1 >1 >1 >1 >1 >1 Silstatin 5 (15a) 0.03 0.0031 0.0044 0.021 0.0044 0.005 Silstatin 6 (15b) 0.53 0.12 0.05 0.32 0.09 0.22 17a 0.023 0.001 0.004 0.009 0.0024 0.007 17b 0.09 0.032 0.06 0.12 0.052 0.04 Silstatin 7 (18a) 0.0038 0.0014 0.0031 0.0032 0.0015 0.003 Silstatin 8 (18b) 0.006 0.0011 0.003 0.004 0.0021 0.0054 28 0.20 0.031 0.05 0.07 0.04 0.13 aCancer cell lines in order: pancreas (BXPC-3); breast (MCF-7); CNS (SF268); lung (NCI-H460); colon (KM20L2); prostate (DU-145). - To demonstrate the utility of the new silstatins feasibility for forming prodrugs and linkers to monoclonals, prodrug 28 was synthesized and evaluated against the same mini panel of cancer cell lines (Table 1). The use of glucuronide prodrugs has been validated by in vivo studies showing superior therapeutic efficacy compared to the parent drug.17
- In turn, that proved to be a prodrug that should have greatly reduced toxicity during transport to the tumor where a glucuronidase would release silstatin 7. Evidence of that expected result was obtained as follows. The cancer cell growth inhibition activity for prodrug 28 was found to be decreased 16-52 times with respect to the parent silstatin 7. Also, prodrug 28 was tested against two normal cell lines and compared to the parent drug (18a) (Table 2) and, as presumed, the prodrug 28 normal cell growth inhibition activity was decreased 62.5 and 12.5 times with respect to the parent silstatin 7 drug (18a) in MCF-10A and CRL-2221 cell lines, respectively.
-
TABLE 2 Growth inhibition of human normal cell lines (GI50 μg/mL) Cell linea MCF-10A CRL-2221 Silstatin 7 (18a) 0.004 0.004 28 0.25 0.05 aNormal cell lines in order: breast (MCF-10A); prostate (CRL-2221). - The quite high activity of prodrug 28 displayed in cancer and normal cell lines might be attributed to the fact that the prodrug could be crossing the cell membrane and releasing the drug (18a). The difference in cell growth inhibition activity of prodrug 28, as shown in Table 2, could be due to the level of β-glucuronidase expression in each cell line. Recently, a doxorubicin glucuronide prodrug capable of binding albumin through a maleamide moiety was synthesized. The effects of this capability lead to a relatively non-toxic prodrug with higher accumulation in the tumor (more selective) as compared to the glucuronide prodrug without the maleamide moiety.18
- Compounds of the present disclosure are tested for antimicrobial activity in NCCLS broth microdilution assays following a protocol similar to that described in Pettit, G. R. et al., J. Nat. Prod. 2009, 72, 366-371.20,21
- Briefly, test compounds are reconstituted in a small volume of sterile DMSO and diluted in the appropriate media immediately prior to susceptibility experiments.1 The MIC is defined as the lowest concentration inhibiting visible growth of the microorganism.
- The following references are hereby incorporated by reference in their entireties:
- 1. Pettit, G. R.; Knight, J. C.; Herald, D. L.; Pettit, R. K.; Hogan, F.; Mukku, V. J. R. V.; Hamblin, J. S.; Dodson II, M. J.; Chapuis, J-C. J. Nat. Prod. 2009, 72, 366-371.
- 2. Pettit, G. R.; Hu, S.; Knight, J. C.; Chapuis, J-C. J. Nat. Prod. 2009, 72, 372-379.
- 3. a) Fu, P; Johnson, M.; Chen, H.; Posner, B. A.; MacMillan, J. B. J. Nat. Prod. 2014, 77, 1245-1248. b) Bouhired, S. M.; Crüsemann, M.; Almeida, C.; Weber, T.; Piel, J.; Schäberle, T. F.; Köning, G. M. ChemBioChem 2014, 15, 757-765. c) Myobatake, Y.; Takemoto, K.; Kamisuki, S.; Inoue, N.; Takasaki, A.; Takeuchi, T.; Mizushina, Y.; Sugawara, F. J. Nat. Prod. 2014, 77, 1236-1240. d) Kong, F.; Wang, Y.; Liu, P.; Dong, T.; Zhu, W. J. Nat. Prod. 2014, 77, 132-137. e) Sun, Y-L.; Bao, J.; Liu, K-S.; Zhang, X-Y.; He, F.; Wang, Y-F.; Nong, X-H.; Qi, S-H. Planta Med 2013, 79, 1474-1479. f) Um, S.; Choi, T. J.; Kim, H.; Kim, B. Y.; Kim, S-H.; Lee, S. K.; Oh, K-B.; Shin, J.; Oh, D-C. J. Org. Chem. 2013, 78, 12321-12329. g) Meng, L-H.; Li, X-M.; Lv, C-T.; Li, C-S.; Xu, G-M, Huang, C-G.; Wang, B-G. J. Nat. Prod. 2013, 76, 2145-2149. h) Kuramochi, K.; Tsubaki, K.; Kuriyama, I.; Mizuchina, Y.; Yoshida, H.; Takeuchi, T.; Kamisuki, S.; Sugawara, F.; Kobayashi, S. J. Nat. Prod. 2013, 76, 1737-1745.
- 4. a) Skellam, E. J.; Steward, A. K.; Strangman, W. K.; Wright, J. L. C. J. Antibiot. 2013, 66, 431-441. b) Lin, Z.; Koch, M.; Pond, C. D.; Mabeza, G.; Seronay, R. A.; Concepcion, G. P.; Barrows, L. R.; Oliveira, B. M.; Schmidt, E. W. J. Antibiot. 2013, 67, 121-126. c) Jang, K. H.; Nam, S-J.; Locke, J. B.; Kauffman, C. A.; Beatty, D. S.; Paul, L. A.; Fenical, W. Angew. Chem. Int. Ed. 2013, 52, 7822-7824. d) Lu, Z.; Koch, M.; Harper, M. K.; Matainaho, T. K.; Barrows, L. R.; Van Wagoner, R. M.; Ireland, C. M. J. Nat. Prod. 2013, 76, 2150-2152. e) Wu, C.; Tan, Y.; Gan, M.; Wang, Y.; Guan, Y.; Hu, X.; Zhou, H.; Shang, X.; You, X.; Yang, Z.; Xiao, C. J. Nat. Prod. 2013, 76, 2153-2157. f) Felder, S.; Kehraus, S.; Neu, E.; Bierbaum, G.; Schäberle, T. F.; Köning, G. M. ChemBioChem 2013, 14, 1363-1371.
- 5. a) Xu, D-X.; Sun, P.; Kutan, T.; Mandi, A.; Tang, H.; Liu, B.; Gerwick, W. H.; Wang, Z-W.; Zhang, W. J. Nat. Prod. 2014, 77, 1179-1184. b) Du, F-Y.; Zhang, P.; Li, X-M.; Li, C-S.; Cui, C-M.; Wang, B-G. J. Nat. Prod. 2014, 77, 1164-1169. c) Wu, G.; Sun, X.; Yu, G.; Wang, W.; Zhu, T.; Gu, Q.; Li, D. J. Nat. Prod. 2014, 77, 270-275. d) Haga, A.; Tamoto, H.; Ishino, M.; Kimura, E. Sugita, T.; Kinoshita, K.; Takahashi, K.; Shire, M.; Koyama, K. J. Nat. Prod. 2013, 76, 750-754. e) Bao, J.; Sun, Y-L.; Zhang, X-Y.; Han, Z.; Gao, H-C.; He, F.; Qian, P-Y.; Qi, S-H. J. Antibiot. 2013, 66, 219-223. f) He, F.; Bao, J.; Zhang, X-Y.; Tu, Z-C.; Shi, Y-M.; Qi, S-H. J. Nat. Prod. 2013, 76, 1182-1186.
- 6. a) Pavlik, C. M.; Wong, C. Y. B.; Ononye, S.; Lopez, D. D.; Engene, N.; McPhail, K. L. Gerwick, W. H.; Balunas, M. J. J. Nat. Prod. 2013, 76, 2026-2033. b) Thornburg, C. C.; Cowley, E. S.; Sikorska, J.; Shaala, L. A.; Ishmael, J. E.; Youssef, D. T. A.; McPhail, K. L. J. Nat. Prod. 2013, 76, 1781-1788. c) Tan, L. T. Drug Discov. Today 2013, 18, 863-871.
- 7. a) Guo, W.; Peng, J.; Zhu, T.; Gu, Q.; Keyzers, R. A.; Li. D. J. Nat. Prod. 2013, 76, 2106-2112. b) Um, S.; Kim, Y-J.; Kwon, H.; Wen, H.; Kim, S-H.; Kwon, H-C.; Park, S.; Shin, J.; Oh, D-C. J. Nat. Prod. 2013, 76, 873-879. c) Peng, J.; Zhang, X-Y.; Tu, Z-C.; Xu, X-Y.; Qi, S-H. J. Nat. Prod. 2013, 76, 983-987. d) Pettit, R. K. Mar. Biotechnol. 2011, 13, 1-11.
- 8. Suwan, S.; Isobe, M.; Ohtani, I.; Agata, N.; Mori, M.; Ohta, M. J. Chem. Soc. Perkin Trans. 1 1995, 765-775.
- 9. Glueck, S. M.; Pirker, M.; Nestl, B. M.; Ueberbacher, B. T.; Larissegger-Schnell, B.; Csar, K.; Hauer, B.; Stuermer, R.; Kroutil, W.; Faber, K. J. Org. Chem. 2005, 70, 4028-4032
- 10. Bollenback, G. N.; Long, J. W.; Benjamin, D. G.; Lindquist, J. A. J. Am. Chem. Soc. 1955, 77, 3310-3315.
- 11. Duimstra, J. A.; Femia, F. J.; Meade, T. J. J. Am. Chem. Soc. 2005, 127, 12847-12855.
- 12. Grinda, M.; Clarhaut, J.; Tranoy-Opalinski, I.; Renoux B.; Monvoisin, A.; Cronier, L.; Papot. S. ChemMedChem 2011, 6, 2137-2141.
- 13. Alaoui, A. E.; Schmidt, F.; Monneret, C.; Florent. J-C. J. Org. Chem. 2006, 71, 9628-9636.
- 14. a) Bouvier, E.; Thirot, S.; Schmedt, F.; Monneret, C. Org. Biomol. Chem. 2003, 1, 3343-3352. b) de Bond, D. B. A.; Leenders, R. G. G.; Haisma, H. J.; Van Der Meulen-Muileman, I. H.; Scheeren, H. W. Bioorg. Med. Chem. 1997, 5, 405-414. c) DeWit, M. A.; Gillies, E. R. Org. Biomol. Chem. 2011, 9, 1846-1854.
- 15. Iacobazzi, R. M.; Annese, C.; Azzariti, A.; D'Accolti, L.; Franco, M.; Fusco, C.; Gianluigi, L. P.; Laquintana, V.; Denora, N. ACS Med. Chem. Lett. 2013, 4, 1189-1192.
- 16. Halsey, C. M.; Benham, D. A.; JiJi, R. D.; Cooley, J. W. Spectrochim. Acta Mol. Biomol. Spectros. 2012, 96, 200-206.
- 17. a) Houba, P. H. J.; Boven, E.; Van Der Meulen-Muileman, I. H.; Lenders, R. G. G.; Scheeren, J. W.; Pinedo, H. M.; Haisima, H. J. Br. J. Cancer 2001, 84, 550-557. b) Bosslet, K.; Straub, R.; Blumrich, M.; Czech, J.; Gerken, M.; Sperker, B.; Kroemer, H. K.; Gesson, J-P.; Koch, M.; Monneret, C. Cancer Res. 1998, 58, 1195-1201. c) Woessner, R.; An, Z.; Li, X.; Hoffman, R. M.; Dix, R.; Bitonti, A. Anticancer Res. 2000, 20, 2289-2296. d) Legigan, T.; Clarhaut, J.; Renoux, B.; Tranoy-Opalinski, I.; Monvoisin, A.; Jayle, C.; Alsarraf, J.; Thomas, M.; Papot, S Eu. J. Med. Chem. 2013, 67, 75-80.
- 18. Legigan, T.; Clarhaut, J.; Renoux, B.; Tranoy-Opalinski, I.; Monvoisin, A.; Berjeaud, J-M.; Guilhot, F.; Papot, S J. Med. Chem. 2012, 55, 4516-4520.
- 19. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Viagro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. J. Natl. Cancer Inst. 1991, 83, 757-766.
- 20. NCCLS. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Fifth Edition. NCCLS document M7-A5 [ISBN 1-56238-394-9]. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pa. 19087-1898 USA, 2000.
- 21. NCCLS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard-Second Edition. NCCLS document M27-A2 [ISBN 1-56238-469-4]. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pa. 19087-1898 USA, 2002.
- While particular materials, formulations, operational sequences, process parameters, and end products have been set forth to describe and exemplify this invention, they are not intended to be limiting. Rather, it should be noted by those ordinarily skilled in the art that the written disclosures are exemplary only and that various other alternatives, adaptations, and modifications may be made within the scope of the present invention. Accordingly, the present invention is not limited to the specific embodiments illustrated herein, but is limited only by the following claims.
Claims (38)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/550,727 US20180030095A1 (en) | 2015-02-13 | 2016-02-12 | Silstatin compounds |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562116344P | 2015-02-13 | 2015-02-13 | |
PCT/US2016/017834 WO2016130969A1 (en) | 2015-02-13 | 2016-02-12 | Silstatin compounds |
US15/550,727 US20180030095A1 (en) | 2015-02-13 | 2016-02-12 | Silstatin compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/017834 A-371-Of-International WO2016130969A1 (en) | 2015-02-13 | 2016-02-12 | Silstatin compounds |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/536,039 Continuation US11174291B2 (en) | 2015-02-13 | 2019-08-08 | Silstatin compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180030095A1 true US20180030095A1 (en) | 2018-02-01 |
Family
ID=56614906
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/550,727 Abandoned US20180030095A1 (en) | 2015-02-13 | 2016-02-12 | Silstatin compounds |
US16/536,039 Active US11174291B2 (en) | 2015-02-13 | 2019-08-08 | Silstatin compounds |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/536,039 Active US11174291B2 (en) | 2015-02-13 | 2019-08-08 | Silstatin compounds |
Country Status (2)
Country | Link |
---|---|
US (2) | US20180030095A1 (en) |
WO (1) | WO2016130969A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10435435B2 (en) | 2015-07-24 | 2019-10-08 | The Arizona Board Of Regents On Behalf Of Arizona State University | Quinstatin compounds |
US11174291B2 (en) | 2015-02-13 | 2021-11-16 | Arizona Board Of Regents On Behalf Of Arizona State University | Silstatin compounds |
US11629167B2 (en) | 2017-11-09 | 2023-04-18 | Arizona Board Of Regents On Behalf Of Arizona State University | Betulastatin compounds |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4306071A (en) | 1979-11-14 | 1981-12-15 | The United States Of America As Represented By The Department Of Health & Human Services | 1,4-Bis(2-haloethyl)-1,4-diazabicyclo[2.2.1]-heptane dihydrogen dimaleate and selected salts |
US4414205A (en) | 1981-08-28 | 1983-11-08 | University Patents, Inc. | Cell growth inhibitory substances |
US4388457A (en) | 1982-02-11 | 1983-06-14 | University Patents, Inc. | Phyllanthostatin compounds |
US4560774A (en) | 1982-11-17 | 1985-12-24 | Arizona State University | Macrocyclic lactones |
US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
US4985436A (en) | 1984-02-17 | 1991-01-15 | Arizona Board Of Regents | Composition of matter for inhibiting leukemias and sarcomas |
US4611066A (en) | 1984-08-10 | 1986-09-09 | Arizona State University | Bryostatins 4 to 8 |
US4833257A (en) | 1986-07-28 | 1989-05-23 | Arizona Board Of Regents | Compositions of matter and methods of using same |
CA1338645C (en) | 1987-01-06 | 1996-10-15 | George R. Pettit | Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins" |
US4996237A (en) | 1987-01-06 | 1991-02-26 | Arizona Board Of Regents | Combretastatin A-4 |
CA1328661C (en) | 1987-07-09 | 1994-04-19 | George Robert Pettit | Rolliniastatin 1 and means and methods for inhibiting cell growth therewith |
US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
ATE97321T1 (en) | 1988-01-13 | 1993-12-15 | Univ Arizona State | IMMUNOMODULATING BRYOSTATINS. |
WO1989008655A1 (en) | 1988-03-12 | 1989-09-21 | Arizona Board Of Regents | Isolation and structural elucidation of cephalostatins 1-4 |
US4873245A (en) | 1988-03-14 | 1989-10-10 | Arizona Board Of Regents | Isolation and structural elucidation of cephalostatins 1-4 |
US4973394A (en) * | 1988-09-02 | 1990-11-27 | Sri International | Immobilized valinomycin molecule for K+ sensor |
US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US4940726A (en) | 1989-04-26 | 1990-07-10 | Arizona Board Of Regents | Cell growth inhibitory macrocyclic lactones denominated Combretastatin D-1 and Combretastatin D-2 |
US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
US5047532A (en) | 1989-07-28 | 1991-09-10 | Arizona Board Of Regents, Acting On Behalf Of Arizona State University | Isolation and elucidation of Cephalostatins 5 and 6 |
US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
US5130414A (en) | 1989-11-30 | 1992-07-14 | Arizona Board Of Regents, A Body Corporate Of Arizona State University | Isolation and structural elucidation of the cyclic peptide hymenistatin 1 |
US4997817A (en) | 1990-01-19 | 1991-03-05 | Arizona Board Of Reagents | Phyllanthostatin A |
US5072004A (en) | 1990-12-31 | 1991-12-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthetic conversion of bryostatin 2 into bryostatin 1 |
US5514689A (en) | 1991-08-08 | 1996-05-07 | Arizona Board Of Regents | Cribrostatins 1 and 2 |
US5196447A (en) | 1991-08-08 | 1993-03-23 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting On Behalf Of Arizona State University | Neristatin 1 |
US6569834B1 (en) | 1992-12-03 | 2003-05-27 | George R. Pettit | Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides |
US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5426194A (en) | 1993-01-19 | 1995-06-20 | Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University | Isolation and structure of Halistatin 1 |
US5352804A (en) | 1993-01-19 | 1994-10-04 | Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University | Isolation and structure of Halistatin 2 |
US5583224A (en) | 1993-01-19 | 1996-12-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and elucidation of cephalostatin 7, 8 and 9 |
US5436400A (en) | 1993-01-19 | 1995-07-25 | Arizona Board Of Regents | Isolation and structure of spongistatin 1 |
US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5393897A (en) | 1993-07-02 | 1995-02-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structure of spongistatins 5,7,8 and 9 |
US5328929A (en) | 1993-07-02 | 1994-07-12 | Arizona Board Of Regents | Isolation and structure of spongistatin 2, spongistatin 3, spongistatin 4 and spongistatin 6 |
US5430053A (en) | 1994-04-19 | 1995-07-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structure of dictyostatin 1 |
US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5646246A (en) | 1994-11-14 | 1997-07-08 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the human cancer cell growth inhibitory cyclic peptides phakellistatin 4, 5, 6, 7, 8 and 9 |
US5494893A (en) | 1994-11-14 | 1996-02-27 | Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University | Stylostatin 2 |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5801222A (en) | 1994-12-20 | 1998-09-01 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structure of the human cancer cell growth inhibitory cyclic octapeptides phakellistatin 10 and 11 |
US5561122A (en) | 1994-12-22 | 1996-10-01 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Combretastatin A-4 prodrug |
US5529989A (en) | 1995-01-09 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Pancratistatin prodrug |
US5519050A (en) | 1995-04-07 | 1996-05-21 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of halistatin 3 |
AU2337997A (en) | 1996-03-20 | 1997-10-10 | Arizona Board Of Regents, The | Method of treating cancer using c-26 modified bryostatin |
US5883120A (en) | 1997-06-16 | 1999-03-16 | Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University | Antifungal activity of the spongistatins |
WO1997048278A1 (en) | 1996-06-18 | 1997-12-24 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of The Arizona State University | Antifungal activity of the spongistatins |
CA2282504A1 (en) | 1997-02-25 | 1998-08-27 | Jun-Ping Xu | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
US6686445B1 (en) | 1997-09-24 | 2004-02-03 | Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University | Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same |
CA2298639C (en) | 1997-09-24 | 2005-07-05 | Erik J. Flahive | Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same |
CA2314510A1 (en) | 1998-01-09 | 1999-07-15 | George R. Pettit | Synthesis of phenstatin and prodrugs thereof |
CA2315230C (en) | 1998-01-09 | 2004-06-29 | Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University | Anti-cryptococcal peptides |
WO1999035150A1 (en) | 1998-01-09 | 1999-07-15 | Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University | Synthesis of combretastatin a-4 prodrugs and trans-isomers thereo f |
US6281196B1 (en) | 1998-06-10 | 2001-08-28 | Arizona Board Of Regents | Isolation and structural elucidation of the human cancer cell growth inhibitory compound denominated agelagalastatin |
US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
DE69912808T2 (en) | 1999-12-08 | 2004-09-30 | Centre National De La Recherche Scientifique (C.N.R.S.) | Use of hymenialdisine and its derivatives for the preparation of therapeutic agents |
DK1278758T3 (en) | 2000-04-27 | 2012-01-23 | Univ Arizona | Combretastatin A-1 Phosphate and Combretastatin B-1 Phosphate Prodrugs |
EP1299337A4 (en) | 2000-04-27 | 2004-10-13 | Univ Arizona State | Hydroxyphenstatin and the prodrugs thereof |
WO2001084929A1 (en) | 2000-05-09 | 2001-11-15 | Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University | Antitubulin assembly and cell growth inhibitor denominated 'dioxostatin' |
US20030216361A1 (en) | 2000-06-28 | 2003-11-20 | Pettit George R. | Therapeutic compositions effective against gram positive bacteria |
WO2002050023A2 (en) | 2000-12-21 | 2002-06-27 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of The Arizona State University | Synthesis of pancrastistatin |
US6437128B1 (en) | 2001-02-16 | 2002-08-20 | Arizona Board Of Regents | Cribrostatins 3-5 |
EP1385846A4 (en) | 2001-04-18 | 2005-11-30 | Univ Arizona State | Synthesis of pancratistatin prodrugs |
WO2002102766A2 (en) | 2001-06-15 | 2002-12-27 | Arizona Board Of Regents | Combretastatin a-3 prodrug |
JP2005514450A (en) | 2001-12-21 | 2005-05-19 | アリゾナ ボード オブ リーゼンツ | Synthesis of combretastatin A-2 prodrug |
US20050014849A1 (en) | 2001-12-22 | 2005-01-20 | Pettit George R. | Antifungal phenylethylene |
WO2003086414A1 (en) | 2002-04-10 | 2003-10-23 | Arizona Board Of Regents | Structural modification of resveratrol: sodium resverastatin phosphate |
US20040127467A1 (en) | 2002-04-17 | 2004-07-01 | Pettit George R | Synthesis of pancratistatin prodrugs |
US20060100179A1 (en) | 2002-08-14 | 2006-05-11 | Pero Ronald W | Compositions and methods for use in targeting vascular destruction |
WO2004052875A1 (en) | 2002-12-05 | 2004-06-24 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Tyrostatin and related anticancer drugs |
AU2003302237A1 (en) * | 2002-12-06 | 2004-06-30 | Adaptive Therapeutics, Inc. | Novel cyclic peptides comprising alpha-, beta- and gamma- amino acids |
EP1990346A3 (en) | 2002-12-09 | 2009-02-18 | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA acting for and on behalf of ARIZONA STATE UNIVERSITY | Process for the preparation of narcistatin prodrugs |
WO2004074248A2 (en) | 2003-02-20 | 2004-09-02 | Arizona Board Of Regents | Isolation and structure of cribrostatin 6 |
WO2005007084A2 (en) | 2003-06-20 | 2005-01-27 | Arizona Board Of Regents A Body Corporate Of The State Of Arizone, Acting For And On Behalf Of Arizona State University | Pancratistatin cyclic phosphate prodrugs an phenpanstatin cyclic phosphate prodrugs |
US7223747B2 (en) | 2003-09-24 | 2007-05-29 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Halocombstatins and methods of synthesis thereof |
WO2005054809A2 (en) | 2003-11-25 | 2005-06-16 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Irciniastatins a and b |
US20050187240A1 (en) | 2004-02-23 | 2005-08-25 | The Arizona Board Of Regents, Acting For And On Behalf Of The Arizona State University | Aaptamine and isoaaptamine and structural modifications thereof |
EP1720552A2 (en) | 2004-03-05 | 2006-11-15 | Arizona Board of Regents, acting for and on behalf of Arizona State University | Methods for treating inflammatory and autoimmune diseases |
WO2006036743A2 (en) | 2004-09-24 | 2006-04-06 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Halocombstatins and methods of synthesis thereof |
US7709643B2 (en) | 2005-01-14 | 2010-05-04 | Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University | Synthesis of sodium narcistatin and related compounds |
WO2006122296A1 (en) | 2005-05-11 | 2006-11-16 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Isolation and structure of turbostatins 1-4 |
US20090221666A1 (en) | 2005-05-12 | 2009-09-03 | Pettit George R | Stilbene derivatives and methods of inhibiting cancer cell growth and microbial growth |
US8415294B2 (en) | 2007-06-05 | 2013-04-09 | Arizona Board Of Regents | Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth |
WO2008151306A1 (en) | 2007-06-05 | 2008-12-11 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Synthesis of cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity |
US9044518B2 (en) | 2011-03-30 | 2015-06-02 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Auristatin tyramine phosphate salts and auristatin aminoquinoline derivatives and prodrugs thereof |
US9175041B2 (en) | 2011-04-25 | 2015-11-03 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Crystal structures of dolastatin 16, dolamethylleuine and dolaphenvaline, and methods for preparing dolamethylleuine and dolaphenvaline |
US20180030095A1 (en) | 2015-02-13 | 2018-02-01 | George Robert Pettit | Silstatin compounds |
EP3325497B1 (en) | 2015-07-24 | 2020-09-02 | Arizona Board of Regents on behalf of Arizona State University | Quinstatin compounds |
US11098052B2 (en) | 2016-03-02 | 2021-08-24 | Arizona Board Of Regents On Behalf Of Arizona State University | 4-azapodophylotoxins compounds |
US11629167B2 (en) | 2017-11-09 | 2023-04-18 | Arizona Board Of Regents On Behalf Of Arizona State University | Betulastatin compounds |
-
2016
- 2016-02-12 US US15/550,727 patent/US20180030095A1/en not_active Abandoned
- 2016-02-12 WO PCT/US2016/017834 patent/WO2016130969A1/en active Application Filing
-
2019
- 2019-08-08 US US16/536,039 patent/US11174291B2/en active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11174291B2 (en) | 2015-02-13 | 2021-11-16 | Arizona Board Of Regents On Behalf Of Arizona State University | Silstatin compounds |
US10435435B2 (en) | 2015-07-24 | 2019-10-08 | The Arizona Board Of Regents On Behalf Of Arizona State University | Quinstatin compounds |
US11629167B2 (en) | 2017-11-09 | 2023-04-18 | Arizona Board Of Regents On Behalf Of Arizona State University | Betulastatin compounds |
Also Published As
Publication number | Publication date |
---|---|
US11174291B2 (en) | 2021-11-16 |
US20190375794A1 (en) | 2019-12-12 |
WO2016130969A1 (en) | 2016-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022069604A (en) | Targeted delivery of tertiary amine-containing drug substances | |
EP3725798A1 (en) | Bioactive conjugate, preparation method therefor and use thereof | |
US11174291B2 (en) | Silstatin compounds | |
US20210163458A1 (en) | Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use | |
US20220118105A1 (en) | CD38 Antibody Drug Conjugate | |
CA2976064A1 (en) | Antibody drug conjugates | |
AU2022204711B2 (en) | Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation | |
CA3025931A1 (en) | Antibody drug conjugates having derivatives of amatoxin as the drug | |
EP2740493A1 (en) | Conjugates of the B-subunit of Shiga toxin for anticancer therapies | |
US11098052B2 (en) | 4-azapodophylotoxins compounds | |
CN107108693B (en) | Peptide compounds, process for their preparation and their use | |
US10435435B2 (en) | Quinstatin compounds | |
US11548889B2 (en) | Emetine auristatin compounds | |
US11970506B2 (en) | Bioactive molecule conjugate, preparation method and use thereof | |
KR20240016231A (en) | Novel auristatin prodrug | |
TW202408582A (en) | Novel auristatin prodrug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STAT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PETTIT, GEORGE ROBERT;ARCE, PABLO;PETTIT, ROBIN K;SIGNING DATES FROM 20170808 TO 20170901;REEL/FRAME:043700/0319 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:ARIZONA STATE UNIVERSITY-TEMPE CAMPUS;REEL/FRAME:044217/0417 Effective date: 20160111 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |